var title_f41_56_42880="Iliac spine avulsion fracture";
var content_f41_56_42880=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F54327&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F54327&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Iliac spine avulsion fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 371px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This AP radiograph shows an avulsion fracture of the left anterior superior iliac spine.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jim Fiechtl, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_56_42880=[""].join("\n");
var outline_f41_56_42880=null;
var title_f41_56_42881="The metabolic syndrome";
var content_f41_56_42881=[" <h1 id=\"patTopicTitle\">",
"  Patient information: The metabolic syndrome (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?41/56/42881/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/56/42881/contributors\" id=\"au7055\">",
"       James B Meigs, MD, MPH",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?41/56/42881/contributors\">",
"       Section Editors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/56/42881/contributors\" id=\"se6384\">",
"       David M Nathan, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/56/42881/contributors\" id=\"se1375\">",
"       Joseph I Wolfsdorf, MB, BCh",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?41/56/42881/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/56/42881/contributors\" id=\"de1470\">",
"       Jean E Mulder, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"mobipreview.htm?41/56/42881?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      METABOLIC SYNDROME OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     The metabolic syndrome, also called insulin resistance syndrome or syndrome X, is not a disease but a group of characteristics. These characteristics include obesity, high blood pressure, elevated blood sugar levels, and high triglycerides (fat-like substances in the blood). Having a combination of these characteristics increases your risk of developing type 2 diabetes and heart disease. Keeping your weight, blood sugar, and cholesterol and triglyceride levels under control can help you to live longer and decrease your risk of heart attack and stroke.",
"    </p>",
"    <p>",
"     There is controversy as to whether metabolic syndrome is really a \"syndrome.\"",
"    </p>",
"    <p>",
"     More detailed information about metabolic information is available by subscription. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/11/32954?source=see_link\">",
"      \"The metabolic syndrome (insulin resistance syndrome or syndrome X)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      WHAT IS METABOLIC SYNDROME?",
"     </span>",
"    </p>",
"    <p>",
"     The metabolic syndrome is a group of characteristics. You do not need to have all of the characteristics to have it. However, a person with one characteristic is more likely to have others. Most expert groups define metabolic syndrome as the presence of three or more of the following characteristics in a person:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Obesity, especially in the abdominal area (defined by some groups as a waist size greater than 94 to 102 cm (38 to 41 in) in men or greater than 80 cm (32 in) in women)",
"      </li>",
"      <li>",
"       Impaired fasting glucose (fasting blood sugar of 100 to 125",
"       <span class=\"nowrap\">",
"        mg/dL",
"       </span>",
"       or 5.6 to 7",
"       <span class=\"nowrap\">",
"        mmol/L)",
"       </span>",
"      </li>",
"      <li>",
"       Increased blood pressure",
"       <span class=\"nowrap\">",
"        (130/85",
"       </span>",
"       or higher) or if you take medicine for high blood pressure",
"      </li>",
"      <li>",
"       Increased fasting levels of triglycerides (greater than 150 to 180",
"       <span class=\"nowrap\">",
"        mg/dL",
"       </span>",
"       or 1.7",
"       <span class=\"nowrap\">",
"        mmol/L)",
"       </span>",
"       or decreased fasting HDL cholesterol (less than 40",
"       <span class=\"nowrap\">",
"        mg/dL",
"       </span>",
"       or 1",
"       <span class=\"nowrap\">",
"        mmol/L",
"       </span>",
"       for men or 50",
"       <span class=\"nowrap\">",
"        mg/dL",
"       </span>",
"       or 1.3",
"       <span class=\"nowrap\">",
"        mmol/L",
"       </span>",
"       for women), or if you take medicine for high triglycerides or low HDL cholesterol",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      HOW COMMON IS METABOLIC SYNDROME?",
"     </span>",
"    </p>",
"    <p>",
"     Metabolic syndrome is becoming increasingly common. In one study performed between 1999 and 2002, more than 34 percent of participants were classified as having metabolic syndrome [",
"     <a class=\"abstract\" href=\"mobipreview.htm?41/56/42881/abstract/1\">",
"      1",
"     </a>",
"     ]. This number is significantly increased from a similar study performed between 1988 and 1994, when 22 percent of people had metabolic syndrome.",
"    </p>",
"    <p>",
"     The following factors are thought to increase the risk of developing metabolic syndrome:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Being overweight (body mass index of 25",
"       <span class=\"nowrap\">",
"        kg/m2",
"       </span>",
"       or more) (",
"       <a class=\"calc calc_patient\" href=\"mobipreview.htm?41/23/42366?source=see_link\">",
"        calculator 1",
"       </a>",
"       and",
"       <a class=\"calc calc_patient\" href=\"mobipreview.htm?36/47/37630?source=see_link\">",
"        calculator 2",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       Menopause (in women)",
"      </li>",
"      <li>",
"       Increasing age",
"      </li>",
"      <li>",
"       Smoking",
"      </li>",
"      <li>",
"       Eating a high carbohydrate diet",
"      </li>",
"      <li>",
"       Lack of physical activity",
"      </li>",
"      <li>",
"       Family history of diabetes or metabolic syndrome",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Health risks associated with metabolic syndrome",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h3\">",
"      Diabetes",
"     </span>",
"     &nbsp;&mdash;&nbsp;Type 2 diabetes is much more likely to develop among people with the metabolic syndrome [",
"     <a class=\"abstract\" href=\"mobipreview.htm?41/56/42881/abstract/2\">",
"      2",
"     </a>",
"     ]. Healthy lifestyle changes, such as weight loss and exercise, can help to reduce the risk of developing type 2 diabetes. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/22/9572?source=see_link\">",
"      \"Patient information: Diabetes mellitus type 2: Overview (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h3\">",
"      Cardiovascular disease",
"     </span>",
"     &nbsp;&mdash;&nbsp;People with metabolic syndrome are at increased risk for developing cardiovascular disease. Cardiovascular disease includes coronary artery disease (collections of fatty plaques inside the heart's blood vessels), cerebrovascular disease (collections of fatty plaques inside the blood vessels leading to the brain), and high blood pressure. Cardiovascular disease can lead to heart attack, stroke, or angina (chest pain).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H7\">",
"     <span class=\"h1\">",
"      METABOLIC SYNDROME DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     The metabolic syndrome is diagnosed based upon a physical exam and a blood test of your fasting (before breakfast) blood sugar, cholesterol, and triglyceride levels. A description of how blood glucose and cholesterols levels are measured is available separately. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/22/9572?source=see_link\">",
"      \"Patient information: Diabetes mellitus type 2: Overview (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?6/4/6212?source=see_link\">",
"      \"Patient information: High cholesterol and lipids (hyperlipidemia) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H8\">",
"     <span class=\"h1\">",
"      METABOLIC SYNDROME TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     The goals of treatment for the metabolic syndrome are to:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Reduce or eliminate underlying problems (eg, obesity, lack of activity) by losing weight and becoming more active.",
"      </li>",
"      <li>",
"       Treat cardiovascular risk factors, such as high blood pressure and cholesterol, if these problems persist despite losing weight and exercising.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Weight loss",
"     </span>",
"     &nbsp;&mdash;&nbsp;Management of the metabolic syndrome usually includes losing weight and becoming more active. Your diet should be low in fat and cholesterol.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The Mediterranean diet is high in fruits, vegetables, nuts, whole grains, and olive oil. This diet can help to lower weight, blood pressure, lipids, and improve insulin resistance.",
"      </li>",
"      <li>",
"       The DASH (Dietary Approaches to Stop Hypertension) diet can reduce blood pressure, weight, lipids and fasting blood glucose levels. The DASH diet requires you to eat no more than 2400 mg of sodium per day, four to five servings of fruit, four to five servings of vegetables, two to three servings of low-fat dairy products, and all foods must contain less than 25 percent total fat per serving. (See",
"       <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/61/39890?source=see_link\">",
"        \"Patient information: Low sodium diet (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Exercise",
"     </span>",
"     &nbsp;&mdash;&nbsp;Exercise can help with weight loss and can also help to reduce the size of the abdomen, especially in women. Experts recommend at least 30 minutes of moderate physical activity, such as brisk walking, most days of the week. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?7/42/7844?source=see_link\">",
"      \"Patient information: Exercise (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Reduce the risk of type 2 diabetes",
"     </span>",
"     &nbsp;&mdash;&nbsp;Losing weight (if you are overweight or obese) and staying active can reduce the risk of developing type 2 diabetes.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Reduce cholesterol",
"     </span>",
"     &nbsp;&mdash;&nbsp;High levels of LDL (bad) cholesterol increase the risk of coronary artery disease. In people with metabolic syndrome, an LDL level of less than 80 to 100",
"     <span class=\"nowrap\">",
"      mg/dL",
"     </span>",
"     is recommended.",
"    </p>",
"    <p>",
"     If diet and weight loss do not adequately reduce your LDL levels, a medicine may be recommended. Treatment of high LDL levels is discussed separately. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?6/4/6212?source=see_link\">",
"      \"Patient information: High cholesterol and lipids (hyperlipidemia) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Reduce blood pressure",
"     </span>",
"     &nbsp;&mdash;&nbsp;Keeping your blood pressure in a healthy range is an important goal, especially in people with the metabolic syndrome.",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       High blood pressure is a BP greater than",
"       <span class=\"nowrap\">",
"        140/90",
"       </span>",
"      </li>",
"      <li>",
"       Prehypertension is a BP greater than 120 to",
"       <span class=\"nowrap\">",
"        139/80",
"       </span>",
"       to 89",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Some experts recommend treatment if your blood pressure is greater than",
"     <span class=\"nowrap\">",
"      140/90",
"     </span>",
"     and possibly if greater than",
"     <span class=\"nowrap\">",
"      130/80.",
"     </span>",
"    </p>",
"    <p>",
"     If diet and weight loss do not reduce your blood pressure enough, one or more blood pressure medicines may be recommended. Treatment of high blood pressure is discussed separately. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/32/37380?source=see_link\">",
"      \"Patient information: High blood pressure treatment in adults (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Quit smoking",
"     </span>",
"     &nbsp;&mdash;&nbsp;Smoking cigarettes significantly increases the risk of coronary artery disease, and has many other health risks as well. You and your family are strongly advised to stop cigarette smoking. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?19/13/19670?source=see_link\">",
"      \"Patient information: Quitting smoking (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H15\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1784970042\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5395195\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/44/33475?source=see_link\">",
"      Patient information: Type 2 diabetes (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?5/24/5507?source=see_link\">",
"      Patient information: Metabolic syndrome (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?20/28/20930?source=see_link\">",
"      Patient information: High triglycerides (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5395220\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/22/9572?source=see_link\">",
"      Patient information: Diabetes mellitus type 2: Overview (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?6/4/6212?source=see_link\">",
"      Patient information: High cholesterol and lipids (hyperlipidemia) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/61/39890?source=see_link\">",
"      Patient information: Low sodium diet (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?7/42/7844?source=see_link\">",
"      Patient information: Exercise (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/32/37380?source=see_link\">",
"      Patient information: High blood pressure treatment in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?19/13/19670?source=see_link\">",
"      Patient information: Quitting smoking (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/57/28567?source=see_link\">",
"      Insulin resistance: Definition and clinical spectrum",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/11/32954?source=see_link\">",
"      The metabolic syndrome (insulin resistance syndrome or syndrome X)",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/metabolicsyndrome.html\">",
"      www.nlm.nih.gov/medlineplus/metabolicsyndrome.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Diabetes Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.diabetes.org/food-nutrition-lifestyle/lifestyle-prevention/weight-loss/healthy-weight-loss.jsp\">",
"      www.diabetes.org/food-nutrition-lifestyle/lifestyle-prevention/weight-loss/healthy-weight-loss.jsp",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Heart Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.heart.org/HEARTORG/Conditions/More/MetabolicSyndrome/About-Metabolic-Syndrome_UCM_301920_Article.jsp\">",
"      file://www.heart.org/HEARTORG/Conditions/More/MetabolicSyndrome/About-Metabolic-Syndrome_UCM_301920_Article.jsp",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"mobipreview.htm?41/56/42881/abstract/1-5\">",
"      1-5",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 1, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"mobipreview.htm?41/56/42881?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/56/42881/abstract/1\">",
"      Ford ES. Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. Diabetes Care 2005; 28:2745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/56/42881/abstract/2\">",
"      Wilson PW, D'Agostino RB, Parise H, et al. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 2005; 112:3066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/56/42881/abstract/3\">",
"      Grundy SM, Brewer HB Jr, Cleeman JI, et al. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004; 109:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/56/42881/abstract/4\">",
"      Kahn R, Buse J, Ferrannini E, et al. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005; 28:2289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/56/42881/abstract/5\">",
"      Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365:1415.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f41_56_42881=[""].join("\n");
var outline_f41_56_42881=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           METABOLIC SYNDROME OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           WHAT IS METABOLIC SYNDROME?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           HOW COMMON IS METABOLIC SYNDROME?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H7\">",
"           METABOLIC SYNDROME DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H8\">",
"           METABOLIC SYNDROME TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H15\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        CALCULATORS",
"       </h1>",
"       <div id=\"relatedCalculators\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a class=\"calc calc_patient\" href=\"mobipreview.htm?41/23/42366?source=related_link\" title=\"calculator 1\">",
"           Calculator: Body mass index for adults (Patient information)",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a class=\"calc calc_patient\" href=\"mobipreview.htm?36/47/37630?source=related_link\" title=\"calculator 2\">",
"           Calculator: Body mass index for adults (Metric, Patient information)",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f41_56_42882="DEB2";
var content_f41_56_42882=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86595&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86595&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 596px\">",
"   <div class=\"ttl\">",
"    Recessive dystrophic epidermolysis bullosa (DEB)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 576px; height: 384px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Dedee F Murrell, MD, Johann Bauer, MD, and Martin Laimer, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_56_42882=[""].join("\n");
var outline_f41_56_42882=null;
var title_f41_56_42883="Bisacodyl: Pediatric drug information";
var content_f41_56_42883=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Bisacodyl: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?6/4/6213?source=see_link\">",
"    see \"Bisacodyl: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?14/49/15124?source=see_link\">",
"    see \"Bisacodyl: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F141442\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Alophen&reg; [OTC];",
"     </li>",
"     <li>",
"      Bisac-Evac&trade; [OTC];",
"     </li>",
"     <li>",
"      Biscolax&trade; [OTC];",
"     </li>",
"     <li>",
"      Correctol&reg; Tablets [OTC];",
"     </li>",
"     <li>",
"      Dacodyl&trade; [OTC];",
"     </li>",
"     <li>",
"      Doxidan&reg; [OTC];",
"     </li>",
"     <li>",
"      Dulcolax&reg; [OTC];",
"     </li>",
"     <li>",
"      ex-lax&reg; Ultra [OTC];",
"     </li>",
"     <li>",
"      Femilax&trade; [OTC];",
"     </li>",
"     <li>",
"      Fleet&reg; Bisacodyl [OTC];",
"     </li>",
"     <li>",
"      Fleet&reg; Stimulant Laxative [OTC];",
"     </li>",
"     <li>",
"      Veracolate&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F141443\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Bisacodyl&reg; [OTC];",
"     </li>",
"     <li>",
"      Bisacodyl-Odan [OTC];",
"     </li>",
"     <li>",
"      Bisacolax [OTC];",
"     </li>",
"     <li>",
"      Carter's Little Pills&reg; [OTC];",
"     </li>",
"     <li>",
"      Codulax [OTC];",
"     </li>",
"     <li>",
"      Dulcolax&reg; [OTC];",
"     </li>",
"     <li>",
"      PMS-Bisacodyl [OTC];",
"     </li>",
"     <li>",
"      ratio-Bisacodyl [OTC];",
"     </li>",
"     <li>",
"      Silver Bullet Suppository [OTC];",
"     </li>",
"     <li>",
"      Soflax [OTC];",
"     </li>",
"     <li>",
"      The Magic Bullett [OTC];",
"     </li>",
"     <li>",
"      Woman's Laxative [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1045564\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Laxative, Stimulant",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1045559\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?6/4/6213?source=see_link\">",
"      see \"Bisacodyl: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bisacodyl (Dulcolax&reg;) tablet: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 3-12 years: 5-10 mg or 0.3 mg/kg/day as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &ge;12 years and Adults: 5-15 mg/day as a single dose; maximum dose: 30 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bisacodyl (Dulcolax&reg;) suppository: Rectal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &lt;2 years: 5 mg/day as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     2-11 years: 5-10 mg/day as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &ge;12 years and Adults: 10 mg/day as a single dose",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F141427\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, rectal [enema]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fleet&reg; Bisacodyl: 10 mg/30 mL (37 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suppository, rectal: 10 mg (12s, 50s, 100s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bisac-Evac&trade;: 10 mg (8s, 12s, 50s, 100s, 500s, 1000s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Biscolax&trade;: 10 mg (12s, 100s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dulcolax&reg;: 10 mg (4s, 8s, 16s, 28s, 50s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 5 mg, 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, delayed release, oral: 5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Doxidan&reg;: 5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fleet&reg; Stimulant Laxative: 5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, enteric coated, oral: 5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Alophen&reg;: 5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bisac-Evac&trade;: 5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Correctol&reg; Tablets: 5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dacodyl&trade;: 5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dulcolax&reg;: 5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ex-lax&reg; Ultra: 5 mg [contains sodium 0.1 mg/tablet]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Femilax&trade;: 5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Veracolate&reg;: 5 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F141416\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes enema",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1045567\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer on an empty stomach with water; patient should swallow tablet whole; do not break or chew enteric-coated tablet; do not administer within 1 hour of ingesting antacids, alkaline material, milk, or dairy products",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1045561\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store enteric-coated tablets and rectal suppositories at &lt;30&deg;C.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1045566\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of constipation; colonic evacuation prior to procedures or examination",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F141486\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Doxidan&reg; may be confused with doxepin",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Dulcolax&reg; (bisacodyl) may be confused with Dulcolax&reg; (docusate)",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F141485\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Rare but important or life-threatening: Electrolyte and fluid imbalance (metabolic acidosis or alkalosis, hypocalcemia), mild abdominal cramps, nausea, rectal burning, vertigo, vomiting",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1045571\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to bisacodyl or any component; do not use in patients with abdominal pain, appendicitis, obstruction, nausea or vomiting; not to be used during pregnancy or lactation",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1045558\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Bisacodyl tannex powder for preparation as a rectal solution should be used with caution in patients with ulceration of the colon",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1045557\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stimulant laxatives are habit-forming; long-term use may result in laxative dependence and loss of normal bowel function.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298866\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F141423\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May diminish the therapeutic effect of Bisacodyl. Antacids may cause the delayed-release bisacodyl tablets to release drug prior to reaching the large intestine.  Gastric irritation and/or cramps may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1045574\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administration within 1 hour of ingesting antacids, alkaline material, milk, or dairy products will cause premature dissolution of the enteric coating and resultant gastric irritation",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14206265\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Plasma concentrations of BHPM (the active metabolite of bisacodyl) are low (median: 61 ng/mL; range: 21-194 ng/mL) following doses of 10 mg/day for 7 days (Friedrich, 2011). Although not first choice for the treatment of constipation in pregnant women, short-term use of stimulant laxatives is generally considered safe in pregnancy; long-term use should be avoided (Cullen, 2007; Prather, 2004; Wald, 2003).",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1045556\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stimulates peristalsis by directly irritating the smooth muscle of the intestine, possibly the colonic intramural plexus; alters water and electrolyte secretion producing net intestinal fluid accumulation and laxation",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1045569\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Onset of action:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Within 6-10 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rectal: 15-60 minutes",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1045570\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral, rectal: &lt;5% absorbed systemically",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: In the liver",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Conjugated metabolites excreted in breast milk, bile, and urine",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1045563\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?14/49/15124?source=see_link\">",
"      see \"Bisacodyl: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should not be used regularly for more than 1 week",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1045572\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     In a randomized prospective study of 70 patients, bisacodyl tablets were given orally once daily in the morning for 2 days before colonoscopy to 19 patients (dose for children &lt;5 years: 5 mg; 5-12 years: 10 mg; &gt;12 years: 15 mg) with a Fleet&reg; enema given on the morning of the procedure without any dietary restriction. Results showed that bisacodyl without dietary restriction provided unsatisfactory colon cleansing.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      BaKer SS, Liptak GS, Colletti RB, et al, &ldquo;Constipation in Infants and Children: Evaluation and Treatment,&rdquo; 2000, www.naspgn.org/constipation.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dahshan A, Lin CH, Peters J, et al, &ldquo;A Randomized, Prospective Study to Evaluate the Efficacy and Acceptance of Three Bowel Preparations for Colonoscopy in Children,&rdquo;",
"      <i>",
"       Am J Gastroenterol",
"      </i>",
"      , 1999, 94(12):3497-501.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/56/42883/abstract-text/10606310/pubmed\" id=\"10606310\" target=\"_blank\">",
"        10606310",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13080 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-197.136.42.3-3357F5F93E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_56_42883=[""].join("\n");
var outline_f41_56_42883=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141442\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141443\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045564\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045559\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141427\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141416\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045567\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045561\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045566\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141486\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141485\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045571\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045558\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045557\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298866\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141423\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045574\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14206265\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045556\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045569\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045570\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045563\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045572\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13080\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13080|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?6/4/6213?source=related_link\">",
"      Bisacodyl: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?14/49/15124?source=related_link\">",
"      Bisacodyl: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_56_42884="Hairy cell leukemia";
var content_f41_56_42884=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F81031&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F81031&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Abnormal circulating lymphocytes in hairy cell leukemia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 419px; height: 407px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGXAaMDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6MUAcgdeDmnDt09KTGPT3NO9e49cVmiwzge/Wg4OMjjt7UlOAx1xTEKO/TNL7HgdBSc89BS4NMQ6j3opeo9qAA9KTqaU9sZoThxmgRw3xC1t4pF022cq2MykfyrjbW1aQ5x9TV/xXG0ni29DZxuq5Yw5Che3aqm7aHq0koQVimtgp6g5qM2ABJAIrroNOLDcxxmr0WhJNCNzjJqLkuukct4d1ObTLtVyzW7cMpPFehqVdVdeVb5hj0rzfUoxZ3bxnDYOMjvXaeE7s3emlWGTGcU2Y4iKa50amKXP6e9OZTn1ppBOOOOlI5AzxxSoeR/nNKqk8fnTXeGIHzJUX6npRYB45GeTSMuP89KkjKSDMciuv+yacUI7EUxEK8YANEyLNDJG3KuCtSFRSEHH6UIDmrIixk8plwVOOa1XvBjgDHrU19ZpdJnA34wCOtYU2m6gvA+Yexps3TjPcmvLhcM+4nvzWdp8TX+oIqj5c5Y+wqVNJ1C5cxMnlrnJZjXSaZpsGmw7YvndvvSHv7Ui5TjBWW5cxhQB0HAopSPekHPufSg5BKQn8/wCVONJ3z3pgYmuaSlxm5i+S5QZyv8VUNMnMrqk6qSOORzXVYzWVqGmBmM1uNsnX60G0KmnLIvhFVPkUDjtXG+MLPcrSZJI6VuR6g0SbZ0KkDBzWHrV4bpfLj5JpGtGMoyuZlw39p+E0kwWuLRsEn0rBgvSqD16V2/hjQZVguPOYrBMuCD3rH1bwPeRsTZlZYvY8ig6Y1oJuLZmtqRZcbugrGvbszuAOgrSl0a7jjaLyn39+Ku6P4TvbjDtCUXpluKDXnhFXuVfCemPealGduRnPPpXriLsjCDoowKz9F0mDS4MJy56tjpWjk0zzsRW9pLTYQ/TFJgZ9qX0657il6E9M0jATjHTrzxRk+mKX170hPHX60ABo49AaD0/GjJ5oACM8fhR+AHfFGfQ0YoAKPWjp14oPHXHHWgBpXJycD60UhIB6Z96Kd2BJ06dKaeOffHNOYZJ9KaR6c57VBQLj8ueKXPtgjrSiNz2J4xmjBHbj6daBCpx2yB0NOHApvfn/APVXlfjT4mTaD8Q7PS4Wsf7Jt3t4tSMrYlVpt20qM9FAVm4P3hTEerjmne+eTSdaUdfWmAmM0Z/SlI59aMHoetAjh/HOmeTdDUkXKSfLIQOhrO0q7iiOXxketejTRR3ELwzKJInGGU1wWu+G5rN/Mso2ltz2HJX2qtzso1U1ySLj6vGBjcMetULnW3UFLdzz6GsRkEb4lWQH3GKuaTa+fKdiA+hqdjo9nFajlBkk826PvzWtp2vwaakiQReYH5OO1cxqksv2trZiF29ecUsMiQIQo3sRx6U35jdNTWpqah8Qb6O4CW9kgQH5i5NdN4b8V2OsRlZQYLof8sz/ABfSuC/sprhDLjC55Y1QhLWt4ksLEbDwRQ7MTw9OSstz1G9u7u4YxxfukPGR1NZl1YP5eWZn9cmuk0+NZ7KCc9XUZqvrnl2lk0hwOMAUk7nJGSi+VHA6jdXFvhbaWRCPQ0af4m1ezcF7gyJ0KtUdw4ldjgY61TkXI4Gfwoud6hGSs0d/oXi62v5FhvNscp4Ujoa6cqB3HIyDXiCgxyhl4Oe1ereD9R/tLSAHOZYflOe4oOPE0FD3o7Gxgdjj60DPbtSnrye1HfJoOMOvXOPWgdPb1ox07mjnOetABj2zQRwT+ope+M4o9vyoAaff8KOTz+lO/HNJQA3jJzRTuOecCkFMCCa2hmGJIwfeq0Wl2kUm8RDd71fxTWPIAoGpNbAMgYxx7UmcZwT+Heo2YIOo6cCoWvFxwOTTsBZKjngZ+gpef/relZ8t0U+aYrEvXLHGarRazayMyJe27NntIDT5GPlb2Nc/Sl4zyKyxqcKHa93bgnn/AFgq2s7ugZFVlx1HIo5WKzLGOP8APFLz06A1X+0f7Ap8cyP1+VvSpsFiUZ4xwKB+tOIzwORSYznnA9KQDepzjk0evtS9c0nYZ/CgBfbI+tA9s5oAJOP8mql9qFnYIGvLlIz6Zyfypgk27ItZ5/XNHv0Paudl8Y6OjlA8jc4yFq5b+INNmi80T7V9W4osy3Smuhrf8BH4UVi/8JXoy8fas47hTRStIXs59h+q+JLGxyoJnfuqdq5LU/GWpykpZRRQJ/eIyaqTQDZhQOe9Pt7IOPnGO+KLpbHfCjCOr1KMuv604BN2wIOeBirFn4u1S3IE7iYDvjk0XlrHGCEJyKyZIdrc9O1F2bKEGtj17Qr9NU02O6ToeCPQ1k3fgbw3e2+pw3elQzLqUpnumkZi7ucch87lHyjAUgDtTfh2jR6HNv4BlOK6bvjFSmeZVioyaQ23jSGKOKPcEjUKNzFjgDAyTyfxqUdKaTjk0BvwpmY4cjjkZo9wTj3oPTqfUUZH50xAR2pAT1Xj1p3fJx7U36Dr2oAimt7ef/XwRv8AVaitdPs7ebfFCFOfyqz374ooHzPY8Z8dwyWXjK4MikJMqsvp+FbHh23t7rYZCPpXQfEXQ/7V01LqFSbi39OpFecaddyWr4ywOaqWtmenRl7SlZbnq3iGW1i0E21vGoJGA2OleXyYV9uO+K2V1N7hFRySPTNLpujzX1+vlKSM5bjpS6DpxVJO56RobINEtASBhOa5fxhf/aHEMZ+UccVc1CeWwhK7CERcZHSuMnvTcXLE9M0lojGjSvLmLNtAMjceSKguQqscdv1pzXWBtXP4VD5TysXfKp/OkdS7sg8veck4Tp06V13hXU7XT1MRO13xknpXNbM4A6dsVBcqFQ/zoCcVUVmeyqweMOvKkZzScD39a5b4d6ob6xltZSS8J4JPauqPY5pnk1IOEnFh0980fj+VHUHHejrgn/8AXQQGeOaDjBHvQPwNAPuPrQAdvajsP19qMfy60nfAoAPT86O+cZzR6+9J079KACq80gD7QetFxNgbVPJ71QnulgJYjPt6VSQ0h8z4J55Hc15f8QPixp/hx3tdORbzUFOT/dSl+Mfi59F0UW1k+Lq8yoOeUGOtfLNzLI00heQyOT8zZyTXfh8Op6yPSweFjNe0qbHV+I/iD4h166mnur1wrZASP5VUewrFi1y7gtDDDJIhbq4Y5NY4YjgGpopW27AFOe9d6pxWiR6kHD4Yqxbk1S+k2uLu5LAdS54rqfD/AMRPEOhbPsepSyqMEpN8w+nNcvHfJHEYo4gNwwSfWqVxE8DASArkbgKThGWjRUlFr3ldH1V8NPira+K5BYajGlnqgXjnCyfSvSTKMnHUV8JQXslvPDNbExSxkMHB5zX1P8LPGD+IvDcMty3+kRfJKfpXBXw3LqjycZhY0/fp7Ho63D7wqE5q4l0rEB8Kx7Vh210hL7X3MT2qZ5SuCOtckoWPPsbwIIyMe1CjJAXmse31AqwUgbTTPFeqHTdCeSLIll+VD6Vm1YFBtpIxvGPitrWVtP0kjzhxJL12+wrifKkuZC9w7SOTnLHPNNtYzIxZiSzHJJrZtbYtjjkUj1IU40o2RQSz3MqADmnXqKNsK5Kr1461vW1sFdyRyFOM1jSxMrMxz1pFKV2VBBGABtFFSnrwaKPmUbkKloQcc0LMEJGTwOcUllcr5R3EY6GlKxyKzRjvSRg99SrKd7YJ98Go47FrydYol3MTV23sZrqTZEmWNdbomjx6aPMY75m7A9KG+xM6qgvMv6TZrpunx2yHO3lj71b/AE70wH16/WlB6ZBoSsefJtu7Hn6ZoGaB3paYhQcUA889D6Ucf/Wo+v4H0pgKMYJ96Dgjpn3o/A0mepoEJk9c+1J+tLxSUAJ67uQeCO1cjrPgqC7uGmspFhZuShHH4V15+6aMZHtTuXCcoO8TjtP8FeUw+03KgDsoOa6yytobG3ENsgUdz3b61Iefal45NIc6sp/ExHRHUrIiupGCGFefeJdIi02/81I8W8nIIHAPpXoX8PXrVXU7KPULN7eYfK3Q+h9aaHSqOnK/Q8zjlikkAij6d6tTOlwwUEKqjGB1qGe1k0nUZrabqvQ+oqnHIEdmHrSeh6atLVF/yyAViXJ9qyrwncQQVI7VftdUNtP5m0OPeqN3N9sumkC7QxzikUr31N74aSGLX5I/4ZYzn6ivSG+8QOM1wngOzK6l57A/Khrum5J45pnnYpp1Bff370g9aO+aUdcelBzCdu/NB+nHpSj86TPHHWgA9On1oyKP6e9GO3U0AJ0yKjnYKh5qXtnvVe75QH3poClcSFVLbc1i30uRv3YYHJXPWte6fy0JJ4x1NczO7NHkLld33j1raBokeNftAbTNYymTbIBsCD6da8bSKKOdhMWwBxjua98+Muj/ANq6I92qbp7b5tw9K8BnuPNt40K/MvRvWvVwzvTsj2cHJOkl2K5IDEjpQwyNwxz2pYjh8kBgOufSklKl2KLtUngd63Nb6A3IHPNSSSNOoLuWdRgE+lMkIbaD1Ax0xTVHOO5oE5vms9hR1xjJr1L4EatJbaxcaczkQTpnGeMivLzkLnGPeun+GUxh8aWO0jL5AzWdWPNBoVbl9m4pn1lo0yyTvGgUFByR0NXHJabbuBH865OTV7bTJmuRKNygiSId/pVK48WXd7NH9ltfs9vnLO45P4dq8trTU8WMJzfuo9Bt7Ri27BwP1rD+IkyiGytOjnL49KpWvjbUY2UPDE0XTGB0q740jj1Czs9UThz8jqOgFc0nc3hSlTmnI5uyjwRu61fEpVRsbGDkmqIbgBRVu2tGlwz8DpUHZLzNSwuRMZcnLFaq74pcg4B6c06O1a2lV48gDqKo6orQ3G9QQrc5o0M0lfQkktIy5PFFZZupQeG4/OiixdmdJH4U1BCoEkW3vk1rWfhpYV+e4LEnLAdBW9g46cdKcB68etK557rzfUbbQR2qBYVxjv3qdSAM9/Smj26U8D8u9FjJu44DjPqKcByMH8KbwBk8Z9KaZVBwOvamiSVfQDil71V89uoIx09zRvfdkHnPT1qrBYuD19KM9DUHnY+gpyyg4z+dKwiX8aOuf50BgTwR9aMZP1oATBx0pKHOBkkfWqU87knoOetNK4Fp5FUdRUX2ld47A9azpLpUJaSVEGOrMBVF9WtWYBLiF/YOM1agykjo0cP0OfQ0/qOD0rGt7kSICrYyOOatx3DKAOQB60nFoVi/6etHP4VCswK7jU6jdjtUiMvX9Jj1WxkG0C6RSY3/AKV5RtZSVYfODtYe9ek6v4kWGZ7awUOwysknYfSuSvfDs82Z7OTfu5Knrk0dLM78M5QXvbGEz4wKsabE0kyjBb6VNF4Y1maXCQ/n3ru/DPh37FEsl8g80dEpWsb1K8Yrc0fD1mbSzBcbXfqPatPPFB5wOmaOhzig8uUuZ3YHGTR2PvSdDzx65prTIuOcjtQSSE8+/pSdRUXnqRxx7UqzKejdOKdgJMZxzR703cOOaM880gHY/LrTJBvVgacD14pDjn0oAxbqNmBV+MdM96x7iLc/KsF6kL6V1NxD5i8de1VHssJ0+Y8NitVIpM5l7WKS3ZHjDwyZBRh1FfPfxR+HlzpV297pVrLLZyNkqq58s/4V9UNYMQjAqCvTinSWCuu11Rg3BDDOa2p13Td0b0sQ6Uro+BZEeNijqVbuDSxP5UquACR2NfXWv/Bzw/q9y9wIvs875JaMcZ+lcPdfs5yeeWttZTyP7rKd1d0cZTe+h6EcZSfWx8+3MnmOWwAT6VA0m1SCMHsPT3r3S+/Z41pWL2up23lLyzOpyBWfpnw30O2vNt3NJqEoOD2XIpyxVJLRinUVZ/u2eRWGn3uoXCx2ME8244X5ete0+APAN3o0Zv75Y/7SlHAbpEPb3r1Xwl4XtLWFPsFnFCijghea6f8AsSOKTz5STsXOK4q2MctIqxjKcI6Hmo0hLNsyEz3LfMzNVyKJiOVJ9ciuoj09Lmd3YdT1pbjTlhQsq/KB2rjlJvVmiqpaHP8AkAqRtrbsplvNJazmwB0U1kPnefrVmxVjE23qrZNIctUQtaNaXBjlHPr6itWzICDtU0iJfWoB/wBbF096jggdody4CjqSaRDldaj7iUbSvY1ReWJ42imOVPQ+lTtFGw5lwPam7beHLRpub+8/agEUDobsd0fzIeQSaKc2oXIJwxx7UVVyvfNGx8eBX26rZ7V/vx112mahZ6rD5tjMsgHVTww/CvH5DubEi5pbW7uNHukurFipU8r2aoa7ETwsWvd0Z7UM5A607oCT+Z4qnomoJq+lw3sY27/vD0NFxc5m8kDOOpojqee007Mklly52NwOMVEW65PBP5UhwAaydUvoLOCWW4nWOFFJdmOABWsY30QJGqZAMEnHpQJe4D/lXz14z+Nkiq0HhxFJBKm4kH8hXBL8SvEUkpkudQmduuF4ANdUcJNq52U8DUmtdD7JRiwORjJxS7s4A4+tfKfhf4x+ItOu1W8IvLXOSjDB/OvobwR4wsPF+k/abBgJE/1sJ+8hrOrh5U9zOthKlFXex1Cvt5BxViKbf2+pqkF5Azyeakhfa5yMDFYNHKF3OvKDPHWvLfif8RLfwxCtpbbbjU5Puxdk9zXW+Ndcj0LRL7UJCAYYyVHq3YV8b+IdZutU1GW6u2DXEhO5vxrswtDnd3sd2Dw6qe/PZGtr3jHXdQuCb28kyH3bYzgD2rHbWrs3zXMN1PExHGH5qiHllcohBYjnPeoTwTwD247V6SpxXQ9ZuMdEj0/wl8VdV0ieCPVW+12PG7b94fjX0H4X8U6d4htVudNvUmDDHlsdrJ9RXxrblVjcMu4twD71Ys7+70q8W40+5ZJFwSUOAPY1jUw0Z7aHNXwkKiutGfc8ExwASQw656UatqBg0+RIyRK42j6V80+FfjRqNjeRDWIhdWhGGK/eB9a9y0vxFp3ifSI7vSpxNGPvDoyH0Irz6tCUNWedPDTpNOS0LOnaepiJx8zDP41ivNqemXTqwJTOQDXY6QVYLkHOOavX1pHLHh0DGuX1K9tyy1ODTxLqJkwqbB612/hzUzqenB5BiZPlf396wtTtLaCJjsC+gp/gudBd3CIRs25Jo9B1VGcHJLY69uOAKgecDOMZqCadm4XIU8Zpu35fm7/nmnY4h7MT/Fx1xSZU59/WoyRgbe/H0pXYKmGxxVWAk6DqM0g6nH51UkmA6846VSu9cs7DJurqGFB13tg01FsaTeiNkMcAjk1Ojh+B1965i18W6JcyhIdStmOecPW7BJHOgkhkV0/vKcihwYSjKO6LoBz60vf2qFXII3D5fWphz+NRsSIR17imtwTj0705h19qr3MoVcLyetADzKqkA8H0qB7wBiAM+prKvbpIELNKOnBNeVeNfjFp2lM9nYp9rvE4ZkJ2qfrW0KLm9DSFKVR2ij2Y36fdbG70701LoM2TuIPA4r471r4keJNRYzLei3QnASPqKxF8X+IlkDDWLrI5Hzn/ABrpWCZ1/UZLdn3JdustjcxhirOhC54OTXilvbm1v3Ei7SrkH868w0T4w+JbCRBdTJdxr0DjH617Lomr6Z4+0RdR00rDqicT22e9Y1MNOmi6dOWHu5bM7nw5qUItUXPOMVo6ndqmmSyZyOAa8yRrmzkKMGRhwQa6W0uzd+HLuLdmVRuArlZE6KvzIuabcIeegNS6nfhYimVw3cda4ePU5EQKCQanineXBds/jQzX2Oty4SBITnjNXdIKxyyPK2ImGCcVn26edMqDoOSfapp5NzhF+4pwBSLa6GjHLFC5dZCVz6daimvIix+RivYCqa7iMKAaR1PGPrQTy9y0Ly3H3om496eIYb5wls7Bv7jVQMb9QBjrmq8kslvKsoOHQ5BFND5ex21v4bi8lPMB3Y5oq9puuQz2EEkhAdlBIzRVe8cLnUuea31thicc1kTA+U6seneut1S3US/I3y+lcvfxsHcqOD1pHpQlc9C+Gdyr+GJY+8bGtaNyBnjJPWsP4dRKvh2Z+pLc4rcJEgLKMUodTzq/8Rle+uY4o2kkk8tVBLEnoO9fM3xe8dHW7yXTdMdxYxnlg33/AF/CvUPjRr8um6H9khGJ7s7dw6qvc180NbPIzujjys/eJ5PvXqYWkvjZ14Ojp7RkIAWNW2lpDyvoPrUbMWYux4PJqV2RVcJv44BqLbyoJBJ/SvQSO59hzyO+MZbIwAK6/wCFPiy98KeJ4ZIJYzFKRFIkhOzBPU1ykJwjlTt2jkgZqOJTyyn5gQ2aiUVJNMUoc71dz74t2320UjOGLqG3L0qUnzCcjtwK5b4a3smoeBNGndyzG3AY+uM11Ee3cpByTxmvDkrOx4M48smux4n+0hfSW3h20tFlZRNJllH8WPWvnCYMTuYEZ55719JftMWb3Xh62mijG22k+ZvQV82OzyKAW4UYGa9XCWdM9fCNexshuc4J4HqKkaJFiJHHcH+9SMoU4J3DGcLUJJLew7V0m0pcq1V2SxzOiFQcBqSJWfITpjJpmTgZPSnIcMTgdKdgi7tXFCEJu4wenvXefCHxY/hzxbbmZj/Z91iKdCeOehrgm+6PmzUisCmFB8wEHdnpUTipR5WaNKScLH3Rbf6NKpBzE3Kn1FbwkVo92QQBnFcH4FuJ9R8B6LPOzPOsABc9wPWrM2s3UUbbIiyjjOK8CceV2PGlTcnbqhni+5xtXoOtSeDVWOzklYfNKdoPpWXIZtXkAdD+XSuj0W3FrGE+8ijkjpmnFF1WoU+XqaquEIUndj8qGmOQBzmm52ITjg85qpf3kNrEz3E8cKdQZGC/zqkr7HGWGkAJySc9BVXUNVtdPsXuLudIYk5ZnNcRrHxS8L6WGSW/a4lB5ES559M14N498caj4k1Ztz+VZf8ALK3B4I9T710U8O5vU6qOEnUfvKyOz8dfGmW4klsvDwaKMZH2nu30ryG+1i+vrl5Lu6mnZzzuc1QZipfK4bP5CgbXLc4I6ADrXpQoxhsj16VOFJWgW4Z5VfbG7ZHJwxru/AHxJ1TwteoJJZbixP8ArImbOPpXnKCTf8hYHv7VatW+zu3mKrlhgZ7UqlOMlZo6LKonGS0Pu3w7qtvr2j22o2T7redAw9vatRAVTBHNeO/s36u994Zu7RjlbWQbABjAxXsh6DnmvGqx5ZWPmsRT9lUcCtdy7AAOT6VmXVwIELvwOpz6Vaun+YsOFXrmvGPj54rvNL0qPTtOk8ua6yZHzyqe1VSp88kkTSpupJRRgfGrx+l1CNL0O6RULlZ5kPP0FeDSn52OSTnr60+WWSRzvYkk5PfJ9adIym2RfLXdn7w617FOmqcbHrxpxhDlj0IjlgOgHoKfB5YmXzgfL6sB6VER0K+tPVG8svjIHHWtCot8w+5eLzm8hWCZ4z1xXq/7PWrCDxbFp4QBJlIPqx968iVm3dBx3rvfgxDNP8RNMMJ+ZX3MfasqyvBg37SEr7H10NKtLyZ1u4VdcfKw6rWXJ4VlsbiR7CQSwuCGQ9RXSQKQ4xjmrnavDlueNGrKOzPF9T0i6s7txJbuozkEDg023ilzhUb34Nezyoki4kRHHowqBbW3TlbeIc9hU6HSsY7ao82WB7LTDNICJJDgcVFbIzuK9E1jTo7+wkh2gOOUOOhrg7NGt7jZLwQcGg1pVudN9Ta0/STKM461pJoK9XYfhV7TpFWFdvTFXiwAJz2/Kkcs6srnPXWmRQqWOMAVxOryL5z+WBtHFdV4t1ZYVMMTAE9awvDOiSeIJ/OnLJYRtyehkPoPahK500m4x55lSykma1jKJKVxwQDiivTY5tPtEW3VYoxGNoUDpRWntUZOv/dPNLm9Mp24yazrqOVkY7D6ZrUJtLCMNc/6w9hVKfVXmf5EAT0NZpncvJHTeAt8OiXkbN8pYY/KugmZVgGQVAGWIHQVzfh7V7aOxa1CbbmRgw9Ki8fa/HpPhS9mLqs8kZSNQeSSKumuhwVYuVW3c+fPij4jbxF4mvVilZLe1zHDj+IDrXnkJZZFPIAOcVZlkdfN3t87tkk9SarZYg+uK92nFRVke2qaglFdDWisVnMtxM4RQOF/vH6VQuI2gwHXG7vipbJo5VKzTbChyoP8XtVuR7ZpvLnVzkEluy/Smm09SPQy3ZBGFiyFPUe9OihaSDz+AisEI9ajRN8hjTO4tgE+lXNNV7jULO0YcecowO/NW3YaufYvw1hFp4K0hANqi3BIHTNdLCS5DLjHaqejRNb6ZaQgDEcSjbitFAFYbRjNeFN3bZ8/N3k2cx410aHW9JurG8zsmQrgdQexr5D8WaBfeHdXk02/j2iNj5b44Yeua+2r6FWbGTux1rgPiB4Js/FFjJDcZSZFzHKByrV04at7N2exvha/s3Z7M+SlAViScY44pAhJGAWzziun8S+Bdd0C4aO5tHki6rKgyCKoWChEEYmGCcONvzLXp86avHU9aHLNabGbcIqhSrbnxyMYAFQEHAJBwenvWm9sj3MiLJ+4U5L461DciB8FcvgdVHApp30G431KYwSPTvWlplkk8VwWJyigj65AxVONUnmCqNgPAA5ya9C8AeBNUupoL3UEeHS0kDncMeZjkVFSair3sNzjTXMz6Z8BW3k+GNHtmAjRbZdysa6hf7NKlI5bc+2c14prPiG7uJHhikKIPlCqcYHpWIi3O75J5lPsx/OvEqas8xYSUvek7XPoWeyha3byFj+qVkkbYgvRV7DjNeU6Vrl5pjh2upcdCrMSDVb4m/E4aXokcenlRf3gITnmMY606UJTdkZVMNKMkk73Nf4l/E638LxGCxK3WoMMBP4Y/r/hXzr4h8TajrN1JNf6hNOz8hQSFU+gFUbi7kulWW5cySs+5ixyWPvUd2gD+YFQE/wDoBXrUqMafqevRw0aC037lIjKZH41Mk2ImJVXOMAnqKlSIPBuYgueMelJYLbiRxdHGRgE9M1vdGliq8jMT79RSq5jIZNtJMFRyI33jPB9acSsrqGAQY5IpmUW776ji+SW3c96Xd5jbwMe1RD75UYIJxmtXQtNm1XUrfTbdGaeeQIgUZ696ltRV2dFN31Z9Jfsx6fJbeEr28kXCzzfKfXivZ3BaDGcE/pXPeDNDj8OeG7HSoM/ukG/3bvXREALgHPGK8KtLmm2fO4mp7WrKSMS7k+Rl2kkcD3r5A+MeqXGo+OL9ZpdyRNsRR0Ar7FuU+RhwpOetfFnxKtjbeMtUU5z5p+tdmCs5M6MAryfocupKgkcZ4pOuO1Ic59hQxJUAHgdK9I729GOdCm3kHPPFJg8c8+lNDNjbnp2pR7elO5MJai98CvVf2dLBrnx2J1BMVvEWY+9eWwybASPvdMGvqD4BeGW0fwv9vn+WW+beARgqoFc+JmowfmKvUUKTd9z1+1k3SsSCMfrV1A7DIUkfyrktQ8X2Glh44Ea7u+gRfur9a5LUNf1nV5MtM0MXaOI4ArxZbnmU8PKeuyPXG2KCXkjX6mmKEkJ8qRHP+yc140tjNL/AK+6l98yH/GpoLaa1kDWl7IrjphzUmv1T+8evlSM+3Sub13RTM5uIBh+6+tZ2heJr23fytWxcw9pB95a7SGWK4hWWFg8bDINBg4zoyucTa38tr8jggDg5qW+18C2Plk5I64rqbmxguAQ8a56ZxWafDenux3RswPOKLXNFVg9ZI8/sbK48SaqLcZEX3pX9B6V6Bq99b+H9LWC3CqVXai+nvU6QWXh/Tria3h2IoLH1Y+lecXd9PrN61xc8AnhfQUPXRGq/fyv9lDZb+5kkZyW+Y56UUyR3DkKVx70UrnWkuxltI9zK0knc/KD2p/AA3Dn2pIon2KCO1XYNPklIwpANOWjHdWMm6LqjSh9pUZBrxrxh4yvNU1T7NczYhtGMca45P8AtGvZNQtriWd4du1U6D1rnNQ8DaZq4dryEwzHnzYztOfU124eUaSvMzcryTj0PH3VJFVmbdK3YCo7m0eGNXfjd0FbPiLw1qHhzUfLnXzLZ/8AVXC9GHv71j3pl8tBIDx6nrXpQlfWOx6SmpxuQNKDFGgjUFf4vWmZcJsJG0803tinRlQ2XBI9jWhhfmdmKhG4bgT2zXZfDOGK98V6TZxxAzPcAlyM4UCuPRkEy4BK9ge9eyfs66D9q8RvqvJ+y/KUx90msq8koNsdWahTlI+lbT5VAJyBgVPnDA43c0yNVRflOT1qS3xI5z2rxG+p86VrrLTHA2+9V5Y1Ztv8WM5rQu+MgYJI4FU0X5DuHzZ7U0wRk6jpyzRt56JIpXGGGa4XVfhroN6JZPKNnNMpVmg4z9a9RjQFWD9fSo3t0OQRkY/KrjUcdjSFSUNUzwqb4MRrdpLaamy+qtzximQfBaZiYrjU41U5ztQgt7CvcYreFdzlNp6ZPelaIMUJT7vAJOK1+sT7m/1ur3PMvDHwr0LQgsslv9ru0bcry8gfhXSeK3NvYCMOFQLwF9fSuolVYopHcHaik/WvM9Ru5L0Nv6FjwaiVVv3mxUlKtO8nsZNjbbsM/OefrWoYMJ8y5HbFWNKtTK4CgEZ/KujubSK2twSAeO/auY9CVSzscRcQZUhwOeorw34jxSW3ihUkBMe0Bd33ee9e/wCpbWJ2EDNcR4+0OHWdFI2f6VGcxNnHNdOFqqE9dmKcXKPmeNJKFkOCTtOPyqwqrPZyyb9siHO3PUVBJp97ZkxXltNDIp5DLgEetO8iSDl0ypGQR0r2t9UdNGcpx94ayyEKVxhhkc0+GWNbV0AxI38R54qIbvM3KDt6cVJBbPNcrFEjzSucLGgySaLFS7sroMsoAyc9PWpxGju4bCY5Cj+VeqeBfhBPqKpeeIWktLfP+oXiQ/4V7Hpfw78N2Lq8Wmo8gx/rDu/E1z1MVCDstTieKhT03PmXw54T1nXLpRaabPIrHG7G1R7819IfC74aWng/dqd6yz6kRgMekQ74967iygjtYSsSpBGnYcACsDWNVOoTC0s5M2p4kccZ9hXFWxMqmmyOeeKqV/cjojdj15fOYJGZAvfNbNjqlvd4XIikP8LVzOnafsiB28gdKWe2dEyOPT2NcL1MnSg9EdFeIwZsKCD6189/Hrwa7Xra7Z2rSRuu2URjlT64r3qwv/tFukU2fOQYP+1T54klR0dFZGHKnkVvRqOD5kRSqSoTufBTKzS7CNj56HimzCTfiVfu8ZFfVni/4TaBrkhuEhe0umOd0TYU/hXHN8DFVXC6k+WztVh0FenHF02rs9L63SqLV2PAlBbCqo3E8GpbW2muZhFBC80h4VYxnJr6H0f4FaZDzqd5NK45AX5R9K9E8M+CtG8PhTZ2UayD+MjLD8ameMgttTOWLpw1jqzxL4bfCSe4uY9Q8UKYbVfmS3/ic9s17N4rv/7KtLbTbMCN5lwAv8CDiuwisFnuEaQcZ4Ga898YzfaPFVwcfLCBGox0rgq13Ud5HLGTrzV9kZtrbgZdh8vc+tW48yMFjGFpG4RYwRjHatXTbJXOWIGPeubc7ZSSRBFYluTk0S2aqvTkVsL+7faoBxVa8cGRj0pGam2znrgGI5RmDfWuz+HmrGfztPuP9YPmQ+o71ys6hmJq34YJh161eMZ5wfxql2CtFTgz088GkI9Scilc4OSeKQ8D+dI8ooa1CZ9Kuo+N2zOK8uszsn2njBxzXrzqCrAgYIxXlniCwfTdTkUj92x3KaDtwklrErTwfvmyueetFPiuAY1JG446560UHZqTW8SqRkZIPSt6xVDjAFQ65os1pqTXEA3WshyMfwmoIZfJbD547+lEl1MLqaujR1LS7W5jEjDDgYytYGoaakaAQrge9bf2oMoG4kHp71WupYyMZ5oUmKF4sxrPRlvopIr6FJbU8FGGfxHpWPr/AMEdIvv3mk3L2shwSG5H6133hOJ5Lpw+TFjn0rongaNsqNy+3atIVpR+Fmc686U/cdj438ZfD7WfD95IHspZLUE4lRcgj1rkPIkjYF0YfUV95zJFcRGGVEcEYKuua8p8feBfDkm+eRfJmP8Ayzj4BNehSxjek0dVLHRk/wB4tfI+a4LN7t4orGN5rh2ACqO/pX1P8HdPh0Dw4lpLsTUJyHmUHocY5NcF4U8N2+iGRrPJZyTvkGSPYV0KLLC4kSVhJnOQe9ZYnEqfuxLr3rq2yPZbaKcuQw2jufWr8aCNcD6muB8KeMZopEs9XBeI/Ksw6r9a9BIHBByCMgjvXA5Xep5VWnKm7MiZAZMtjJ6U3ygWOKmNJnnnjii5mUJEKyHapI9fSoiRj6djWn198+tRNChB45P6VVwKLxCTnJIxVa0sZkVtztKWbIJ7CtaCJQPVe1SjCqQuMU+aw72MrV4mg0W6lKl3RC2BXkjTwTHejAAn9a9xwpBV/mVhgj2rx7xp4Vm0fUnuLQE2MxJUgH5T6Ghe8rHVhJpNxfUbpV+toHJILGm6jrD3KkEgKPesJQVypBBFIQSD95j0+lRY9HkV7kk02fqPetjwZ4bk8RahvuMrZp8xOOtRaB4YvtYuUjCFISckn0r2TSdOt9I0+O0tQMKPmb1NUvdOfE11BcsdznNR0DTpk+z3VpFMmNoJQZx9a47XPhL4bvRvCSwEDGI+QK9adFccjiqr2WR8vJHPPStI1WtmefCrOHwux4fH8FPD8MTM1zdSqTkcAECuk8P+GdC8NsGsraFWA+/Jhm5q94t1adLhrWykVY04d1HJPpXGmWR3ZnL5Pqa0lXb+J3OuMK1Ze9LQ9Nt7m1bc73CbccAHmrM19a26qfNG31z0ry+2J89Q2cfXrWnNIZplEhJCjAHpWLmmL6m09Wbesao+oTNBaMfJbhiO4rW8OaKvyuy7UXoMVzmngJJuXBx+lejaFtfTUdR1PNQ3cKv7qNok4gVVG1eB3qpcxBvl4weuK0nUY9BVW4AUHuTUnJGWpkpB5c6Y4UGtiUKpGASxFZV3IETI/nWta5a3jd87iM1SZVRdSsqGRivUCpGgyelWgg6jNSDp607mJQEB3ZYcdqnjt1zkj6A1YPI6UevFK4XEXCkFexrzPx/pzWmsm7RT5M+DkdAa9M9s1U1Owg1K0e2ul3K3Qjqp9RQjWjU9nK55cU2iOQcqR1FatrKoTkgCrT+FbyyhkjDi4gzlSvUD3rNk0fUkXdHA7p7UrHoe0hJblqS82phSM96oTTmQnrnvSjT75vvW8yn3FX7Xw/fTDPlFR3LUcoc0I9TKbIHQmum8HaWxuPtcq4ROh9TV/TPDMULbrwh2HO0dK6NFVEVEAVRwAB0p7HPWxCa5YjmOeo796bkEUuevPFID07e1I4hD1yB+FUdW02DVLUxXA+jDqpq8eD1/Gk/DigabTujgJfA915jeVOpTPBJxRXeHJPAGKKfN5m/1ifcHQOgBGQRiuX1nQJJH8y1bj0zWtoN813Zqzn94vWtLse2KzjJivKnLQ4KSyvIBtaBjx1xmm2+lX2oMBDblRnl34C13+CQc8+xpwJwOy+1Vcv6xLsV9Os47CzSJCGYD529TVrt2pAOlO6elCOdu+rIZ4YjFI8ny7VJLDtXjuqCe7vp7icnYWxGpPRa9Z18n+y3UZAb73PavL765SeVsDCDgCrTsjrwkdbmYSx4T/wDVQEmJ9fX6VOFyRtGa27FbWK0JkcGQ9faoud7lZFHRirSeTcIOeM16porMdOjjYkmP5RnrivMbYI98hjHVhXqlrF5Nso74zR1OLF2sib+P+lZOteILPSj5bZnuT0jTnH19Kp+JtQuLDTnuLf8A1zHy0z296wrGyDxedId0j8szdSau1tTnp0lLWWxqf8JdKkgM1gPKIySG5FWk8W2Ei4eCdAevBqpHYLgGRMqe1PfTEKY2gA/pUmrhT7HR2c8N1bLNbPviPH0PoRTTDI0gJbHPaua8ITPb63c6e5xG67gPeuu7Youc848krCdOvXvTZY45YmimUSRsOVIyKeaTOeQKDM5688H6Tc8xq8LdcA8Uln4O0y3IZy0p9Ogroj/+ujtjtT5mae1na1xtvHFbxCO2jCJ7d6cSMc80g5A7dsUentzikQHVvaud8a6+mk2otYDm7lGCAfuit25nW2tpJ5OijPFeR61M2o6jJMCWZjzTN8PS55XeyKM9xJKSxHX0qFFXcSeDV6G0kK479hTpLZgPmXGfapPUTSKgIRlPQVcPO1hmqsiFQcjK46GprV+AOfalYdy/aHbJ7Gu+8ISt9hlRjkA5xXAW+cDjvXZ+D2ZZJCTwwximcmJV4nUMQV9jVS6+7kEVYdgB149azNRukSM5NBwwTb0MnUXCsMdM966qHBhj442jj8K5bToPt16A2Sg+Zj/SurHQAcAcCmXWtpEOMj+dKenvR2oHp6UGAHpg0nXtz2pe/tSdBkdKAE9ec9qQZxgnntSng/Sk6d80DAH9fSjPTBP0pP8A9dHGffvQIdvOMFjk/pTWJPfPek7H34ozx2/CgYvfP1oHP9KDzmkPU9+1ACnkUE8dqb754HFKOlACknOBTSaOpxnrSHp+lAC89ioH1oqpKrGRiMgUVN2Oxh+DWJgfB3epPaul696wvBlrs0oTH/lp0rf25Azz1qUbVn77EHb9c04dcjqaMfjSgcVRiKBjOad746UgGO3NOx70xFHW4TPo90q53hCQfSvFLaRnwCeQcV70gySrYwwIP5V4vd6XKmt38Ea/KsxwParWsWjtwcrXQyNRjJNRTykttTJx6VrRaBdPjBxVy1tINOU+cm+brUWOxzXQqeG7K4e+gPlsQXHb3r1uQBWKjoABXnUWv3VjIr28cJx/CRWnD46jbAnsGDnupyDR1ucdeE6jukWfiCMaRaAcbpx9BUOleW8QTIZ0xuAPWpr/AFKx8QaNNatFIjtyAR0PrmuU8l9BQXVtNNO/R1YE4qt0FKL5eV7noIAkQKABiq1xMIkY+1Zuk+Iba/hByElxypqpruopHtSM7mPUCoREacuazINCvFbxnCw5LZUmu9PBIz0OK4TwVYm48QG7K4jhG4nrg13fUk+pzVPcjEWUrIBQM45o9h1ooOcB70gzznGaWigBMY9qaeB0OafTTg8g+xoA53xxdNbaMApxvPPvXC6DEJrkGT15rtviDbmbRVdVJMZ7VxXhyYRzDJzTex6GH/hOx283h1XgEkGBIR0rntQtZbdjHLHyvtxXoFjMs1rGykHjFLc2tvcRublV2KMsx7CkncwjXlF2Z5JchQpIHsap2mPtOw8A8CtLXmtVlkaB8xgnbWn4O0FZo/7R1BhHbLyC5wMUWO7nUY8zJ9I0G5vFlMfHljqRw30rVsfMsVYFdrL61pHxRo8EO1JJGjTgbU4NZ83inRLuQLIsqKerbaLo5XKpN6x0Lb6gXwMVWjtp7y6UbWEfcmrNq+jRN5yXJmTqOPu/hWla6rptySsF3Hleob5aV0ZtuPwosW1vFbR7IVCjufWpAcL7U2KSKcnyJYpGH91smnc8Z/Gg53fqA9OMUE9j+NIBwPf1o6d6YhfT0pOCRzz2pTjnANBHbqaAE5wKM8Ek0H69P5UfhxQAnPXpnr7UnTHTpR/+ug8dvb6UDEz+XejtzRnA6ck0nTGKAAnr1/CkB6880ck4A57YqlfanbWbbJJVaX+6D0+tLYaTbsi7n+XbtQzY+ZsD3Ncle+Kp13Lawop/vEZrDm8Q308n+ktvT0XijU3jhps7ufWLCBwk10obmrNvcRXSeZbyrKnQkdq84ubZLu2+02p3BT86nqKl8NakdM1FScm3lO119PemkXLDLlvF6no+R3XJ9aKkUHaNvIIyDRS0OQ57T/FejyRrGZRAFGFGOBW/C8VxEJYJEljPRlPFcLJ8ONSfP76x5/23/wDia1vDPhXXdEuwVurJ7U8PH5j9Pb5alxa2OupCla8ZHTY4pwHX+VWjaNk4K0fZJPVfzqkchWFL2qx9kk9V/Oj7I/qv507AVx1FcH4nvYrXX5xaRiSTA3MOgNd9d2l19lmFo0SzsMKXJwP0rkf+EL1Igk3FoXY5LFm5/wDHaaN6DineTObOq6kfuFVA9qUXq3X7uYBJT1kroD4I1LacXFpn/fb/AOJqOPwLqQbLz2f4O3/xNKx1+0p9zFOmgHBYsCOtQS6Yy52MRkV29p4XvoogsslsxB4wzdPyq1N4cmkXG6Efif8AChX6kPEJdTz+Ce9sSGQiRe6kda6jTZbTULQXMSFSPlmhbnaatt4SujnEtvkjH3j/AIU/R/C99Yah5zSWxjPDKrNz/wCO0NdUTOpCSvfUzb/wgtw/2jTZRAzDOxuBRa+D3O0396CM8hACT+NdubR+cFcU37HJngoPxp3Zz+3na1ylZW0Fjbi3tE2xjr6k+pqYVOLOQd0/M0v2Rx/Ev50jJu5X60VZ+ySeq/nR9kk9V/OiwitRVn7I/qtH2ST1X86AKx7U1sdPWrX2ST1X86Psj+q0WAz723W7tJYH6OuBmvJb+0n0y+ZGQrhuPcV7T9jkGRlPzNUtU0CPUYts4TdjhvSqXY3o1vZuz2OB0fxK9rHtbkDjFV/EPim4vYfJaTy4O6J1b6mugfwDMGPlTwbe2Sf8Khi+HMj3Cm6uITEDyEJyf0pcqOnno35jnPCuhvqjvf6gRFp8PJLcZA7UviPWm1mVbS0zFpkPCovAbHr7V23ijwxqN/Z2+n6VJaW2nxj5lZ2DMfwU1jW/w/1KIAedZY9nb/4mk9Rxqwk+aTOXihYphBgY/CmPZFiTzXeQeDr6IY820wevzN/8TUq+Eb0D/WWuf95v/iaCvrEO559Ektq26MnjqOxrSMMN5YtdQIFZeJABXUT+DL91ISW0yfVm/wDiaNK8HahaJcJLNaFZFwNrtwf++aAdeFr3PPoJri1uPNtZnjcHOQa9Y8P6g2qaRBctjzPuyfWuX/4QDVSw/f2OB/tv/wDE12mjaM+m6ZFbK6Fxy5GcE0W0McTOEkrbkn1z/jScAEk4GOp7VZ+ySZ5KfrWXrWk6neAR2s1vHDjnczAn8hQckVd2ZHdatZWx2yz5btt5quNfsn+6X256kVRXwXen/WT2x/4E3+FWH8IXW3CS24/E/wCFFmb8lJdTXt7iK5XdDIrr7VKevI6dqwYPC+q2riS1ubZXHq7YP/jtdHBaXfkKZ/I88Dnax2k/XFGplOMV8LuRYOCc8Z61Vmv7OJtsl1EG9M1l6poHiK+mZheWcadFVZH4H/fNZQ8A6oWLNdWjMepMj/8AxNFmXGnD7UjrY54ZT+6mjb2Bp5BHXjNcivgXWEOY721Ujp+8f/4mt/Q9H1q0cre3NtLD22uxP6rRZhOnBK8ZXK3iTVxpluI4+bmQYX2HrXC20BklaV2ZnY5Jbmu513wpe6jftcRzW4UqAA7Nx+lV4fB1+n3pbQ/Rm/8AiaEjalOEI76nNNb5yFHbmqt1abACB/8AWruE8KXipgy2+c9dzf4UsnhO5dMGSA/Vj/hRYtV4rqcNpUn2W/j7JJ8jj1BqPUofIupY8YAOVrsJPBN8zKVltODn7zf/ABNLqPg3ULqbzEmtBwAcs3/xNHUpVoXvcuaJqyjSbUSEFggzmiqkHg/U4olTzrP5Rj77f/E0VpaJyuNNvcSG+vVi3NczbNx2s8rc8fXpVqG+uSo/0mY7COS7cgfeNReWXCPJsDrggFcgf7IHt1pHLF23s/zsp80nA47Af1ryqcpNI1nFJ7E3266zgXM2QrZBc55OR+lSJdXJIb7XKyq25jvbr/h/WqsOZTGjB8MxBCnPGe59ParbEpgCMKRllxyPTHua1Te7MnZFgXc8ZlaSdgufu7yeO2PrTmupgVxcMo4bBck7R1qtbbZVGyNVJb5gxyUx0GKsxKuAwRVbJAxzjmqUuxOiLYmlxkyuQBzhulPaV/L4lfOAMhjx9agG3I/u+3epBtUvlmGB8r47e4qk7kNDnlmGN0kgHc5xkdqW3klkmVPNfBPr2phXKx5VmAyePT+lLECksbjgZzx2HvVXaEfOXxD8Za//AMJvrMdrrGo2sENy8CRQXToihDt4AIHOM/jXOjxf4lJH/FRaz/4HS/8AxVWfiZZS2PjzXI5VK77p5k4xlXO4foawrGLzJOoC5Gc1u3ZXLhTdSfKuptJ4p8TtwPEOtE/9fsv/AMVS/wDCTeKim9fEGtEZ/wCf2X/4qrEP2WCJsgSOeAD0PtXVaF470jStMEF7osMjLkYRR83HfNc6rSb0R6VXAQpRvL/L8zhv+Ew8TA/8jFrPH/T7L/8AFV7x4G1668R+GrW7+2TfaYh5EwErcsMYZue4r5xvJFuL2aWKNY1kcsqLwFyegr1z4Cy21rFr0eoXMNuGWMqs0gUN97kZ64/rVV72TW558Iu0kldHoz390rsi3krEjaP3jfMfXJqKTULwKVS6naQjJAlb5Pbr1qvqHibwrC+LjV7QNgKojcNgZ9ulaNtYx31vFcWEiXkDsXWeNw4fJ9R6Vg1Ld3Bqz7EAur1oiBe3W5gAg8w5LfXPSpbO71Ah2ea4MaH5gZGye23r+OaxfEXizQfDKGOef7ZcAFVt4SGPJ5DHPHNcFqHxg1Z2B02wtbePsJV8w/nxVxhJ6j5W0ezLLchdjXk7S8gFWOcjqMdKklluH4a4uIjhQvznr6GvIdN+NVzFGU1bRbedzj5oH8rA+mDXUaV8W/C96wS7ivdOc/xOvmJ+YOf0rRRkZuLvodc11exbC80u4/OVLnOemPp3p4vLjy8tcTFgoYksQOeNvHf0qfTLuy1i2Fxo97Bew9GaNuVPoR2/GnNbKVfAwM5faep96SunqJ+aPHPHUHivQLyS5tNd1ibTmwwP2yQmLPUN83NcvJ4811l/5DOo7gOCty4GPz619CXNhHcwCC7jQpgjG3Bx6D2rmLv4YeGbtwwglt9xyfKY4B/HNNu+p10sUorla19Lni1x428QtEca9qoboMXbj+teifB+18V6rfJq+r6tqx0mHIRJruQid+g+UnlQep6frXS6V8LPDWnXjXT2896c/LFcNlFPXO0Yz+Oa7hgJBGflXC7RtHHHYCjm6GNWrzO4sk8pC/vHDAnPPFM86YkfvH9PvGnDc6gBV+6cD0+nvSbCAeskYb+HjJo8kc9waWYEgyP74Y1B5lyXAM8gjBBUhjk+xqZ1ODtA+X73GDk9qaVG8KhBz396d2gKOtRXl7p9xDb3s9tJIpAljlZWX3GDwa8L1PUvF/hjVxHqWsau8KyfK8l3IVcficV9BCNssMZK+9Zmu6LZa3Yva38IdGHDfxA+xpa2NqNRU5aowtM8XJqGmqy3jrIY95xOdwI9ea8s8deMNUOoM2m65qsSk/dS7dV9OADWlrfwz1nTCZdJkFxCThMNh8VzVr4B8SajfLE1i8QY8vIcKvvTjdtHXL2Sg3T1v+BHp3i7xBPY3tu2va01xtEsLLeSE5U/MDz025P4Vm/8Jh4m/wChi1n/AMDpf/iq968B+DNP8LWryqyXd/Ivzz7TwvoAaZr3gTw1rQMtxYNaXL8iay+T6bl5GffGapSs2+hxzlFpLt1PCP8AhMPE3/Qxaz/4HS//ABVH/CYeJv8AoYtZ/wDA6X/4qu+m+D+ZJGi1uJIl52vAxZfyre0T4V6FYn/iYyz6jcJy3PlxD0Hr+tU5JEcq6swfhaPFGu6kL2/1zWP7LtzuffeS4lP90fNz717JNeyCbK3UgzyAWO0e3HWqSn7LZwwWkawCIqiRqMKAexH+c0gR93loBkZYDPCnuR71lLV3ZXMtkPa6nGAlzc4KjG6Q889alFxdu7k3UoOXwQ5xwOOOmKqAYQZLLFGNu0H5sk9Pf606QLluinOxYguc7e1J3X9f1/XTcRN511KrKlzcnaMbhIRknnPXtQ9zNgtHdzHfhoz5jYPYg81Gx+UfaGGSpJX+77++KTEjJu3KUHKkdB7D396P6/r+v8x3JnublQf9JmHzlclz09fp/kUj3Ny28LeSnCgAq5AHqT7D86h2Es8aElcBiRwB6KBSbA2VbALg8D3659vane24icXs+QTdzZLhgu48DGOfami9uQIwJ5iMFRukOT7nnrUWVId5Jei4OB90enuPal2ockqwR9u0kZOc8nNLX+v6/r1GTLeXW9QZpssBtAkPP61GL26/dgXUxZwcBXPQHk896YwU7igCqXKgkbj9T657UyYEblCLGgGS4GRGvfB9SeaNQVn/AF/X9epImpXu0eUzlOxklbd+PNFU57C5nmaTzk+bn5W4oqOX+/H+vmUmn1/r/wACL8xZZDklnBC5xj5hyT+VVbhmfzEB+csXTJ3bl9R6VpTREidl2Mw/idtuPz7CuT1nxl4b05CtzrEVwwxmG0UuWPf5gMAe2a54Rb0ijZ2aNeFikTNGz/6sv028g/qKsKoUuokIUuDEM9OPvZ9K4Nviz4dSRHTTNRkIOMlkGB9KsWXxQ8OXD/Ol7aueGeQK2R+FX7Oa6CSTdl+h30aKJXcBnLHEjAY+70q3F1YbAqH7vaqenypdwRXVnIkkJGYypyMdz7muc+Ivis+ENN027htYJZLy+Sy/0iVo0QOGJkYqrHA29gTg1UfeZElY7hD5eCNrq38PenxksQqtnA5LDkg+1cv8OfFDeLfDsWpvbJAzyPE0aSiRSVJGQcAjPXBANdOvPXawGADnoPQVfWxk0OXqCqlt2QWztwo9ai4+YxyADHzc9R6D1qdvnAbbkk7FAPGO9NLoWZdpChslGGB0qk7EnA/FjwUfFWlx3emoP7ZslwE6GePun1HUfUjvx85sJrWV45FeKRDhkYYII7EGvspcgb3O7avBBxtz6964vxp8PdG8USC4nL2OoHC/a4QGEmP768Zx68H3rSMujKTs7p6nzQ08hJJY/hTPmdiTye9epar8FdbgZjpl7YX6DkAOY3P4Hj9ao+HfhZ4iuNXWDUbE2kIOHlkYED6YPNU2oq6LinUklOWnmzzwNtPy0hZmxljwPWrmt2J0zWb6xZgxtp3hLDodrEZ/SqkaNI21ASarTcj3r8qG10HhXxbq/hppU0y8eK3nGJYuqn3Hofcc1s658ONS0TwXFr9/PAhdkzbEneobp7Z749K4aiykg1g7npll4Jl1GSK7i3PBcjzEkPVs/wBar+KvC0ulWe+5i2qOpU52n0r1z4VAyfDjQ5WA34kAPUkByP6VxPx+1yJFtNGtWXzBmWYoeD6A+9ckISk9T1frzu1yrl66HiznLHNJRRXYeQ9dTV8N+INR8OalHe6VcNFIp+Zf4XHow7ivqfwtrkPiTw9aavZ7E81dssfUJIOGB/z3FfIde0/s7am9udXs7iVVs5AjoGPSTOOPqMfkKzqWSuzSCc1y7nshJXKqQ+0Z+YZJ/wDrUqlS3QFS2d5OF6dKkfefuHCAAEdzjriowWZvkGwkEgt1f2xWSM7gmflZclyfmfOfwx7UBlDYUruAI3ngY9vepFzKrfLgDGOcbj3JppYMMgk4wo2AHp0zTuSK5iyrPkANngc49/ehgSrZwrvgt2Cjt+NOOS3mLkbjkLxk46mkO5ckp3wUzwWp77gNwGxtYjjLMw6j1qNVTYMDKcnLDG7HSpNxyPM5lBOR05pGIJDcA7s/Kcn3xR6AR7TGWYOA69s8Y9qYq5PYcdTU5dkPDKecKR296YGfeVXa5UfK3bFAyH6f4VDcSeUqlnb52xt67jjp7VOWyrcDJ53elZOoTrFKzSsMx8qP7x9B7U7XGKk8TkbkCO4UsVfAC545qSVgqzP5v3j8z9MgdFHv71xus+IgIgsaqkDfuXPbI6Yri73ULjYjXmqRw227y3eVjnb6qo5JHsK6Y0HLyNOTq9D1S716xilKeYkmXG0hs445ye+KjTxBpcqO63A8lGwM9G/2ia8M1HxJaWd7KuhW5kiHy+dckkvj+JVGNoPvk/TpVCLxVqEdw8oWAhusZQ7PpjNWqVJbyF7tnqfQFtruk3Ue5Lo4ViuTzk9jn2q4bi2Qo32mCLcpKhmxg+v4188r4uu0LGKzsI93J2xt/wDFVr6Z40sWjSPU9OdGAI82CX5ee5VgT+RqXSp9Jfn/AF/XQFytnuu6ICPY8PA2gGTt65pSFDhkUbIxlmD5+YdBn1PevMIru2uIBNZXsdxBtyxR/mUk4wynlfyq/pmu3WkyBEl32oBLBjkfX61nOi46f1/X9eZapX2Z6GqiNB8oaTrh+jBuSB60wkRyFWP7xBuCAYUE8YFY0HjLTpHia7HlArtDk+tb8EsYA8mRJ0I+XHJyf/rVg047kuMk9SEoEQq2SI/mKnhiT3pq5ZH2r/rFKnPG339/epfKEYYM0WQd2ST8pNNVGZYVwkfzHzCSeQe341Kk+grDBIFbeAGk2fu0K4DDOPzoQgttJZ0zzg4Gex+h6Yqn4h1zTPCuni91qQxyyg+Vax8yS44wvoOhJOK8f1z4r65eRiDSRFpNsp48jmRh6M5/oBVxV9hPQ9ta3uv3kzRNkfKQvYdsf403a6Yg8twh6gnqvU8fWvmS58QazczGW41W+kkP8TTtn+dXLPxl4hs4ykOrXeD/AH5CxH0Jp8j7jun1PpKG0aeJZBGAG54baPyor5vl8beJ5ZC7a9qW49cXDAfkDRUPD3d+b8F/kZON3e7+8Z4l8W614jl3aneyPGPuwr8saj2UcVg0pGRnj6VJEAMkqTxW+ysjVJzerIqKVzuYntSUyHue+fAK/Nz4W1G0ly32KYMhPZXHQfiD+ddX4u8LW/ie0so7q6vbV7K8jvoJbVkDJKgYL95WBHzZ6dQK5j4EWclr4Lu7hlKPdXWULDqiheR7Z3CvQN2JVZ8hgcYQ5xn1rzI6Tk492dEtd/IzPCHh218L2tzBYzzzfabl7uae4O6SWV8bnYgAZOB0AFdEhCqinO3OMgcqfaqU/mbcRHGev+z/APXpLeQBECMee56jHrWvXUhq6LzFFX94C53HJ24I/wDrmnMG2sWZyc4BI6j0x/Wo1feGBJ3bCWzzk9jS73ztLEykYyOd30ParMyR9rTDgbgMsfw71AqFcl1DOAG5PGPepUBGRhFUHDMOQx9B61GYz5akpuRDz2JPf6iqQhh+8AqtnrtPrTUkMREi5yv8qkJTzWIkbH8LY/Soupwe9MLs+e/jdoQ0rxe15bxeXZajGs8eBwHwA4+uRn/gVcLZXTWkyyKAdpBwa+nPGWgQ+LPD9xpcrlZ4mEttM3ASQAgAn05INfM+r6ZeaRfy2WowNDcRnBU9/cHuPcVsrTiXGcoy546M3vFnjG+8R2Ntb3crFIei54zjrj8K5WlRGdgqKWY8AAZJr174d/Ck3MUep+KvMt7c8w2Y4kc+rf3R+p9u8+7TVipydZ80tETeFvH/APwjfg+z0wRhp40fay443HPP615RrWoT6pqU93dOXlkcsxNex+KfhO9/LPPoV3FC5BYW8vCn/ZDdq8UvbWayu5rW6QxzwuY3Q9mBwRU0YtK7N8VVpy92ktCNSAQc8/Smk5OaCCOop0ibCBkE+1anI72G1Zsb+5sZkktZWjZSG4PHBzVbHrRQ0nowjKUHdaH1T8NvE6+LvC4ncD7fbHypkJzz/ex7/wCNdLLtOd0nJIwxXn868D/Z4vzb+NJ7QuQl1auAuerKQw47nAavfpCVBVyPlJIJGQTWDVtBz11XUJADuZsDyyONvGPSlJYFFA3Bh8hUYOabk8q3Kk4y/wAueKbGWGFPByASepHt7UehDHBSwkCBOPvEfyHtTiASSH2xkbgFHC8frTMnDHZgjIHGM+//ANaj5kbrGHzkYHynjrml6AOY/u1JDfKo5BGcH2ppyoVCMOn3MdcHuaNwULJiMfKFBz098etNZWMmTwD8uOhYUxAMqW/heMdQepprMCF8zdv9fakPKncpAXgYHX2JqC9uhb20khGRwoB5PtTSGRalew6fbtNOcR54BPOK4a+1Ke/1QlpFt/LXO1yNp9AKg8Sag9zdRu0sRRMjBbK57nHtXk/ivV3vLt0R28pW+Rs9feuynS0uzVR5Y8zNnxPr6xz3W5N8pfbsP3cjuK4e6uZruXzbmRpHxjLHoPQe1JcyvLJmRtxwO+aiq689eSOyIlK4UUUVzkhRRRQBa02+m0+5WaHB5+ZGGVcehHcVvQ6utzlpJGTcAvlgcL6Ae1cvSoxU5HXtW9Goou09vyLjUlHY7HS54rm/kmuZW+zxYXaRwfrW7Y+J5dLmgS3uNlki8o/zEHPX3rgtMLzTeW8+yNhk8cZpbuZSyorE44H09xXTWo03FTV7Pvb/AIJ0wqc0byPoTQPE9lqMKwyTwfaH+bZnJdux9q0dW1WDQ9Eu9Y1XMkUC7BEvAkY8BAD796+bNMkuBexm3YiTdhXA5ya734u6hcv4c8NWcz53JJLJhshmU7QfwGfzrzKtLlat1InGLXMjgvE+vXviTWZ9R1GQtJIflQH5Yk7Io7Af/X61lUU6PaDlv0qrWWhzrVgilj7DrTauRbC820lhtxmqrIR70lK7NZ0uWKa8xtFFFUYk0QBQjv0FRMGBORjBxQGK9DTo1Z/lCs2TgAdyanbU0upJLqMrqPAPhaXxLrEcbK62SHM0gHGPTPqa2/B3gBruaK410tbWp5MRGHYf0r1uwhitbSOxtLaGztFG7ZCOSvufXvzXLWr3XLD7zWNLkd5f1/Xb7zWUJHbxwWsfl2sSBVUAAR47DHf2qwkjPsKK3zKeoABPvWbGAPMOAEC7gFB2898deasQIrSQIXmUj5wp+7+NZU1bRCk76l8hZAVbnHDYPen7cHgctzUduMJkqUJ52E5K1KOp61rYy8iTbJuChSHHAGacqlcMC425Dkdj6Ck2tgZbKN3Hb/8AVT+FdWXCnOAwGQfwoSsDlceGPltzzkNu7DJ7im/eJVizMuSWU8Ae1JgMpIMgKgBSex+lIykI+4s2T1Hf6iqJ8iMjCD5SdxyG9qikAKMGDEHHA61IGYLweWGD9Kafbj0qnqgsRPmOJjlVCAnHY+maq6jY2OpxoNTsLO+2gCNbiJWAyOgYgnFXWXEbAEKSOv8AWoROqTCGRgrnAT/a4p3dwTKtlpWl6Q6zadpFjbYH344VLgn0OM4rRd5C5LfMoHUnLfSoFkXaZFJ2F/nyPufSpJGCJyz/ADDqOw9fwpeb/r+v6YOT6il/3JfY+R/Bjk15R8a/CRu4m8RWET+emFvEAHzLjiQe46H6Z7V6ud2xNjBuQCWHUev1qN/KdQRsbOThxkN2OR6YyKcZcuo0z5BHPU0oYg5zXofxW8Dy6JdvrGmxBtEunyPLH/Hu56qR2Gc4P4emfO623FsT20a3E215Ame5qKRQrsoYMAcZHQ02ii2pTknG1te53fwPDf8ACzNJKgnAmz7Dynr6UmyJWbaWQFjnOc8/0rw39n/Ri2s3WsSZAt4jFFkdXbjj6D+de3v8+GJO7qQO3rXPOV5aFTi4pJir98KAcHLBmOSRikjVyoC7jkZOOwHpQUZmbCg5bGc449qMlS787V4UMOQKRkl2HbRIihd5GCBg8k+/pTWCuu4rxnkg/dHpTnUBsSMN2cF8cc96YVJAU5cgcDGAPY079QFw25OG3beeB932pp3BMg5TPGTyPSlO1QxOW3DoBgLntS5LuHZWdCvOeuB3FGwDZAdxKj5Nw6HIzXOeNbqeG1VYSTvcbio+99K6InCBScYbgHrisTxZZPd6XIINrPF84J6HHWrg0pK442ueS+J4reewlEsrR4JLswwc+39a8wkkLIBwFHAHpXfeOL7fEhhI3MoXk/cPtivPWXaSOpz2r0JSajbuaVeghxk46UUY/OiuZmQUUUUgCiiigAooooAuaROlveq8iqy4I+boCRwTT7qQJcu8jQyEtyIjwR65qhRXTDFSjT9nbQLtbM9Y8KW/goQr9o12GK7lQZR43Cq3puK4/Wsf40RNB4jtI4W8zTVtEFpKpykg5LFSOPvE5rz+uk1DU5dR8G6dZysHOnyv5fqqNyR+YzXHUk+ZN9zqinWUkuiuc3RRU9vFuwc81TdjCEHN2Q23ba5UnaGGM+lMJKEgE1ZniVVLDqDjn0qKQCQF1OSPvZ/nUpp6m06corl6ohJySaKKKs5j2dPDfh5JFf8AsaNiqBtvnOynJxzzzW3DDaxKkVvYQJFFkwhVwN3qP8aNNi0/V0UaPqNnfyg7nWOQo/pwrAcVdMElvKY0jCkE7tx5U98D0ryW5N2b1O5O2xKuJOJiQxGfXJ9M/wBasIsiQmIkbQQTgZ389z7VHB5bD/WfNkfMw+UDvV23O7dKqFlU4Dngr7Y6dauKV9CHcuRsyKxCu2wFd6HJJPTj0q0Gxky/NHGoYkj7pxWDfazBZSJabjHPgOzAfLu9Ca5251yWZ32tu2Md0O4jc3Y59PauinTb1IcWztotQsBMn+lZmKYCk5OM9x600azaG9WJ2YAEhGHIY9815812Gba/3pG3O4HP+6DVlL+F5CDC4QtuwvVif5Vv7JX1D2bR6eksI+TzFDuR0PQf/Xo3hlQoRtB++o61wZvd/mlZBvUBRt5YH0x61bhv5bSOKQvhlPIzwPrSdKyM+S7O5YgH74wSMOF5/wD11HkFnxkvyWYnGRWBp/iItOFvBGjHjchz83fj6V0KSqSJFYOqgbfUn1qHBxdmS1YikaJFY54AzvJwAPesbVdesbAlzMsixnHDYyfTFJ4q1Y6dYF41UzFS2GHDc9MV4t4i8SWgaSWCNWuHfLI2cD/69b0KPPr0GlfU7/VPGImZ0jbZGBw4T1/g965q68SSQ3MLW90XmBAAkOM5/wAK89bxJc+Y7xwwq7Ajcdxx7gZxn8KzLi9nuG3TPvb1NdajQj9r8P8AOw+aKWx7vpHjARrJJeZlCj96T0Le36V1djr9tcQKbg+XLKNwTGcA9K+bNL12ex2rtWROjK3RhXTWGuwNKy2rzjyxuYzY4HpnPbtUTw0Je9FgrS0R7/FOkoUow8nGORjJ9qn2LvB2jfjbu/p9K8u0nxIkthCrTNGkmVErDIB7Yrur3xDZ6H4YuNWuDvW2j+WMHO+Q8KpPucVyTpyi0mJxsS+K7rStO8OX6a/cQxWdzBJCImPzSnH8A7kZ4Pavk2tnX9W1LxNqc2panMZJHJIH8KDsqjsBUdtPYzgLexkMOAytjj8qV+RWWpvTw/Po3btfZmVWz4V8O3/iXU0s9NhLsT87fwoPUnsK1dIh8HxXSnVpNQmhxysTKMfjjNfQHgi00Kx8OxS+FY/+Jfc/N5m8l3boQxPII9KTqXWm4p0HRfvWfo7lrw7ott4a0ODTrM7vLO55CvMj9yD6cVp7SW2Nt+X5iwobKFSBgL0Unr9KjuXWNWZmVQPvMDxis1pqjCUnJ3e48kMz5wu/G0sKfj7oOenIJ9Oh+lc9feIoo5AsETNLnhG6georJu9Z1O4XG4KyuWcgf6xewHpWipMSi+p27kBdp+6DnYv8Xvmm7gVKO7ENzn0P9a4aPUboROTc/uic7sc49D6UttqeowtIZLgMpf7zrjC47VXsu4crR26zAbcjJxjBPXHTihXyAoABIIyegz6VzcetPKI8hBkj5+2PX8a1ycDzUGC/OCfvHsAPSs2raMGi+CCWYrl1HJY/eNV50zG6uvVSCP6VHFKryMEVmyeW7A07cCzorMJCSSTzj3oEjyLxj4bjshLPaxj7NJ/rQ43bfUj6V5tPodwkTT7XEJXMLKM7+cV9L3Vql1E8bAPtUqynqwPXP1rLvNEs5kWBojDCpDKOhAxjAH1rqjiPdtLU0U7r3j5yuNMeDyFkddr8s6jO32qzJ4culUtujA/hDEgsfTpX0ONBsY7dI2tYQRhTuUbdwPJ/EUlxYacsinbFsycFwPmPp7AVUqsXpYTcb6I+X3VkYq4KsOCD2pK+nJbHSmhMhitpPkKmN8Hdz029DWW9n4WvWa2Tw/pzFQNzRRKjZJx1ArJyXS5FmfO9Fe8+I/BXha08L61fppDpdW1uzRgXL/K3QMVzjrzivBqFJPYBVG4gdKlitpZZhGikk89O1dz8MvDthq8k0l/KV8td2CBj/wCvXX+K9P07T/C1/dWUawsIo44yBy244JzWU6jTsjshQirc++h4oyEyFUBOOKaVYdQa0LBAz5PBJxkVd1G0gjtTILlJGJ4VfvAeppupZ2NFg+an7S5g1LbzNCTjlTwRUVTW0YlLr/EBkH6VpK1tTjpc3OuTckvYVXbLEMRv29DTImKKDkfjU1rISHhkyQ3QEUiKI1ZBH5kg7noKzvZcrOtxUpe1hpf8H/wSB5Wz+P4UJHISW+6OpLcCpV8/aCIx7cfrUMxfgSbs/wC1VLsjGSt70r/kSDyD95ju74FFRrbzMoKxOQe+KKqzFzS/k/BjYpHicPE7I6nIZTgivRvBnxKurV0sfErvf6c5wZnO6WL3yeSB6V5vRUVKUaitIyjNx2PqMQwEQXEbxz2zLmF4+RKDyGP4VR1vUY7G1Z1CPPJhk3t8x/AVz/wXvmfwJqImLP8A2fcF48ckAqDjH1zXE3F5/a/iCbVbi6aKDftjjU5IGeh9q5cNTc21L7L/AK+86rc2qOkurm5u5Jp7oo7nJO3jHtXMX/iMW5dVjKyoQ2D0bHaptX14WZeERkq5yDjIYf8A164nUL6e7nLSkAj5QP7o9BXpwgor39ETOaitDoZ/FDCOMQOVXHzkcsx/p1qq3iYkAMt2+MctcDt/wDrXOUUe1t8KS/H8zB1JPQ9I8O+M9ORVguIJrdjKGB3BlPuWOMflXXwsrRR3UVxFcDJ2jeGAP+yRwa8IrqPAurx2moCx1CUR2FwdvmN0hfs30z1/PtVRlGT10fl/l/kEZvZnpv8AaDsmAdo3FSzDjH4dz0rf8KXLfatkjkyKpKHPy89B+Fczaagtz5F3bRCS1xtVlX5WYnBNWX3aXeSSWZM8gjO9Qcbc9vpUThdcljRpdDB8ca3N/a915902xVLoydu2PTrxXllzcPOQGY7F+4ueFFa3ifUHvLoy8oJc4QHjYDx/48D+VYdaVZcq9mvmZSb2CiiiucgKljnZAAwDqOzVFRVQnKDvFgdHoOrtFOkKPtTJ2pK4CA9ScnGDWl401C6u7CyQ3LizlYym3OQN443e/FcVV+yM1/Pb2bylixEcO85wT0XPYGt5VVVVmrPyNKbu7M6vwZop1G5EOCImUgn1HpSeJ/AF3prCaxbz7dj0IwV9qm+Hl+ljrEILOpZtmM9K9u1ixh1O1FuApBByh6D3J9a8mMnGTPVxfK1BSWlj5ansp4GZZUKsvUGvXP2etUfz9T0h5SEZBcxA8gOCAcD3BH5VwfjYLa6lJbxEYXKgdSOa0fhNdXGnazfalbKGNtascnsSQP6mulKVRHFXpwpz5Ia6f8Me96/rVlp0LG5clmGPLX7x9a4q71O6uVmlix8y7kVidxXp9Ky7dm1R7e4DuZXbdI0vCHHp61om4t44hHBIkQBIDHjI74Pbmto01H1MHG2nUe9y+HFysaKiAsT13dsUNJMlisxl8x2wGVvu89elYUl+JXER8yV7dt7HG0uP6n3qTUL3fp5eIiy3MGG5ex649/WtFDWyKS+RpS6wiBFgRGXHzluiUW2pWrylbqfErcrGxGFPTC15drOrqyFFuHcnI2p8vQ9/rWMdUuvNMiuA3TLKGIH1IrZ06cF771+9/ov1JbS0PcYZEZYYXBYA/IoP3gPX3Faen381rcASq80TEgITyF7nNeBW/iHVIJYpI7o7oySm5FIGfYiu88KfEGOeRLbXUEbk4W4iXCkn+8o/mKykqMlZN/Nf8EUU5uy3PZ7a4t7to/LIMg6qDgqKt7cHIA4HGa5hYo1Mctu7C6CBgQOoPIH5c5ro9OmNzaJM4Xj72D/nFctWk6WhnZBMCysu0HcuSTwoIrO1WUQ20ssh+Vl2YYjbjGcj8qs6veJawuGUESA7ARwB3JNeZ+I9dfUpGilYRxbSoXopI6c+ntSpQc3/AF/X9dxxINR8d+TMDbMY4IxllkBOc8CuS1nxDI8n2wXJmMnTbJgp/uj0/CsHxDfXU9xsnljbbkZjAGfrWNXa1Tou3Lr/AF/XQpytojd/4SfUE+WGZ0jz0B5P4+tOtfE11A6vvnMmfnZZQCw7AfLxz9awKKl4ib7fcv8AInmfc9Ak+I1xNp9xYvFIILuPyZzI4kO09SOBzXFahp81l5bSANBMC0MynKSAHBwfbuOo71UrR06a5u0h0kSFraWbesZ6LIRjcPQ9AfXFEbVWoWSb6/5g22RadqVzp7lraV0PscV099rVzqnge4WWQlorqMkegIbH61jWnhjVr+a9i060e6ezG6ZYiCyj6dT+FUYZZIYbq0kBUMPmRhghh7etclWnZ363OujVlZwns07evQhgnMRyBmiedpSD93jtUNFXyq9zn9rPl5L6BUkbtA4ZGxIO47U1BwWPRf502jcSbjZrceZXJJLHJ6n1phJJySc09Iy3Y4pwhY9OfoKNEPlnLUiBI6GrFvOqyILgGSEMNy55x3waT7LJkAj05qFgVYg9RRox2qUtdj6c8OaBoc+hWMtikUlu8QZG459c++c0V882HiPUrG0jtra5dIkztUHpk5/rRWDoO/xP7v8Agm3tL68/4GSylWKsMEUlS3Eolfd3xioq3W2pzTSUmou6PRvhbd3NvoHihIULRyQICQcYb5sYPrzWNNbPp6CPYsipy8ifxE9vwrU+H1zDD4M8Whz++VImUA4JHzD/AArNaCW00kT3OJvtA+QAnOT/AFpYb4p/4v0R2Rfuq3Y5++unLsEk3IDhc9QKoU6XHmHAI9QfXvTa2qSu7djjlJt6hRRRWZIUUUUAetaJqscnhrS5FkEEsduY9iD5Sysy5I9cAN+NaGkmSW4C+Xvs5ISXkDfNI4HPP9K5P4fyobJ7afeGZy8ZAzgYPP510NlqDfbLSK4nWQJKWZ1GFODzmuqeyfl+htHWJwfjux/s/VYIflGYN+0fw5d+D71zlb3jaQT6/cTCRpA5JGegGcACsGsKl+bUye4UUUVAgooooAKASCCDg+1FFAHW3exLLS9VtC5adD57ddk6sQR7cBW/4FXdWnxGhTRJracxmVoyuRndntzXH+F9KTUNHitN7SXVyXlgiU4AOSmT+K1sRfBnxA1q0ksttFNnhGYn8zU4iioSUnpdJnprE89NKSTfm7f1c4DXLlLrUJJUYsG5yTmtTwWs8979ntpGjY/vGxyGUdiPStnV/hlq2iabJf3728kUf/LOFizE/kOKzdMSOwgW8BaS+lyFjj4VB7mtsPHquhzy5pTdR7s6+M3NyXuDcrCkb4EWOPqPaszVJkh/fTSu7W52tHs+U55yar6jr9mqeRHNIsixjMgAIDfTv+FctqGtSXRbbGAWA3M53NuHccDH05rqSjHWTsYuaNm51Oe9jMsLTGJG25VQGfj+QrEutZupLZ7XzS8W7hiSSB6CqE11PMiJNNI6J91WYkL9B2qKonibK1P7/wCtjNyctwooorkEFFFFAHuXwV137XotxZXWZZbNgqk9oWB/kRj8a9SjhhhjSODhMAke9eDfAmGSXXtTwWEa2Z3AdzuGP617vql0ttpMlwy70jB/dL1apraxivU0m7tSfVf8A858f3vnXyWk8phDZOxTycdPzryjxVdxfLb28jnY53AnOT65rtfFsznT5rqFBLM+HWVj/qvQD6V5VdsGuJCrb13HDf3veuuP7uF/69SXtYjZizFmOSeSaSiiudu7uyQooopAFWdKlFvqdpMwLLHMjkA4yAwNVquaNF5+r2MJUP5k6JtJxnLAYqofErArdT3TwYiWWvy3YMcFxKApAO3eOvNdb4m8LaJ4kxNqtjG11/z2i/duAPUj7341heGZIzq6weUhK8hhyCOmRXYJPE7OEYEocN9azxLftLo0b7Hj3iD4OSK/maHqMRVukN2dhz6Buh/KsSL4R+IHPzzaeik4B+0A/wAq98cFlkDBCpwVznP41SbahOFVAp5dMnZ7Vl7SVhXXY8D8XeAr7w9oMV8ZUuIRKY5ig4Q/wn3B55riUG5gK+qr+CC9tLqC7UvbTIYplI6ZGAoHt618zeIdIuND1aayuVIaM5Vj/EvYirjK90Nu+r6HffD/AMNWV6BNqK5U8BM4P19xXokOi6dbRnyrOGJY03PIEHzZ6Y9frXkfhHxItjEY5JCmR1H16V2uqeOLSC0kdGVn2jZg8+4x6VzTXc9KtGc7OHw/kc98SmgsdsIVEuGCuqBeQCOvtXm0MclxOkcKNJLI21UQZLE9AB3q3rOpT6rqEt1cMSzngZzgdh+FewfDrwzaeE9Cl8SeIAiXYTzFSUcwIRxgf32yPcfnWq/dQ5pbnHObrNR6IwNP+Des3FlDNcX1layuu4wu2SnsSOM0Vm3/AMUNfa9mawu2trUuTFCADsXsMkUU1Ot/KjO0PL8Tg1Ut0BoYAHrn6UFs8DgelJW5k7dDqfD0U8Xg/XbuNtkBkhgc+udx/wA/WjUrhPsAZZHMcChY9rj7zDjP865gSOIzGHYRsQSueCR0OPxpTI5iEefkBzj3optwv63/AANfaK1rDKKKKDEKKKKACiiigDvfCYiTTrVLe7eK8nRx6KnzMBz+RroPDunSWxZdSA3ksC5BO8eo9T71S8JaPbXtpChm3bYkJCrwh6nJ+prr7PTpHv4hHcFjGSp3jO0H0Hp711VpKL5e36G8fhPKvHFqYr/MVu0Vu2WXd1xXLMMMeCB2zXrnxAtzHqpW4kVodmw7fnI56e1ee6vpMkDtIoIh6Lu+9j1IocfaRTW5DjfUxKKfKqh8JnbgdfXvTK5mrOzMwooopAFFABNOZQFHzZbuPSqUW1cDq/C/i9fDs9pNFp8F5JbxMg804G4szZ/Dd+ldMnxv8R7iZLTTHU/w+UwGPT71eWUU603Wacuit8hxk47HtEXxnt9QspbTXNECrIhXzLeTIHplSOn4151qep2ypLFbAMCxJYHsR0HoK5yiijP2N7Ibm+g6SRpCC5zgYFNooqZScnd7khRRRSAKKKKACiitLw9pUmsanFbKdkWcyydkUcn8eOB3OKaTbsgWp6n8F7Uaf4d1DUJEYT3sqxQtt6RqGDEfUnH4V64uU0qOLYVjWPcuTk854NcPod5pxmtrKzljitLYLFHHNJg8f44z9TXok6NJGS5i8uQAZU8Ee3vWdfR2Rb2Wh86+LdLlSK/mmnZS53+WvKkDp9PevPK9s8WxiD7VbxLEgj3bVnOd5b69RXjN5bvaXc1vLjzInKNjkZBxxXRPWCFK99SGiiisiQooooAK0/DTLHrEEroZAhJCj+9g7f1wfwrMrcsbyPS7CN1RTd+YzYPIYYGAfpyfxrehHXney/pAev8Aw+014l1C+luPsloDuluJm2RJ6gE8Yo1z4n+G9IlW3sLafWZ4XOZRJ5UWf9k8k/lj3rxK/wBWv7+NY7u7mkhU5WIsdin2Xp+NUawqLnk30L5+p7Dd/HG8ZMWeg2MLesshk/kFo03423PnY1fRbWWE4/49XMTL785z9MivHqKjkQubSx9SeFfFWh+LWlXSLhkvCvzW1woSUr6ryQ34dO9QeKfBthrlj5E6MHX7r9HU/wCetfM1vPLbTpNbyPFMh3I6NtZT6givo74TeJ7jxXoE4v3Emo2LKsj4wZEP3Sffg1nOPIrplLuuh5Lr3w41rSizwbLqDGQ8ZIPXpg9/auc/sPWpXaP+zr52U4I8pjg19TOAZmVlDBpOdy+3aq6sySITJOw8v5lBKkf7R9zR7Xqx8yta33HkHws8AzS6n/aXiO0aCytwWjinG3e46FgeijrzWP8AFjxf/wAJFrTW9hIf7MtiVjxwJD3b/D2r0r4q3U0fgLUDbzSbneJHYk52E8jP4CvnmhR558z6Bz2jZf1/w/5BRRRW5kFFFSxw7mCscHr0pN2KjFydkRUVLNA8WM8qehHSoqE77BKLi7SCiiimSFFFFABVvSLYXmrWVs2As0yRnPoWAqpXSeB7KCa9kvbwnybUj5RwSxDbeegxtzV01eSGk29D0fwrFOls7zhYVaQkcYbgDP4YFbkNtJfXiLCfMCYkyhw+Ow9MVjaX4ggvSYp5gFyViCjJfjqcV2XgvTbi1ilubqQjzW2qmP4R0Jp1pyTcpG0tDlvFWixW99dXxcBlQGTceDXHES3rtehQ1ljyhHjOSOa9R8U6dLqt9LbKiC2VfnI+8x9PeuYi8NTWvn20MxhicgttB/75op1VZXeoouy/r+v6Rwt5o8epwM1jCsTRjHA4Y9yKwJdGvYwQI+UGSpHJHrXpltBLpslxaxFYYC3zgjkAddvoTVe5DSSq+zc44yxA2r2zW3Pfp/Wg2r9DzVNJvXCn7KyqQSCR6damOnSQvA8UfmR3CE4YAkAdfp9a6a5t59LE0VgJnlmzI0rDkKBk/wBaxbW4huo2kS0LSRsu6SWTI69B0x9OaqNt/wDhw9nHYzDYSEEKjjguR6AetU55BKwIRUAAHHeu51PT2j8O32pWQfbIoSVugALDiuCrOtLS0TOdlogpdrYzg4p0IVpFDnC9zU11OsmAgxjiuVt3siowi4OTZWooo68DrVGQUVYFnOysVjdiv3gFOV+tQOrI211KsOxGKqUJR3QCUUUqruOMgcdTSSbdkAlPWGRvuxsfwqSGF5GKRIWfrwMmtq1sUCL56Mq91Uchvf147CuiFC+shpXM/TtOW4l23MrQrnGVUNz6HkY/Wuqu9XsNB0Z7LTYv9Kcqwbr9Sx4z3xWTJqUGjSXNvaxJc5CtG8q/cbrkjuRWKoudV1DLs89xK2Sx5JonKNLSG5Sjze7HqFsks8jOXYlsknPJNdb4Q8da14WYfZ5RcWnRrackpjvj0P8AnmtbTvA08cAN1Fgum4FeMe9Yet6E1mAoO7+E+9eZKopPU9enh48nJGV2epa7FpniLSrLU7VBIt7HvCs3MbL1HHcZ715b4h8NS+ZNKjgTpyVYj5vx9aj8M6pdaZdpao8htZ3CSRE+vGR6V6LdaNIGbeoSIplXxgL9c9a66M/d5XsedXpunozxGe3mgIE8Tx56blIz9PWoq9A1LQ4Z4gttjcp/ejg5P+P0qrdeDhHNGEbC4yQ+ST9MfyrV047pmLhZ2OJqxZWc15KI4E3H3OK7S38PCO8kWyClWGGWRA2B3AzW7pnhS4Nw0FlD5TR4YnpyeOvpT9nCPxMah1ZwEOiX51X7DYxPNcM3l7kXjB4/Cp/HloNN8RzaarRuLJVgLR9CcZb8QSR+Fe+eGPDtvpt3bzSRqjh/3knQsw+vavnzxtFPB4w1pLpWWb7ZKSG68sSP0IrOVbmXLHYmSSehi0AZOBRU1swTLEA/Ws27IcIqUrMdFEp+8cDuajnj8tyo7VMdpO5jhTz71BK5Zyc+2fapV7m9RQjC1tRldp8IdbfRfHOnndi2u2+yzLnAIfgE/Q4NcXW14KtJL7xXpUESlmNwjHHYA5J/ACqexzw+JH1Nd488xJvyCcYx8oz1qtuJTCAhCudq8kg+uam1FZHH7jYZSduW+7j/AGh6VXnwIuV+TI2ZOQPpiuVXD0MjxNpzah4d1a0McarPAESLqQ4+7+ZFfMJBBIIwRX1lKzeYYwFjkYjDnnHv9a8S+J3g6SzuptX01PMtJCXmRAf3Rz19wfbpWlN2bGldWPOqKKK3IJbq3ltLmW3uEKTRMUdT1BBwRUltKV7A+p9BXsXj/wAHJroXUbRVh1BkJkfOBMQOhHZuK8ZuIJLaZo5lKOpwQRWUJqqjdKVJ86NKW4LW4jzhBzjGM1nToQAcDPU00SMerfnTWdmzk8GnGHKa1sQqq1Rf0LS31i9Wzt2xcyZ8sEcEgZwfSu3gjS+mFrqltFcNbosJ8wnKsBg4wQcVo/CDwrcRNH4iuv3cQBFujDBk7Ej26iu61bw7Y6qQ0qxRzqSRIpK5J+nXFRGvabV9COWKiro8b1TwcYrVrmxu4yBktDL8rL9D0P44rkXUoxDDBFez6loOsWG+dYzqGnxKflVfn/EdxXkeq3zXty7BdkW47I85CD0FdSjFxbbMppLVFOrFleS2silWYxBwzR5O18eo/Oq9FSpOOqM9j6B+FcPhTVS91pKtHqipuktJefL9SnqPf88V6GMceg9K+RNMvLvT76K70+WSG6hO5HjOCK+p/Cuup4k8NafqnyieRdkyL0WReo/z7VyVHNT953v1/Q1fvLmLssP+low2gqNzHbnP49jSCKNZWU4fcMsG+99akaTdJ5IHuxPHHtQYGVXkjdI1jTBaU4VfcmhdEQ2zltU8NW19cvcl5vPx8pbIB9iO9cpd+GdVit7n7rxxnJyNxxXo9rfadc3JtLbV9OuJMDdGtwpkY9yBmrd5ZXf2UssHnSAcRq4AJ7EnPpWsazWiaf8AwxabiedaPpl1qMC+fE/m42MzN91R0IPatTTPA+mrbhr6NZJFJlMQbaGPYtTvE+pap4W8J3GsWlrHeXVqwlvIJMrmLncFI6FeGyQRgGub8PfGLQfEDxWx8y3upmA23GFKnsARw3t/Krc5NvkDVu0Ts9d8Pxa54V1HRtPiWCR4t0OOB5gIYLnuDjGa+ZJ4ZLeeSGdGjmjYo6MMFWBwQR65r64jkZmR1kBjyNpHy5Ptjv7VwXxJ8AJ4oL6touyHVQP3sTYVLr/aB7N256+1RCSV0yNXoeA0Vrav4c1rRz/xM9LvLYZwGkiIU/RuhqHTNF1TVZCmm6fdXTdxFEWx+Vahyy7GfXtfwM8FmIr4p1aEhFBFjG3VieDJj8wPxPpSeAPhL5E0Wo+L9oVCGSwUglv9/wBvb8/SvWZJzMi/Z1TYmFRfuqq+g/Cs5T6IPh3PMvGXgiW+1Jry1mETklniVflP4+p9K4vWLbUHs0jMc9uivhTkqiAfxH3r3h2ORHktIW3ruGMgdvwrI8W3Om6D4dn1LVoVdVBWCHI/eSHooz19fYA1rTxLWjKU9k9T5v1RTCFSa4Es+NxKHJ5/vGszNWNRu5L+/uLuYKJJnLkKMAZPQD0qvV1Kjm7mbLFre3Fp5n2aQxmQbWKgZx9e34U65v7q5ZTNMxK8jHAB9cDvVWilzyta4Dsl3y7ck8k17R8HPDqf2dJqpjUyFikZY54HXj3/AKV4qOtfQHwJu4b3wjdWjHFxZ3IfJPUP0/UGuerexvSnyxl3OpvbdI4P36t5oyVw+QP8BXEa7Yl5JJnRRHEoxgbRz/nrXpd7lY/kwXPyhcA7vb+tcJ41DJG5ZsRqSHPYk9q5pbanRhZy57LqeXXqJa3qTrGwdGD47cdK9Zbd4itrO4jlkWzKA47kY7n0zXi+sXEkjCOQbWX5Rg9c19BeGdLaz8KabbxPh0t1cZ6bmAOffqa0hLl1OjMWtLbr+v0OTu7KPw7BeavqNvNNBCPMkSGLlBnl8Z6Ac/QGtrw5NoPieye50PUbe8UHgLwyH/aU8jPuK6V7Pz7dobhQ8LqVZX5JBHcd/pXyVqvgjxB4d8f6jZ6Et/FDZHzxe24bMVs3IYleTgZGBySpABrbnc3q7Hk36H1G3h63gLTqBvyCxx1+npWnbWkdsjRBAyffOWyW/CotJmjn0Oxmtbo6lEYkKXOR+/4HzHHHPWrTqfnx8yk5bn5h7Coc29/6/r+ugvUjkO6MMW3uxOxSMnnoSPQV5X8Y/Ck2ou3iHTE82REC3kSLzhePMHqB0P0z616mJtzNhvlPALDBz/dFRRTKSJUmOyM/MoGCD/c9waISsUkfJnalUkZx3r6K8ReAvD+uCaUWYsrrGfPswFTPunAz61zkXwk0loEQ6petcNkeYkS7CR1wM9vrWqkmrgl1ueLk5or2V/g9p/lvImvXICcEGzGSfb56v2Pww8PWkZa4kurw7goaQiNfXtS549GNRu9zxfS9MvNVult7C3eeVuyjp7n0Fe8fDfwTF4XtXvruWObVZUKgp8yxD0HqT3Nb+kWFno7eXpVpDaROCpKj5hgdz3NaHmMFVlwVQhnUjG30J+tRKbeiHdLSJM21cgbt24FiwyOnr2qCNWXbFI6rIckbRwB3x+FI8rqJWLhyvzOw6ZPT8fakYtHCPmj46r1Yms00v6/r+vuJexGyxsCrFhGBtGOqqe/+etRhcLh1ZHH+r2tt2r9Pep5DiZmMgRvkJOBgnsD6YquVRXUknzOdrE5P5evoPSjyv/X9L5fehvzOfuvC/hp7iRrvRbUzscuVlZAT/ug8UVrNHbKxFxtEo+8CcnNFV7Z9n9//AAR+1tp+pT0bVbPXLG1uYGYRFSGJPKnnC/Ss7XvC+naxEHv7RVn6CaLhuOucdvrXE/CC6dnvLN3HkkBwCcc56ivTt2wSlS43fKrZwCP4uK85c1Oo4X2OyaTSkup55d/DGzkz9j1GWIhc4lQHJ9iDWt4e+Gmi2MqS6rLLqsuCVhT93F/wI53GuwRVK4KYjYAjceRj+h64qxFD+8aMbV2dZegZevA/St/bVJdTKSXYkSTdbwokUEQRf3SqMCNfUAcfhVpMmNYyUJY7wD0wOpP1qG3QPtxGRg7wDzx/Cf8AGrwt8nYoTBUl88nJ/pVRWpEjD8eayfD3gvULtSftUy/Z4ASOGYYJ/BST+FfMRGDX0F8ZbR5/A8c8ILR2ku5i3o3y/wAzXz7XXS+EzmkkgpyozKWAJA6mm04SOEKBsKe1aO/QmNvtBG211Poa+ivhJbtY+F5TOT5Ur+cAw+6O+Privna3XdPGvqwFfXcWnJY6Tb2MXyCOBUGB0Nc1fWUUdFOXLRku7/L+kcpq3jXTtK1CQ3asbWMeYzgZYsOAi+54rxvxr431bxbcMju1tpob93aRHCgdi+PvN7n8MV1nxi0j+yfDelhpCzzXcrnI6/KOa880+2eWGMRrudzjP9K2nKMIpxKoUfbT5UZ62sjfdGatQ3OqWmGgvLmIryNkrDH5Gu5ufChtrC1nSVWnkXDIG70y60i0jtd0mEMSZOT9845+lYOtzbnesDStZSdzsvhL4pl8V6feaJrTNcX8EJZJXwTND0ZGz1PI+oNeb2PwV1PS/ENzqktpFf6VY3Qlt7DzB5t5EDnHoCBxg/eII4BzVr4PzfZvijpoibCSNJGc9wUbj8wK+h2IUDcG5Paq1g2o7f1/X5HlTvexmaRqNnrWmx3umTq0EhO0MNrRyDgqVPIYHIIPINXpFYOD5gQkbOOOPX61y+t6Vc6dqT694dhEs7Hde6eDhLwLxvU9FmA6H+LoexHR2bR3FjDKRIUdBIqzKVdQRnDA8gjuO1S1pZGVyyLmWONgZDLFjaFIDFj+NAupDBs+VSMZjVQMeg4pqYIHllflPynH54pu4Nv8uRNo5yD90+9PuF7keW3KZNzSE7vlPBbpio3d3EatjzJeCoPyLj+Linwr5ccSchA5KbWyD659qj5+YCPZE67V2rhgP6/Sn5hfqSWrBrmSTeDHGuJJfp3NfPHxP8YS+K9eYxEppdrmO1h7Y7ufc/ywK9Q+LGqf2P4JaKCR4rjUGEAC8ZjGd3+B+tfPoBJAHU1rCOl2AUVJLBLEMyIVHTJqPHFaXuOUXF2krBRRRQSFer/AO7X+09UsNzRme38wOOoK/wD6zXlFdt8MNTj0XXEu53CRlSjE+h6isqzSg7nRhoSnJqPZn0DNIVtI98oYnq2OW+npXCeOrxodPJOyQKcZ+nIxU+t+L7RYSYpUMzL3OePYd68p8Ra/capOyKxCvgBcdK5LuWiO2hQcJe0mtDJnE1/eCGJWeaVwFXGSSTxX1Dpsf2HSbGCV8vFBHGx6/MEAP615r8LPA13Y3kOtaxiPapNvDn5jkY3N6deleoRBiN+5d7ncwBzn6Vq7aJHPianPIAGISQEE4ywHG4dqkGXjGRtPdeuPamo4eMEEKcZIPVfrRjJldDvyo2gcD86SXc4zjdSs5/Ceoy6lpEbzaNK5mvdOhGWhJ+9PCP1ZB16jnIPTadc2t/p8NxbyRy2twiyI8bZR89CMVbypZCAwcjAyvT61xF/ZT+Erp9T0iKSfRZnMt7YouZLck8zwr787kHXqOc5e+2/9eYI7FycPuCNuJEjnoB6fX0qKNt+AgPlgHzFbA3DsPypVnt7u3hu7eRHhuVUxFfmDgjKsPzpHIldsHO3riPJJHXNCb3QyMY+QBlC5JbAPzL2J/Gkd3YqCS6nJDdC3rj2pZMFpMuwVVClk6uc5/HioxuLA712/MYgP4RjlT+H5UrIduwplKhtshHlRkqv8RHp6YprgHA3JnAGF6Z65oIyoBI+YgBehYnoAe31phY+ThVUcYxGvG7P88d6e+iBEr/I0mCWQOw3dyW4pqs6TbMM23buyR82KjdgrOCHdgVB2jIIU5yPaml0maXzGAjLdU4AQ/e/Gi/8AX9b7jt/X9f1ceHBSNMD7h4989DRvIQAbF3bc9cgg5Kj2qIuHSYhlaYDfuA6AcbR+HNAfBKRlSAAwkLdu+ff2ouw31JJHRpidm/5uIj3J6VBNI4Q/KFABKt689DUnnl9sq75EJPy7eoHv2qAyhvkiIbad2WGFb2I7n3oX5DXkYt54hi0+6ktZbCKV4jtLnJzRVqfw/wDaZWmjdWVzkEybf07UVySTu/eZslTtt+D/AMzzj4OWvm3t/OUyIUGGPRST3r1UK6xgRHzG+Ycj5BnqR9ap/D/ww/h3wzHFKqS3kzebcNEQ+w9AgI9sZ/Gt77NgKnlBwjNnBwBnsPpQ2pzlNbP+v0Lk7RUexSjgaPaUw6KuVLno3+PtVmJGMapIq7FO0DPDKOflP1qVk/d7iM7gSQeuQcA/gKm8gbW5Qyk4PXDcdDVqPQyb7j4ULM4CNGrfNz29P/1VKUyM/PuLDBAxg+p9qdDCNu3ywq8MFJ5z71N0GT3rRIzbszN17Tl1zw1qum8MbiBhCwPG8AkE/iBXyaQQSCMEcGvsm2bZPGQBgNjHseK+WPGukf2T401axlxFElw7J/uE5X9CK6aTsmmJR59Ec7T4omlOFA/Gr0Y09eHdmx3ANVrnCktASIW4HNUp30SNpYdU1zSkn5J6m94N0zSbjxBZLrWqxWdsHDuzZwcHO3PbPqa+pPtNtqC/aLO7tZYWGFdJQRj618a0qsV+6SPoaiVKTd0/w/4b9TOVSEtFG39eZ9A/H7S7m58IafeRqSlhORKAQflcABvpkAfjXiuh6hFDceVc/LbvgEgn5eaZYardrZPYPqE6WTncYC5MbH3FWLzRb4XFvbzQmN5FDQngo6noVI4Iqb6ck/6/r5nXh4zilUpO77f566HqGmXcEdu8hmiuLZh+7JOAR9fWuC8TahmVlyDuJ4z09BWIZ9U0O4e1mE0DAYMT5A574qnc3E9/OuQzueFVRkk1MKMr67G7xkIxbjdTfQ3/AIYRSz/ELQlhzv8AtSucf3Ry36A19NzbjNMUOT5nU9Me3tXmvwa8D3GgyHXtbi8q9eMpa2zjDRg9Xb0JHAHoTXpYGAKqpbmueV0syMBULPu2L/ED0+tOjVVVQgwMcUoU7ickg9B6Uvqen+FQIQAAKABx0pFRVZgFXD9gOP8A69PYoCqqTkjv3pKFoLciddoZgCuBgbRnj6VVuo1K7F3qWUbcsc+9XiSrdRgnoev4VVmdkimWRhK45AxztNUn5/1/XkCueTftAKyR+HwASnlyZIORnIryO2/1yfX0zXv3xh0gap4N8+2BM+nMspQDOIzkH+YP4V8+gkHI61vHWJSdmpH0/pXh/RtU8H2FvcW0Uto0CsCfvZI5IPY15h4x+FN9aXElxoAN3ZkAiIkeYnqPcVt/C7xzZx6bHp2q3QgMPMcjfdI/umuj8W/E7RtCsJf7GuU1HVZE2xqgPlxZ/iY9Dj0HP061z05yj7r3OitGSk3vF9T5zkRo5GSRSrqSGB6gin2dtNeXMdvbRmSaRgqqOpNOAuL+9wqvPczycADLOxP8yTXoy3Nn8M7MRQiC98XzKDKWAeOwHZf9p+foD7deic+XRbmMIJ6vY7fwH8KLOx0uabxDbrfXd5EFEJUAW4PUhs/e6c9sVx/in4Y6vo8j/wBmwSXlsxLIIwGcD3Hc1xdx418TXDO0uvakd5yQtwyj8gcAVSi8QaxFdrdR6rfC4XpJ57Fh+OajlqPexpCvyO6/L/gm9ofhnXNZ1D7Lb6fcI0fEryoVEX1J/lXpnhv4ZWumXsN7qMzXk8RBWMDamfU+teaTfEvxXOIxLq8waMYVkVVP44HP41d0r4r+LNNcma7iv42zhLqMMAfUFcH9anlktkaVMROS0kfQDyOCSxQxk/eJxj2xTBt+zRhGILkqrAYPrXkOj/Gq8+0bdd0u0mtm4L2qlJF9+SQfpxXrdnfWeoWNtf6fMkttdLmGQ9/UY7EdPqKzaa0aOTldu4LJlGldFDb9oDcYHo3vSnmTILowUhAB931470qfL5SgyEZOM4+f60mSwkywO07skfMvr+VN9bAl2HEyNhWX5lIPXrx1H+FNUzZMi4cBcEEfMzeh9BTXcSxl8TPlgflH+r96dcsVbEisUJ2iI8bsc7hTsrhuRkxqqHCgfMGweN57ClJlEXlqyhgP3jDqvoD/AI00zhww3ZYkuAw+6OzU35iwWMb5APvKcImecnPJpcum39f1+gXGt8mMABlyqE9jjqfeo2Zn2BdoVEGSo4BP3gfeglBG+1iUQYX168ke3XrTXMcrAxY2oTsIBGAOx/pT5eq/r+tBjFQsrSMwC/6tXznIPce4qMNwg/1IJxt6n/JpzFNyISBzuOejHsfwpplyxG8naOdv3sf3fpUvTQYyZm2MDkDI3bP4Ae1RK5JcqwCf7oGAOmRUOpXllplhPqWqSFLIAMyoeS3ZFB6k4rxTxX451PxBKUytpYqT5dtDwMf7R/iP+cU+Vv3Yq/5Bp1PY7vXNF08E6hrVlDsGAsRLv9CADXH698SNNh2x6JE91JuLNLMpRT6ACvISc9aK19l1b/r8/wARcyXQ6u68f+JZLneNQeAKTiONFCjPXjH867P4e+N7jXNSTS9daOS6f/j1uMBPmwfkYDjnsf8AGvKbcrKphk64JRu4PpUUUkkEySRsySxsGVhwQQeDTVONuVKxpJtJSvoz6fW0ilG95pUY9VC8Cip/CN5Y+IfDen6ncNDFNPF+8TdjDKdp/Vc0Vjz1Fol/X3iad+v3P/M+btG8T61op/4lmpXNuuclVfKn6g8GvXvhp8RD4gvI9I12JBfyAiG4iTCycfdZR0PXnp9O5RU4uhD2cqiVmle60KpTlOSjJ3PSGgIyjH5VyPcH2NTKm3IZjhhn1x9KKKzj0/rv/kRe4KuwBSScDqeSaXJ247dqKKvdCejsV729g0ywvNQvty21mnmttG4sB2A+vFfLPi7XZvEviK91a5RY3uHyEHRFAAVc98ADnvRRXTSSs36k3/r7jIpUYowZTgiiitRJ21RdjRZk3IAvY47Giez2DPtnH9aKK53JxlZHs06MKlHnktSoY/TpXYeCr241dYfDU0xVZJQ1pOeTbt3A77SM8evNFFOsk4NvpqcNJunUTj1PfW0HT59LgtNWsbXU5YY1j8ydMs5HfPapNPsbDRNq6Zptjp5dgu+GEbm9Rnr+dFFYp6WMXJvUuEyu7PMTkktwf0NETnKbj95eFPJz3yaKKJS5fvSMZSs7f1uPQMB85BPtxTs5oop9bFB29c0hHy4yRu9KKKb7+n42EMkQMYiQTtbI56e9Ryq6sz+ZtVBxxk57k0UUnJpBYjRTNbhXiR4ZVIeN+Q4/+vXz98RvA7+G7t7izcSaa7ZXJ+aMn+E+v1ooq6c3z8vS7/BDXRdzhwSOhxRRRXSSekW8EPw+8N2+o3MEc/ibVYd9nuG5LOEj/Wehc549PzB85lkeaV5JXZ5HJZmY5JJ6k0UVnDW8jWq7PlWyEVS2cdaUITjB4ooqmwjFNIaRxVq3XzbSdSPuDeD6UUUp7GmGV6lu6f5FWvf/AIHmYeBH+1HMB1Ai2yc7TtGcenOaKKVX4GYR6noAV1yEY4wSSxySfQVyfjzxjB4StYt0b3GpTRZijP3F7bmP9KKK5ISbcV3/AOD/AJFwine/Q8b1j4jeJNTlLDUHtFIxstf3Y/Ssk+ItbDeY+qXrPndkzsefzoorrdOC6DhOTu7nd+EfinPFcLB4kTz4nK/6RGoEi89wPvCvXUjjuliaCRngljLxueCATnOKKKwqRUPhFOV4c3W5wnin4l6dot9cWNpZvqF0khEsjkxxqw424/iAI9q4a/8Ait4muZWaKW1tkJ+7Hbqcj0OQSaKK0p04yipS6ilLldl0LNl8WdXRgL6zsLqPgEeUEJH1Fdx4W8YaT4jkS1to57C7C5ZWG9WGezDv9RRRVOnFbDhLm0Z5/wDGPV5LrxO+mRlls7EBFQn7zlQWY+/b8K4EDNFFOkrQRD3JFQsm7tnFI0ZwMde9FFO5v7NNIapKOGHBU5qW8x9ocqMBvmH40UU+qM1/Da81+pds9bvbS2SCGUrGmcD6nNFFFMpYmqlZSP/Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Peripheral smear from a patient with hairy cell leukemia. Panel A: normal view of five hairy cells. The cells have abundant, irregularly distributed cytoplasm. The nuclei vary from round to oval to slightly lobulated. Panel B: same view but with the contrast adjusted to show the irregular cytoplasmic outlines, giving the cells their \"hairy\" appearance (arrows). Wright-Giemsa stain.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From Brunning, RD, McKenna, RW. Tumors of the bone marrow. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 9, 1994, Washington, DC. Armed Forces Institute of Pathology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_56_42884=[""].join("\n");
var outline_f41_56_42884=null;
var title_f41_56_42885="Ergotamine and caffeine: Drug information";
var content_f41_56_42885=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ergotamine and caffeine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?35/9/35988?source=see_link\">",
"    see \"Ergotamine and caffeine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?8/26/8613?source=see_link\">",
"    see \"Ergotamine and caffeine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708747\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F166388\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cafergot&reg;;",
"     </li>",
"     <li>",
"      Migergot&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F166389\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Cafergor&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F166420\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antimigraine Agent;",
"     </li>",
"     <li>",
"      Central Nervous System Stimulant;",
"     </li>",
"     <li>",
"      Ergot Derivative",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F166392\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Migraine:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Two tablets at onset of attack; then 1 tablet every 30 minutes as needed; maximum: 6 tablets per attack; do not exceed 10 tablets/week.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rectal: One suppository rectally at first sign of an attack; follow with second dose after 1 hour, if needed; maximum: 2 per attack; do not exceed 5/week.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15837922\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use is contraindicated in patients with impaired renal function.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15837923\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use is contraindicated in patients with impaired hepatic function.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F166367\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suppository, rectal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Migergot&reg;: Ergotamine tartrate 2 mg and caffeine 100 mg (12s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: Ergotamine tartrate 1 mg and caffeine 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cafergot&reg;: Ergotamine tartrate 1 mg and caffeine 100 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F166354\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Tablet",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F166369\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Abort or prevent vascular headaches, such as migraine, migraine variants, or so-called &ldquo;histaminic cephalalgia&rdquo;",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F166427\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Cafergot&reg; may be confused with Carafate&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F166418\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Absence of pulse, bradycardia, cardiac valvular fibrosis, cyanosis, edema, ECG changes, gangrene, hypertension, ischemia, precordial distress and pain, tachycardia, vasospasm",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Itching",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anal or rectal ulcer (with overuse of suppository), nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Retroperitoneal fibrosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Muscle pain, numbness, paresthesia, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Pleuropulmonary fibrosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Cold extremities",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F166372\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ergotamine, caffeine, or any component of the formulation; peripheral vascular disease; hepatic or renal disease; coronary artery disease; hypertension; sepsis; ergot alkaloids are contraindicated with strong inhibitors of CYP3A4 (includes protease inhibitors, azole antifungals, and some macrolide antibiotics); pregnancy",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F166357\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiac valvular fibrosis: Ergot alkaloids have been associated with fibrotic valve thickening (eg, aortic, mitral, tricuspid); usually associated with long-term, chronic use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular effects: Vasospasm or vasoconstriction can occur, possibly resulting in decreased cerebral blood flow, ECG changes, and hypertension; sustained vasoconstriction may also lead to ischemic colitis, intermittent claudication, aggravation of angina, or precipitation of MI. Do not use is any patient at risk or predisposed to vascular effects of ergot alkaloids.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ergotism: Ergot alkaloid use may result in ergotism (intense vasoconstriction) resulting in peripheral vascular ischemia and possible gangrene. Ergotism is usually associated with overdosage or prolonged chronic use; do not exceed dosing guidelines and avoid prolonged administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pleural/retroperitoneal fibrosis: Rare cases of pleural and/or retroperitoneal fibrosis have been reported with prolonged daily use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CYP3A4 inhibitors:",
"     <b>",
"      [U.S. Boxed Warning]: Ergot alkaloids are contraindicated with potent inhibitors of CYP3A4 (includes protease inhibitors, azole antifungals, and some macrolide antibiotics); concomitant use associated with acute ergot toxicity (ergotism).",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with extreme caution or avoid use in the elderly; due to vasoconstrictive properties and cardiovascular adverse effects associated with ergot alkaloids.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Withdrawal: Discontinuation after extended use may result in withdrawal symptoms (eg, rebound headache).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F166416\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F166362\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adenosine: Caffeine may diminish the therapeutic effect of Adenosine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists: Ergot Derivatives may enhance the hypertensive effect of Alpha-/Beta-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha-/Beta-Agonists.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Agonists: Ergot Derivatives may enhance the hypertensive effect of Alpha1-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha1-Agonists.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: May enhance the vasoconstricting effect of Ergot Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May increase the serum concentration of Ergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clarithromycin: May increase the serum concentration of Ergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: May increase the serum concentration of Ergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Crizotinib: May increase the serum concentration of Ergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Moderate): May decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Strong): May decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Efavirenz: May increase the serum concentration of Ergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: May decrease the serum concentration of Ergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Formoterol: Caffeine may enhance the adverse/toxic effect of Formoterol. Caffeine may enhance the hypokalemic effect of Formoterol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Indacaterol: Caffeine may enhance the adverse/toxic effect of Indacaterol. Caffeine may enhance the hypokalemic effect of Indacaterol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: May increase the serum concentration of Ergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): May increase the serum concentration of Ergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lorcaserin: May enhance the adverse/toxic effect of Ergot Derivatives. Specifically, use of these drugs together may increase the risk of developing valvular heart disease. Lorcaserin may enhance the serotonergic effect of Ergot Derivatives. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May enhance the adverse/toxic effect of Ergot Derivatives. Specifically leading to the development of ergotism.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of Ergotamine. Management: Avoid ergotamine during and 2 weeks following mifepristone for treatment of hyperglycemia in Cushing's syndrome. The interaction magnitude could be lower with single doses used to terminate pregnancy, but neither effect has been studied clinically.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nitroglycerin: Ergot Derivatives may diminish the vasodilatory effect of Nitroglycerin. This is of particular concern in patients being treated for angina. Nitroglycerin may increase the serum concentration of Ergot Derivatives.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Posaconazole: May increase the serum concentration of Ergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May increase the serum concentration of Ergot Derivatives.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: May decrease the metabolism of Caffeine.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Gemifloxacin; Levofloxacin (Systemic); Lomefloxacin; Moxifloxacin (Systemic); Nalidixic Acid; Ofloxacin (Systemic); Sparfloxacin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Regadenoson: Caffeine may diminish the vasodilatory effect of Regadenoson.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin 5-HT1D Receptor Agonists: Ergot Derivatives may enhance the vasoconstricting effect of Serotonin 5-HT1D Receptor Agonists. Serotonin 5-HT1D Receptor Agonists may enhance the vasoconstricting effect of Ergot Derivatives.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May increase the serum concentration of Ergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Teriflunomide: May decrease the serum concentration of Caffeine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May increase the serum concentration of Ergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F166384\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food: Avoid tea, cola, and coffee (caffeine may increase GI absorption of ergotamine). Grapefruit juice may cause increased blood levels of ergotamine, leading to increased toxicity.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F166364\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F166375\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause prolonged constriction of the uterine vessels and/or increased myometrial tone leading to reduced placental blood flow. This has contributed to fetal growth retardation in animals.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F166394\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F166376\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ergotamine is excreted in breast milk and may cause vomiting, diarrhea, weak pulse, and unstable blood pressure in the nursing infant. Consider discontinuing the drug or discontinuing nursing.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F166374\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suppository",
"     </b>",
"     (Migergot Rectal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2-100 mg (12): $424.98",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Cafergot Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-100 mg (100): $378.96",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F166377\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Avamigran (TH);",
"     </li>",
"     <li>",
"      Cafergot (AE, AR, AT, AU, BE, BF, BH, BJ, CI, CO, CY, EG, ET, GB, GH, GM, GN, GR, HK, IL, IQ, IR, IT, JO, JP, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, MX, MY, NE, NG, NL, NZ, OM, QA, RU, SA, SC, SD, SE, SG, SL, SN, SY, TH, TN, TR, TZ, UG, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Cafergot N (DE);",
"     </li>",
"     <li>",
"      Caffox (SG);",
"     </li>",
"     <li>",
"      Degran (TH);",
"     </li>",
"     <li>",
"      Enxak (BR);",
"     </li>",
"     <li>",
"      Ergam (HU);",
"     </li>",
"     <li>",
"      Ergofein (CZ);",
"     </li>",
"     <li>",
"      Ergokoffin (DK);",
"     </li>",
"     <li>",
"      Ergosanol (LU);",
"     </li>",
"     <li>",
"      Ergosanol SL (CH);",
"     </li>",
"     <li>",
"      Ergosanol Spezial N (LU);",
"     </li>",
"     <li>",
"      Ergoton (TW);",
"     </li>",
"     <li>",
"      Ericaf (ID);",
"     </li>",
"     <li>",
"      Fencafen (CO);",
"     </li>",
"     <li>",
"      Gynergene Cafeine (FR);",
"     </li>",
"     <li>",
"      Lingraine (IE);",
"     </li>",
"     <li>",
"      Migrexa (HR);",
"     </li>",
"     <li>",
"      Polygot (TH);",
"     </li>",
"     <li>",
"      Sydolil (MX);",
"     </li>",
"     <li>",
"      Tofago (TH);",
"     </li>",
"     <li>",
"      Trinergot (MX)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F166356\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Has partial agonist and/or antagonist activity against tryptaminergic, dopaminergic and alpha-adrenergic receptors depending upon their site; is a highly active uterine stimulant; it causes constriction of peripheral and cranial blood vessels and produces depression of central vasomotor centers",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F166371\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Ergotamine: Oral, rectal: Erratic; enhanced by caffeine coadministration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensively hepatic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: Ergotamine: 0.5-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces (90% as metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Carlton MC, Kunkel DB, and Curry SC, &ldquo;Ergotism Treated With Cyproheptadine,&rdquo;",
"      <i>",
"       Clin Toxicol",
"      </i>",
"      , 1995, 33(5):552.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Carlton MC, &ldquo;Great Balls of Fire: St Anthony and Ergotism,&rdquo;",
"      <i>",
"       Clin Toxicol",
"      </i>",
"      , 1995, 33(5):560.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Edwards WM, &ldquo;Accidental Poisoning of Newborn Infants With Ergonovine Maleate. A Lesson Application To All Delivery Rooms,&rdquo;",
"      <i>",
"       Clin Pediatr (Phila)",
"      </i>",
"      , 1971, 10(5):257-60.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Husum B, Metz P, and Rasmussen JP, &ldquo;Nitroglycerin Infusion for Ergotism,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1979, 2(8146):794-5.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McGuigan MA, &ldquo;Ergot Alkaloids,&rdquo;",
"      <i>",
"       Clin Toxicol Rev",
"      </i>",
"      , 1984, 6:1-2.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Orton DA and Richardson RJ, &ldquo;Ergotamine Absorption and Toxicity,&rdquo;",
"      <i>",
"       Postgrad Med J",
"      </i>",
"      , 1982, 58(675):6-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/56/42885/abstract-text/7088766/pubmed\" id=\"7088766\" target=\"_blank\">",
"        7088766",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8859 Version 47.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-17F8E0A872-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_56_42885=[""].join("\n");
var outline_f41_56_42885=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708747\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166388\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166389\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166420\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166392\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15837922\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15837923\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166367\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166354\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166369\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166427\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166418\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166372\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166357\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166416\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166362\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166384\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166364\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166375\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166394\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166376\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166374\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166377\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166356\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166371\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8859\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8859|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?35/9/35988?source=related_link\">",
"      Ergotamine and caffeine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?8/26/8613?source=related_link\">",
"      Ergotamine and caffeine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_56_42886="Urine collection techniques in children";
var content_f41_56_42886=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Urine collection techniques in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/56/42886/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/56/42886/contributors\">",
"     Lalit Bajaj, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/56/42886/contributors\">",
"     Joan Bothner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/56/42886/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/56/42886/contributors\">",
"     Anne M Stack, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/56/42886/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/56/42886/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/56/42886/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urinary tract infections (UTIs) are an important cause of acute and chronic morbidity in children. Long-term complications include hypertension and decreased renal function caused by renal scarring. The accurate diagnosis of UTI in children is necessary to ensure appropriate therapy and follow-up for those who need it, and to avoid unnecessary therapy, hospital admission, and further evaluation in those who do not. The manner in which urine is collected and processed before it is cultured can affect the validity of the culture result.",
"   </p>",
"   <p>",
"    Children who are toilet trained can provide clean voided urine samples. Samples of urine from children who are not toilet trained can be obtained by \"clean voided\" bag samples, suprapubic bladder aspiration (SPA), or transurethral bladder catheterization (TUBC). SPA and TUBC are invasive but are the only valid ways to collect urine for culture in febrile young infants under two months of age and older infants and children with unexplained fever who are younger than two years of age and ill enough to merit immediate antimicrobial therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/56/42886/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The procedures for obtaining and processing urine samples in children are reviewed here. The diagnosis, treatment, and subsequent evaluation of UTIs in newborns and children are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/59/14264?source=see_link\">",
"     \"Urinary tract infections in newborns\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/40/21129?source=see_link\">",
"     \"Clinical features and diagnosis of urinary tract infections in infants and children older than one month\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/1/27674?source=see_link\">",
"     \"Acute management, imaging, and prognosis of urinary tract infections in infants and children older than one month\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/27/7606?source=see_link\">",
"     \"Long-term management and prevention of urinary tract infections in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLEAN VOIDED BAG SAMPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The practice of obtaining urine specimens by the \"clean voided\" bag appeals to medical staff and parents because it is noninvasive. However, it should",
"    <strong>",
"     not",
"    </strong>",
"    be used to obtain urine samples for culture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/56/42886/abstract/1\">",
"     1",
"    </a>",
"    ]. Appropriate collection of clean voided bag urine samples requires proper cleansing, rinsing, and drying of the perineum before application of the bag, immediate removal of the bag after urine is voided, and prompt processing of the urine.",
"   </p>",
"   <p>",
"    Cultures of urine specimens obtained by clean voided bag have an unacceptably high rate of false positive results compared with catheterized specimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/56/42886/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. As an example, in an observational study of 7584 children younger than two years) undergoing urine collection for culture, 63 percent of clean voided bag specimens were contaminated compared with 9 percent of catheter specimens (63 percent versus 9 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/56/42886/abstract/2\">",
"     2",
"    </a>",
"    ]. An adverse outcome (delayed diagnosis and treatment, unnecessary recall, unnecessary treatment, unnecessary hospital admission,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    unnecessary radiologic investigation) occurred in 132 of the 3440 children who had a false positive urine culture.",
"   </p>",
"   <p>",
"    According to the guidelines of American Academy of Pediatrics Subcommittee on UTI, clean voided bag urine samples are acceptable for urinalysis in infants and children between two months and two years of age who have unexplained fever and do not appear ill enough to require immediate antimicrobial therapy. An infant or young child should never receive antibiotics on the basis of a urinalysis from a clean voided bag urine specimen. Thus, another urine sample for urinalysis and culture should be collected by invasive means if the urinalysis from the bag sample suggests a UTI by any of the following (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/40/21129?source=see_link&amp;anchor=H12#H12\">",
"     \"Clinical features and diagnosis of urinary tract infections in infants and children older than one month\", section on 'Rapidly available tests'",
"    </a>",
"    .):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Positive leukocyte esterase or nitrite test",
"     </li>",
"     <li>",
"      Greater than 5 white blood cells per high-power field (spun urine)",
"     </li>",
"     <li>",
"      Presence of bacteria on Gram stained urine (unspun urine)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Monitoring the clinical course of the infant or child without antibiotic therapy is a reasonable course of action if the urinalysis is not suggestive of UTI. However, a negative urinalysis does not exclude a UTI (",
"    <a class=\"graphic graphic_table graphicRef82157 \" href=\"mobipreview.htm?27/28/28109\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/40/21129?source=see_link&amp;anchor=H17#H17\">",
"     \"Clinical features and diagnosis of urinary tract infections in infants and children older than one month\", section on 'Diagnosis of UTI'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLEAN VOIDED SAMPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children who are toilet trained can provide clean voided midstream urine samples. Cleansing the perineum with soap prior to urine collection may decrease the rate of contamination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/56/42886/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We suggest using the following technique to collect urine samples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For girls, the labia should be spread and the perineum cleansed two to three times with nonfoaming antiseptic solution or mild soap. For boys, the meatus should be cleansed in a similar fashion. The foreskin should be retracted before cleansing for those who are uncircumcised.",
"     </li>",
"     <li>",
"      Contact of the urinary stream with the mucosa can be minimized by pulling back the foreskin in boys who are uncircumcised and by spreading the labia in girls during urination.",
"     </li>",
"     <li>",
"      The child should urinate into a toilet or urinal. Midway through urination, a specimen should be collected in a sterile container.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     SUPRAPUBIC BLADDER ASPIRATION (SPA)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Suprapubic bladder aspiration is a safe and effective method for obtaining urine specimens in infants and young children (usually not performed in children who are older than two years). The distended bladder, which extends above the level of the pubic symphysis into the lower abdomen, is easy to access percutaneously. Success is more likely if the bladder can be visualized by portable ultrasonography, percussed, or palpated and the child has not emptied the bladder in the 60 minutes before the procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/56/42886/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Percussion or palpation of the bladder may stimulate urination in some children.",
"   </p>",
"   <p>",
"    This method represents the gold standard in the diagnosis of UTI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/56/42886/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. In one study, clean voided bag, clean voided, and SPA urine samples were obtained on the same day from thirty hospitalized children between the ages of one day and three years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/56/42886/abstract/10\">",
"     10",
"    </a>",
"    ]. Compared with the other collection methods, SPA yielded no cultures with mixed growth or colony count less than 10,000 per",
"    <span class=\"nowrap\">",
"     mL/urine,",
"    </span>",
"    suggestive of contamination (0 versus 73 percent for mixed growth from both bag and clean voided samples; and 0 versus 6 percent and 13 percent for intermediate growth from clean voided and bag samples, respectively).",
"   </p>",
"   <p>",
"    The following steps are performed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/56/42886/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The child is restrained in the supine and frog leg position. This position permits adequate stabilization of the pelvis (",
"      <a class=\"graphic graphic_figure graphicRef55808 \" href=\"mobipreview.htm?10/19/10559\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The site for needle insertion, in the midline, approximately one to two centimeters above the pubic symphysis, is widely prepared with povidone-iodine solution.",
"     </li>",
"     <li>",
"      The planned puncture site may be locally anesthetized with",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/57/37776?source=see_link\">",
"       lidocaine",
"      </a>",
"      . Many practitioners do not perform this step because they believe it is more painful than the procedure itself.",
"     </li>",
"     <li>",
"      The urethral opening should be occluded just before needle insertion because the procedure will stimulate urination in many children. This is accomplished by squeezing the penile urethra in boys or applying urethral pressure to the meatus in girls [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/56/42886/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A 1.5 inch, 22-gauge needle attached to a 3 or 5 mL syringe is inserted one to two centimeters above the pubic symphysis. The needle should be angled 10 to 20 degrees cephalad and advanced under negative pressure until urine returns (",
"      <a class=\"graphic graphic_figure graphicRef50311 \" href=\"mobipreview.htm?7/10/7330\">",
"       figure 2",
"      </a>",
"      ). The needle should be partially withdrawn and redirected at an angle more perpendicular to the frontal plane if the initial attempt is unsuccessful.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Urine is not likely to be obtained after the third attempt [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/56/42886/abstract/6\">",
"     6",
"    </a>",
"    ]. Thus, one can either perform transurethral bladder catheterization or wait 15 to 30 minutes for the bladder to become more distended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/56/42886/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Portable ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;Portable ultrasound (US) is becoming increasingly available in the emergency department and helps to improve the success rate of obtaining urine with SPA. In a randomized study of 66 patients, the success rate with US was 79 percent (versus 52 percent without US) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/56/42886/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Minor complications, such as microscopic hematuria, are common. Major complications, such as gross hematuria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/56/42886/abstract/15,16\">",
"     15,16",
"    </a>",
"    ] and anterior abdominal wall abscess, are rare [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/56/42886/abstract/17\">",
"     17",
"    </a>",
"    ]. Intestinal perforation can occur if a loop of bowel overlies the bladder, but the small puncture rarely leads to peritonitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/56/42886/abstract/11,18\">",
"     11,18",
"    </a>",
"    ]. Intestinal (or other viscus) perforation can be avoided if the procedure is not performed in children who have abdominal distension, organomegaly, volume depletion, or congenital anomalies of the gastrointestinal or genitourinary tract [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/56/42886/abstract/7,17,18\">",
"     7,17,18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     TRANSURETHRAL BLADDER CATHETERIZATION (TUBC)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The catheterization of the urethra is another safe and effective method for obtaining urine samples for culture in most infants and children who are not toilet trained. Specimen contamination may occur in up to 15 percent of children under two years of age and is more common in uncircumcised boys, infants under six months of age, and children in whom the urethra is not well visualized or who require several attempts to pass the catheter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/56/42886/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An explanation of the anatomy and the indications for the procedure should be given to parents and caregivers before transurethral bladder catheterization is performed to avoid unnecessary parental anxiety about the manipulation of their child's genitals. In addition, whether the child has a latex allergy must be determined because the condition is common in children with spina bifida and other conditions that require frequent bladder catheterization.",
"   </p>",
"   <p>",
"    The following steps are performed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The child is restrained in the supine and frog leg position. This position permits adequate stabilization of the pelvis and complete visualization of the external genitalia.",
"     </li>",
"     <li>",
"      The anterior urethra is cleansed thoroughly with povidone-iodine solution.",
"     </li>",
"     <li>",
"      A sterile lubricant jelly is applied to the end of an appropriately sized catheter (5 French for children younger than six months; 8 French for those between six months and adolescence, and 10 French for adolescents).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The efficacy of using topical",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/57/37776?source=see_link\">",
"     lidocaine",
"    </a>",
"    to reduce pain during urethral catheterization in children is uncertain. In one randomized trial, children who were catheterized using a lubricant containing lidocaine experienced less pain during the procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/56/42886/abstract/20\">",
"     20",
"    </a>",
"    ]. In a similar report in infants, however, there was no difference in pain scores with and without topical lidocaine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/56/42886/abstract/21\">",
"     21",
"    </a>",
"    ]. If a topical anesthetic is used, it should be applied two to three minutes before the procedure is performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Boys",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The foreskin of the glans is retracted gently to permit complete visualization of the urethral meatus if the boy is uncircumcised. The foreskin must be repositioned after the procedure to prevent paraphimosis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/39/29302?source=see_link\">",
"       \"Paraphimosis: Definition, pathophysiology, and clinical features\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The urethra is straightened by using the nondominant hand to hold the penis perpendicular to the lower abdomen (",
"      <a class=\"graphic graphic_figure graphicRef71956 \" href=\"mobipreview.htm?0/56/896\">",
"       figure 3",
"      </a>",
"      ). Gentle traction is applied.",
"     </li>",
"     <li>",
"      The catheter is inserted with the dominant hand until urine returns.",
"     </li>",
"     <li>",
"      As the catheter is being advanced, it can be palpated along the posterior aspect of the penis. Resistance may be encountered near the base of the penis due to contraction of the external bladder sphincter. This can generally be overcome by maintaining traction on the penis, while applying gentle pressure with the catheter. The catheter should never be forced [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/56/42886/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Girls",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The urethra may be difficult to visualize in girls. An assistant often is needed to retract the labia majora (",
"      <a class=\"graphic graphic_figure graphicRef58640 \" href=\"mobipreview.htm?9/39/9855\">",
"       figure 4",
"      </a>",
"      ). In addition, redundant tissue around the introitus can sometimes obscure the urethral meatus. Swabbing the area from front to back may push this tissue out of the way and permit the povidine-iodine solution to pool in the meatus, making it easier to identify.",
"     </li>",
"     <li>",
"      The catheter is inserted into the urethral meatus until urine returns (",
"      <a class=\"graphic graphic_figure graphicRef50955 \" href=\"mobipreview.htm?4/47/4848\">",
"       figure 5",
"      </a>",
"      ). Catheters that are inadvertently placed in the vagina may be left in place to serve as a landmark for subsequent attempts.",
"     </li>",
"     <li>",
"      The first few drops of urine obtained should be discarded to prevent contamination of the urine with urethral organisms or cells. A prospective study comparing early and later urine samples obtained by TUBC in 86 children demonstrated that inclusion of the early stream urine increases false positive results on urinalysis for white blood cell counts and bacteria detection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/56/42886/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Portable ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;Portable ultrasound (US) is increasingly available in the emergency department and helps to improve the success rate of obtaining urine with TUBC. In a prospective study, the success rate for obtaining urine on the first attempt with US was 96 percent (versus 72 percent without US) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/56/42886/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications of bladder catheterization are minimal and include urethral trauma and microscopic hematuria. In addition, catheterization can cause iatrogenic infection. However, this risk was assessed by the AAP subcommittee on UTI and found to be extremely low, and no change was made in the recommendation to perform the procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/56/42886/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     COMPARISON OF SUPRAPUBIC BLADDER ASPIRATION AND TRANSURETHRAL BLADDER CATHETERIZATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Few studies have compared suprapubic bladder aspiration and urethral catheterization in infants and children:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One hundred infants younger than six months of age who were being evaluated for febrile illness, suspected UTI, or sepsis were randomly assigned to undergo SPA or TUBC. TUBC was more successful (100 versus 46 percent) but took more time (mean time of 81 versus 17 seconds) than did SPA [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/56/42886/abstract/7\">",
"       7",
"      </a>",
"      ]. In addition, TUBC was 100 percent successful after failed SPA.",
"     </li>",
"     <li>",
"      Thirty-three neonates who required sterile collection of urine were randomly assigned to urine collection by SPA or TUBC [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/56/42886/abstract/24\">",
"       24",
"      </a>",
"      ]. TUBC was more successful (81 versus 65 percent), but the volume of urine obtained was insufficient for analysis more often (69 versus 41 percent).",
"     </li>",
"     <li>",
"      Urine samples from 42 children, aged three months to 10 years, were obtained by SPA and TUBC after elective surgery. TUBC samples were divided into first and second portions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/56/42886/abstract/9\">",
"       9",
"      </a>",
"      ]. Sterile cultures were obtained more often from SPA than from second TUBC sample, and more often from second than from first TUBC sample (95 versus 80 versus 60 percent). When cultures with nonpathogenic organisms or colony counts less than 10.000 per",
"      <span class=\"nowrap\">",
"       mL/urine",
"      </span>",
"      were assumed to be contaminated, the agreement between SPA and TUBC for \"sterility\" was 98 percent for the second portion and 93 percent for the first.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     PROCESSING OF URINE SAMPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The urine sample should be sent immediately to the bacteriology laboratory because bacteria will continue to proliferate in the warm medium of freshly voided urine, leading to increased bacterial counts. If such immediate dispatch is not possible, the container should be transported in iced water and then stored in a refrigerator at 4&ordm;C. Cooling stops bacterial growth until the urine is plated on culture medium and incubated. However, urinary leukocytes may be altered by refrigeration, possibly affecting interpretation of the urinalysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?22/59/23474?source=see_link\">",
"       \"Patient information: Blood in the urine (hematuria) in adults (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?42/56/43905?source=see_link\">",
"       \"Patient information: Kidney stones in adults (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?1/9/1169?source=see_link\">",
"       \"Patient information: Blood in the urine (hematuria) in children (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?15/26/15779?source=see_link\">",
"       \"Patient information: Kidney stones in children (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?37/58/38818?source=see_link\">",
"       \"Patient information: Urinary tract infections in children (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13615750\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The techniques for collection of urine in infants and children by clean voided samples, clean voided bag samples, suprapubic aspiration, and transurethral bladder catheterization are described. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clean voided bag samples'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Clean voided samples'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Suprapubic bladder aspiration (spa)'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Transurethral bladder catheterization (tubc)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children who are toilet trained can provide clean voided urine samples. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clean voided samples'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clean voided bag urine samples are acceptable for urinalysis in infants and children between two months and two years of age who have unexplained fever and do not appear ill enough to require immediate antimicrobial therapy. If the sample suggests infection, then a catheterized urine specimen should be obtained for confirmatory testing and urine culture. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clean voided bag samples'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Suprapubic aspiration and transurethral bladder catheterization are invasive but are the only valid ways to collect urine for culture in febrile young infants under two months of age and older infants and children with unexplained fever who are younger than two years of age and ill enough to merit immediate antimicrobial therapy. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Suprapubic bladder aspiration (spa)'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Transurethral bladder catheterization (tubc)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The use of portable ultrasound to visualize the bladder increases the success rate for both suprapubic aspiration and transurethral bladder catheterization. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Portable ultrasound'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Portable ultrasound'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/56/42886/abstract/1\">",
"      Practice parameter: the diagnosis, treatment, and evaluation of the initial urinary tract infection in febrile infants and young children. American Academy of Pediatrics. Committee on Quality Improvement. Subcommittee on Urinary Tract Infection. Pediatrics 1999; 103:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/56/42886/abstract/2\">",
"      Al-Orifi F, McGillivray D, Tange S, Kramer MS. Urine culture from bag specimens in young children: are the risks too high? J Pediatr 2000; 137:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/56/42886/abstract/3\">",
"      Tosif S, Baker A, Oakley E, et al. Contamination rates of different urine collection methods for the diagnosis of urinary tract infections in young children: An observational cohort study. J Paediatr Child Health 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/56/42886/abstract/4\">",
"      Karacan C, Erkek N, Senel S, et al. Evaluation of urine collection methods for the diagnosis of urinary tract infection in children. Med Princ Pract 2010; 19:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/56/42886/abstract/5\">",
"      Vaillancourt S, McGillivray D, Zhang X, Kramer MS. To clean or not to clean: effect on contamination rates in midstream urine collections in toilet-trained children. Pediatrics 2007; 119:e1288.",
"     </a>",
"    </li>",
"    <li>",
"     Ruddy RM. Illustrated techniques of pediatric emergency procedures. In: Textbook of Pediatric Emergency Medicine, 5th, Fleisher GR, Ludwig S, Henretig FM.  (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. p.1861.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/56/42886/abstract/7\">",
"      Pollack CV Jr, Pollack ES, Andrew ME. Suprapubic bladder aspiration versus urethral catheterization in ill infants: success, efficiency and complication rates. Ann Emerg Med 1994; 23:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/56/42886/abstract/8\">",
"      Stamm WE, Wagner KF, Amsel R, et al. Causes of the acute urethral syndrome in women. N Engl J Med 1980; 303:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/56/42886/abstract/9\">",
"      PRYLES CV, ATKIN MD, MORSE TS, WELCH KJ. Comparative bacteriologic study of urine obtained from children by percutaneous suprapubic aspiration of the bladder and by catheter. Pediatrics 1959; 24:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/56/42886/abstract/10\">",
"      Hardy JD, Furnell PM, Brumfitt W. Comparison of sterile bag, clean catch and suprapubic aspiration in the diagnosis of urinary infection in early childhood. Br J Urol 1976; 48:279.",
"     </a>",
"    </li>",
"    <li>",
"     King C, Henretig FM. Bladder catheterization and suprapubic bladder aspiration. In: Pocket Atlas of Pediatric Emergnecy Procedures, King C, Henretig FM.  (Eds), Lippincott Williams and Wilkins, Philadelphia 2000. p.257.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/56/42886/abstract/12\">",
"      NELSON JD, PETERS PC. SUPRAPUBIC ASPIRATION OF URINE IN PREMATURE AND TERM INFANTS. Pediatrics 1965; 36:132.",
"     </a>",
"    </li>",
"    <li>",
"     Hertz AL. Urinary tract infection. In: Pediatric Emergency Medicine Concepts and Clinical Practice, 2nd, Barkin R.  (Ed), Mosby, St. Louis 1997. p.1164.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/56/42886/abstract/14\">",
"      Gochman RF, Karasic RB, Heller MB. Use of portable ultrasound to assist urine collection by suprapubic aspiration. Ann Emerg Med 1991; 20:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/56/42886/abstract/15\">",
"      Carlson KP, Pullon DH. Bladder hemorrhage following transcutaneous bladder aspiration. Pediatrics 1977; 60:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/56/42886/abstract/16\">",
"      Saccharow L, Pryles CV. Further experience with the use of percutaneous suprapubic aspiration of the urinary bladder. Bacteriologic studies in 654 infants and children. Pediatrics 1969; 43:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/56/42886/abstract/17\">",
"      Polnay L, Fraser AM, Lewis JM. Complication of suprapubic bladder aspiration. Arch Dis Child 1975; 50:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/56/42886/abstract/18\">",
"      Weathers WT, Wenzl JE. Suprapubic aspiration of the bladder. Perforation of a viscus other than the bladder. Am J Dis Child 1969; 117:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/56/42886/abstract/19\">",
"      Wingerter S, Bachur R. Risk factors for contamination of catheterized urine specimens in febrile children. Pediatr Emerg Care 2011; 27:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/56/42886/abstract/20\">",
"      Gerard LL, Cooper CS, Duethman KS, et al. Effectiveness of lidocaine lubricant for discomfort during pediatric urethral catheterization. J Urol 2003; 170:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/56/42886/abstract/21\">",
"      Vaughan M, Paton EA, Bush A, Pershad J. Does lidocaine gel alleviate the pain of bladder catheterization in young children? A randomized, controlled trial. Pediatrics 2005; 116:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/56/42886/abstract/22\">",
"      Dayan PS, Chamberlain JM, Boenning D, et al. A comparison of the initial to the later stream urine in children catheterized to evaluate for a urinary tract infection. Pediatr Emerg Care 2000; 16:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/56/42886/abstract/23\">",
"      Chen L, Hsiao AL, Moore CL, et al. Utility of bedside bladder ultrasound before urethral catheterization in young children. Pediatrics 2005; 115:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/56/42886/abstract/24\">",
"      Tobiansky R, Evans N. A randomized controlled trial of two methods for collection of sterile urine in neonates. J Paediatr Child Health 1998; 34:460.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6339 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.247-9662981F41-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_56_42886=[""].join("\n");
var outline_f41_56_42886=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13615750\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLEAN VOIDED BAG SAMPLES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLEAN VOIDED SAMPLES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      SUPRAPUBIC BLADDER ASPIRATION (SPA)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Portable ultrasound",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      TRANSURETHRAL BLADDER CATHETERIZATION (TUBC)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Boys",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Girls",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Portable ultrasound",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      COMPARISON OF SUPRAPUBIC BLADDER ASPIRATION AND TRANSURETHRAL BLADDER CATHETERIZATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      PROCESSING OF URINE SAMPLES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13615750\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6339\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6339|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?10/19/10559\" title=\"figure 1\">",
"      Patient position for suprapubic aspiration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?7/10/7330\" title=\"figure 2\">",
"      Suprapubic aspiration technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?0/56/896\" title=\"figure 3\">",
"      Trans-urethral bladder catheterization boys",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?9/39/9855\" title=\"figure 4\">",
"      Trans-urethral bladder catheterization labial traction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?4/47/4848\" title=\"figure 5\">",
"      Trans-urethral bladder catheterization girls",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6339|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?27/28/28109\" title=\"table 1\">",
"      Tests to diagnose UTI in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/1/27674?source=related_link\">",
"      Acute management, imaging, and prognosis of urinary tract infections in infants and children older than one month",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/40/21129?source=related_link\">",
"      Clinical features and diagnosis of urinary tract infections in infants and children older than one month",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/27/7606?source=related_link\">",
"      Long-term management and prevention of urinary tract infections in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/39/29302?source=related_link\">",
"      Paraphimosis: Definition, pathophysiology, and clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?22/59/23474?source=related_link\">",
"      Patient information: Blood in the urine (hematuria) in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?1/9/1169?source=related_link\">",
"      Patient information: Blood in the urine (hematuria) in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?42/56/43905?source=related_link\">",
"      Patient information: Kidney stones in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?15/26/15779?source=related_link\">",
"      Patient information: Kidney stones in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?37/58/38818?source=related_link\">",
"      Patient information: Urinary tract infections in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/59/14264?source=related_link\">",
"      Urinary tract infections in newborns",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_56_42887="Ramipril and felodipine: Drug information";
var content_f41_56_42887=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ramipril and felodipine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?19/63/20469?source=see_link\">",
"    see \"Ramipril and felodipine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F5951190\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Altace&reg; Plus Felodipine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F5951194\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Angiotensin-Converting Enzyme (ACE) Inhibitor;",
"     </li>",
"     <li>",
"      Calcium Channel Blocker;",
"     </li>",
"     <li>",
"      Calcium Channel Blocker, Dihydropyridine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F5951331\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Not for initial therapy; titration of individual agents to an appropriate clinical response is required before patient is converted over to an equivalent dose of the combination product.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Hypertension",
"     </b>",
"     (dose is individualized): Oral: Ramipril 2.5-10 mg and felodipine ER 2.5-10 mg once daily; adjust dose no more frequently than every 2 weeks",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F5951332\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Initial: 2.5 mg daily based on felodipine ER component (maximum: 10 mg/day)",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F5951333\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dose reduction required. See individual agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;40 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Maximum dosage: 5 mg/day based on ramipril component",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Maximum dosage: 2.5 mg/day based on ramipril component",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F5951334\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dose reduction required. See individual agents. Maximum dosage: 10 mg/day based on felodipine ER component.",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F5951342\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet, variable release, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Altace&reg; Plus Felodipine 2.5/2.5: Ramipril 2.5 mg [immediate release] and felodipine 2.5 mg [extended release]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Altace&reg; Plus Felodipine 5/5: Ramipril 5 mg [immediate release] and felodipine 5 mg [extended release]",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11234290\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not available in U.S.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F5951335\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Swallow tablet whole; tablet should not be divided, crushed, or chewed. May be administered without food or with a small meal that is low in fat and carbohydrates.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F5951196\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hypertension when combination therapy is appropriate (not for initial therapy)",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F5951244\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Incidence observed with combination product. Also see individual agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Vasodilation (3%), peripheral edema (2%), palpitation (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Headache (8%), dizziness (3%), vertigo (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Nausea (2%), abdominal pain (1%), diarrhea (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Back pain (2%), weakness (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Cough (6%), bronchitis (3%), upper respiratory infection (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Infection (2%), flu-like syndrome (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Agranulocytosis, angina pectoris, arrhythmia, arthralgia, arthritis, arthrosis, bilirubin increased, blurred vision, bronchospasm, carcinoma, cerebrovascular accident, colitis, cystitis, diabetes mellitus, dyspnea, dysuria, ECG abnormal, enteritis, extrasystoles, facial edema, gastroenteritis, gout, hematocrit decreased, hemiplegia, hemoglobin decreased, hepatic enzymes increased, hepatic necrosis (fulminant), hydronephrosis, hyperkalemia, hypesthesia, leukocytoclastic vasculitis, leukopenia, liver fatty deposit, MI, myalgia, neutropenia, orthostatic hypotension, paresthesia, peripheral vascular disorder, pruritus, pulmonary embolism, pyelonephritis, rash, retinal disorder, shock, sinus bradycardia, tachycardia, T-wave inverted, urticaria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F5951201\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to felodipine or other dihydropyridines, ramipril or other ACE inhibitors, or any other component of the formulation; hemodynamically relevant bilateral renal artery stenosis or unilateral renal artery stenosis in the single kidney; hypotensive states; history of angioedema; women of childbearing potential; pregnancy; breast-feeding",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F5951202\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Angina/MI: Increased angina and/or MI have occurred with initiation or dosage titration of dihydropyridine calcium channel blockers. Reflex tachycardia may occur resulting in angina and/or MI in patients with obstructive coronary disease, especially in the absence of concurrent beta-blockade.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Angioedema: At any time during treatment (especially following first dose) angioedema may occur rarely with ACE inhibitors. It may involve the head and neck (potentially compromising airway) or the intestine (presenting with abdominal pain). African-Americans may be at an increased risk. Prolonged frequent monitoring may be required especially if tongue, glottis, or larynx are involved as they are associated with airway obstruction. Patients with a history of airway surgery may have a higher risk of airway obstruction. Aggressive early and appropriate management is critical. Use in patients with idiopathic or hereditary angioedema or previous angioedema associated with ACE inhibitor therapy is contraindicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Cholestatic jaundice: A rare toxicity associated with ACE inhibitors includes cholestatic jaundice, which may progress to fulminant hepatic necrosis; discontinue if marked elevation of hepatic transaminases or jaundice occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; CNS effects: Dizziness, lightheadedness, and/or syncope due to a reduction in blood pressure may impair alertness and the ability to perform dangerous tasks (driving, operating machinery).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Cough: An ACE inhibitor cough is a dry, hacking, nonproductive one that usually occurs within the first few months of treatment and should generally resolve within 1-4 weeks after discontinuation of the ACE inhibitor. Other causes of cough should be considered (eg, pulmonary congestion in patients with heart failure) and excluded prior to discontinuation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Gingival hyperplasia: Gingival hyperplasia may be induced by felodipine in patients with gingivitis and periodontitis. Effects may be reversed with good oral hygiene and mechanical debridement of teeth.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hyperkalemia: May occur with ACE inhibitors; risk factors include renal dysfunction, diabetes mellitus, concomitant use of potassium-sparing diuretics, potassium supplements, and/or potassium-containing salts. Use cautiously, if at all, with these agents and monitor potassium closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypersensitivity reactions: Anaphylactic/anaphylactoid reactions can occur with ACE inhibitors. Severe anaphylactoid reactions may be seen during hemodialysis (eg, CVVHD) with high-flux dialysis membranes (eg, AN69), and rarely, during low density lipoprotein apheresis with dextran sulfate cellulose. Rare cases of anaphylactoid reactions have been reported in patients undergoing sensitization treatment with hymenoptera (bee, wasp) venom while receiving ACE inhibitors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypotension/syncope:  Symptomatic hypotension with or without syncope can occur (usually with the first several doses); effects are most often observed in volume-depleted patients; correct volume depletion prior to initiation; close monitoring of patient is required especially with initial dosing and dosing increases; blood pressure must be lowered at a rate appropriate for the patient's clinical condition. Although dose reduction may be necessary, hypotension is not a reason for discontinuation of future ACE inhibitor use especially in patients with heart failure where a reduction in systolic blood pressure is a desirable observation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Neutropenia/agranulocytosis: Another ACE Inhibitor, captopril, has been associated with rare cases of agranulocytosis, neutropenia, or leukopenia with myeloid hypoplasia. Similar effects have been observed rarely in patients receiving ramipril; causal relationship could not be excluded. Patients with renal impairment are at high risk of developing neutropenia. Patients with both renal impairment and collagen vascular disease (eg, systemic lupus erythematosus) are at an even higher risk of developing neutropenia. Periodically monitor CBC with differential in these patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Peripheral edema: The most common side effect of felodipine (dose dependent) is peripheral edema; occurs within 2-3 weeks of starting therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Renal function deterioration: May be associated with deterioration of renal function and/or increases in serum creatinine, particularly in patients with low renal blood flow (eg, renal artery stenosis, heart failure) whose glomerular filtration rate (GFR) is dependent on efferent arteriolar vasoconstriction by angiotensin II; deterioration may result in oliguria, acute renal failure, and progressive azotemia. Small increases in serum creatinine may occur following initiation of therapy; consider discontinuation only in patients with progressive and/or significant deterioration in renal function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Aortic stenosis: Use with extreme caution in patients with severe aortic stenosis; may reduce coronary perfusion resulting in ischemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Cardiovascular disease: Initiation of therapy in patients with ischemic heart disease or cerebrovascular disease warrants close observation due to the potential consequences posed by falling blood pressure (eg, MI, stroke). Fluid replacement, if needed, may restore blood pressure; therapy may then be resumed. Discontinue therapy in patients whose hypotension recurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Collagen vascular disease: Use with caution in patients with collagen vascular disease especially with concomitant renal impairment; may be at increased risk for hematologic toxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Heart failure: Use with caution. Safety and efficacy has not been established in patients with heart failure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; ACEI therapy has been associated with hepatitis, and elevated hepatic enzymes and bilirubin; lower starting dose may be necessary; evaluate hepatic function at baseline before initiating therapy and closely monitor thereafter.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypertrophic cardiomyopathy (HCM) with outflow tract obstruction: Use with caution in patients with HCM and outflow tract obstruction since reduction in afterload may worsen symptoms associated with this condition.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Renal artery stenosis: Use with caution in patients with unstented unilateral/bilateral renal artery stenosis. When unstented bilateral renal artery stenosis is present, use is generally avoided due to the elevated risk of deterioration in renal function unless possible benefits outweigh risks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Renal impairment: Use with caution in pre-existing renal insufficiency; dosage adjustment may be needed. Avoid rapid dosage escalation which may lead to further renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Angiotensin receptor blockers: Concurrent use of angiotensin receptor blockers may increase the risk of clinically-significant adverse events (eg, renal dysfunction, hyperkalemia). Concurrent use with telmisartan is not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Elderly: May be more sensitive to hypotensive effects; initiate therapy at a lower dose in the elderly.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Pregnancy:",
"     <b>",
"      [Canadian Boxed Warning]: ACEIs can cause injury and death to the developing fetus. ACEIs should be discontinued as soon as possible once pregnancy is detected.",
"     </b>",
"     Use is contraindicated in pregnancy as well as in women of childbearing potential; exclude pregnancy prior to therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Appropriate use: Used as a replacement for separate dosing of components or combination therapy when response to single agent is suboptimal; the fixed combination is not indicated for initial treatment of hypertension.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Surgery: Use with caution before, during, or immediately after major surgery. Cardiopulmonary bypass, intraoperative blood loss or vasodilating anesthesia increases endogenous rennin release. Use of ACE inhibitors perioperatively will blunt angiotensin II formation and may result in hypotension.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F5951249\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F5951248\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: May enhance the hyperkalemic effect of ACE Inhibitors. Aliskiren may enhance the hypotensive effect of ACE Inhibitors. Aliskiren may enhance the nephrotoxic effect of ACE Inhibitors. Management: Avoid aliskiren use with ACEIs or ARBs in patients with diabetes or estimated glomerular filtration rate below 60 mL/min. In other patients receiving these combinations, monitor serum potassium, serum creatinine, and blood pressure periodically.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: ACE Inhibitors may enhance the potential for allergic or hypersensitivity reactions to Allopurinol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May enhance the hypotensive effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: May enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May enhance the adverse/toxic effect of Calcium Channel Blockers. Specifically, itraconazole may enhance the negative inotropic effects of verapamil or diltiazem. Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Calcium Channel Blockers. Management: Concurrent use of felodipine or nisoldipine with itraconazole is specifically contraindicated.  Frequent monitoring is warranted with any such combination; calcium channel blocker dose reductions may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprotinin: May diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atosiban: Calcium Channel Blockers may enhance the adverse/toxic effect of Atosiban. Specifically, there may be an increased risk for pulmonary edema and/or dyspnea.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AzaTHIOprine: ACE Inhibitors may enhance the myelosuppressive effect of AzaTHIOprine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May increase the metabolism of Calcium Channel Blockers. Management: Monitor for decreased therapeutic effects of calcium channel blockers with concomitant barbiturate therapy. Calcium channel blocker dose adjustments may be necessary. Nimodipine Canadian labeling contraindicates concomitant use with phenobarbital.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Calcium Channel Blockers (Dihydropyridine) may enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): Calcium Channel Blockers (Dihydropyridine) may enhance the hypotensive effect of Calcium Channel Blockers (Nondihydropyridine). Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Calcium Channel Blockers (Dihydropyridine).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: May diminish the therapeutic effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Canagliflozin: May enhance the hyperkalemic effect of ACE Inhibitors. Canagliflozin may enhance the hypotensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Calcium Channel Blockers (Dihydropyridine). Management: Consider calcium channel blocker (CCB) dose adjustments or alternative therapy  in patients receiving concomitant carbamazepine. Nimodipine Canadian labeling contraindicates concurrent use with carbamazepine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May increase the serum concentration of Calcium Channel Blockers. Management: Consider alternatives to cimetidine. If no suitable alternative exists, monitor for increased effects of calcium channel blockers following cimetidine initiation/dose increase, and decreased effects following cimetidine discontinuation/dose decrease.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clopidogrel: Calcium Channel Blockers may diminish the therapeutic effect of Clopidogrel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): ACE Inhibitors may enhance the nephrotoxic effect of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May decrease the metabolism of Calcium Channel Blockers (Dihydropyridine).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C8 Substrates: CYP2C8 Inhibitors (Moderate) may decrease the metabolism of CYP2C8 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DPP-IV Inhibitors: May enhance the adverse/toxic effect of ACE Inhibitors. Specifically, the risk of angioedema may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: May enhance the adverse/toxic effect of ACE Inhibitors. Specifically, the risk of angioedema may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ferric Gluconate: ACE Inhibitors may enhance the adverse/toxic effect of Ferric Gluconate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May decrease the metabolism of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Calcium Channel Blockers may increase the serum concentration of Fosphenytoin.  Management: Monitor for phenytoin toxicity with concomitant use of a calcium channel blocker (CCB) or decreased phenytoin effects with CCB discontinuation. Monitor for decreased CCB therapeutic effects. Nimodipine Canadian labeling contraindicates use with phenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gold Sodium Thiomalate: ACE Inhibitors may enhance the adverse/toxic effect of Gold Sodium Thiomalate. An increased risk of nitritoid reactions has been appreciated.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May increase the serum concentration of Felodipine. Management: Monitor hemodynamic response to felodipine closely in patients who consume grapefruit juice.  Felodipine dose adjustment and/or modification of grapefruit juice ingestion may be needed. Felodipine Canadian labeling recommends avoiding grapefruit juice.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Icatibant: May diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Dextran Complex: ACE Inhibitors may enhance the adverse/toxic effect of Iron Dextran Complex. Specifically, patients receiving an ACE inhibitor may be at an increased risk for anaphylactic-type reactions.  Management: Follow iron dextran recommendations closely regarding both having resuscitation equipment and trained personnel on-hand prior to iron dextran administration and the use of a test dose prior to the first therapeutic dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: May increase the serum concentration of Felodipine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lanthanum: May decrease the serum concentration of ACE Inhibitors. Management: Administer angiotensin-converting enzyme inhibitors at least two hours before or after lanthanum.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: ACE Inhibitors may increase the serum concentration of Lithium.  Management: Lithium dosage reductions will likely be needed following the addition of an ACE inhibitor.  Monitor patient response to lithium closely following addition or discontinuation of concurrent ACE inhibitor treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May enhance the hypotensive effect of ACE Inhibitors. Specifically, postural hypotension which can accompany ACE Inhibitor initiation. Loop Diuretics may enhance the nephrotoxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of Calcium Channel Blockers. Management: Consider using a noninteracting macrolide. Monitor for increased therapeutic effects of calcium channel blockers if an interacting macrolide antibiotic is initiated, or decreased effects if a macrolide is discontinued.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Salts: Calcium Channel Blockers may enhance the adverse/toxic effect of Magnesium Salts. Magnesium Salts may enhance the hypotensive effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Melatonin: May diminish the antihypertensive effect of Calcium Channel Blockers (Dihydropyridine).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nafcillin: May increase the metabolism of Calcium Channel Blockers.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents (Nondepolarizing): Calcium Channel Blockers may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nitroprusside: Calcium Channel Blockers may enhance the hypotensive effect of Nitroprusside.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: ACE Inhibitors may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Calcium Channel Blockers may increase the serum concentration of Phenytoin.  Management: Monitor for phenytoin toxicity with concomitant use of a calcium channel blocker (CCB) or decreased phenytoin effects with CCB discontinuation. Monitor for decreased CCB therapeutic effects. Nimodipine Canadian labeling contraindicates use with phenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Salts: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May decrease the metabolism of Calcium Channel Blockers (Dihydropyridine).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May increase the metabolism of Calcium Channel Blockers. This primarily affects oral forms of calcium channel blockers. Management: The labeling for some U.S. and Canadian calcium channel blockers contraindicate use with rifampin however recommendations vary. Consult appropriate labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May diminish the antihypertensive effect of ACE Inhibitors. They may also diminish other beneficial pharmacodynamic effects desired for the treatment of CHF.  The effects are likely dose-related.  100 mg doses aspirin appear to cause no problems, whereas 300 mg doses appear to significantly affect ACE Inhibitor efficacy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sirolimus: May enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: ACE Inhibitors may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with ACEIs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Calcium Channel Blockers (Dihydropyridine) may increase the serum concentration of Tacrolimus (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telmisartan: May increase the serum concentration of Ramipril. Concentrations of the active metabolite, ramiprilat, may also be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Temsirolimus: May enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May enhance the hypotensive effect of ACE Inhibitors. Specifically, postural hypotension which can accompany ACE Inhibitor initiation. Thiazide Diuretics may enhance the nephrotoxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TiZANidine: May enhance the hypotensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trimethoprim: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F13382063\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ethanol: Increases felodipine's absorption; watch for a greater hypotensive effect.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Food: Compared to a fasted state, felodipine peak plasma concentrations are increased up to twofold when taken after a meal high in fat or carbohydrates. Grapefruit juice similarly increases felodipine C",
"     <sub>",
"      max",
"     </sub>",
"     by twofold. Increased therapeutic and vasodilator side effects, including severe hypotension and myocardial ischemia, may occur. May be taken with a small meal that is low in fat and carbohydrates; avoid grapefruit juice during therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herb/Nutraceutical: St John's wort may decrease felodipine levels. Avoid dong quai if using for hypertension (has estrogenic activity). Avoid ephedra, yohimbe, ginseng (may worsen hypertension). Avoid garlic (may have increased antihypertensive effect).",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5951197\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use is contraindicated in pregnancy. See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F5951199\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion of felodipine and ramipril into breast milk unknown/contraindicated",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F5951200\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use is contraindicated while breast-feeding. See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F5951252\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken with a small meal that is low in fat and carbohydrates.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F5951337\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure; renal function, potassium; periodically monitor CBC with differential (more frequently in patients with collagen vascular disease and/or renal impairment)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F11390216\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Tazko (BE);",
"     </li>",
"     <li>",
"      Triacor (AR, GR);",
"     </li>",
"     <li>",
"      Triapin (AT, GB, IE, KP, NL, PH, PT, TW);",
"     </li>",
"     <li>",
"      Triasyn (CZ, HN);",
"     </li>",
"     <li>",
"      Unimax (CH, DE, FI, SE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F5951325\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ramipril is an ACE inhibitor which first undergoes enzymatic saponification by esterases in the liver, to its active metabolite ramiprilat. The pharmacodynamic effects of ramipril result from the high-affinity, competitive, reversible binding of ramiprilat to angiotensin-converting enzyme thus preventing the formation of the potent vasoconstrictor angiotensin II from angiotensin I. This isomerized enzyme-inhibitor complex has a slow rate of dissociation, which results in high potency and a long duration of action; a CNS mechanism may also be involved in the hypotensive effect as angiotensin II increases adrenergic outflow from CNS; vasoactive kallikreins may be decreased in conversion to active hormones by ACE inhibitors, thus reducing blood pressure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Felodipine inhibits calcium ions from entering the &ldquo;slow channels&rdquo; or select voltage-sensitive areas of vascular smooth muscle and myocardium during depolarization, producing a relaxation of coronary vascular smooth muscle and coronary vasodilation, increases myocardial oxygen delivery in patients with vasospastic angina.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F5951327\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Chase MP, Fiarman GS, Scholz FJ, et al, &ldquo;Angioedema of the Small Bowel Due to an Angiotensin-Converting Enzyme Inhibitor,&rdquo;",
"      <i>",
"       J Clin Gastroenterol",
"      </i>",
"      , 2000, 31(3):254-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/56/42887/abstract-text/11034011/pubmed\" id=\"11034011\" target=\"_blank\">",
"        11034011",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cooper WO, Hernandez-Diaz S, Arbogast PG, et al, &ldquo;Major Congenital Malformations After First-Trimester Exposure to ACE Inhibitors,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2006, 354(23):2443-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/56/42887/abstract-text/16760444/pubmed\" id=\"16760444\" target=\"_blank\">",
"        16760444",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cvetkovic R and Plosker G, &ldquo;Ramipril/Felodipine Extended-Release Fixed-Dose Combination: A Review of Its Use in the Management of Essential Hypertension,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 2005, 65(13):1851-68.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/56/42887/abstract-text/16114982/pubmed\" id=\"16114982\" target=\"_blank\">",
"        16114982",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mastrobattista JM, &ldquo;Angiotensin Converting Enzyme Inhibitors in Pregnancy,&rdquo;",
"      <i>",
"       Semin Perinatol",
"      </i>",
"      , 1997, 21(2):124-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/56/42887/abstract-text/9201818/pubmed\" id=\"9201818\" target=\"_blank\">",
"        9201818",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9471 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-41275854C3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_56_42887=[""].join("\n");
var outline_f41_56_42887=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5951190\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5951194\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5951331\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5951332\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5951333\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5951334\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5951342\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11234290\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5951335\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5951196\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5951244\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5951201\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5951202\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5951249\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5951248\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13382063\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5951197\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5951199\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5951200\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5951252\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5951337\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11390216\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5951325\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5951327\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9471\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9471|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?19/63/20469?source=related_link\">",
"      Ramipril and felodipine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_56_42888="Ranitidine: Drug information";
var content_f41_56_42888=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ranitidine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?21/56/22405?source=see_link\">",
"    see \"Ranitidine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/1/33815?source=see_link\">",
"    see \"Ranitidine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F217321\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Zantac 150&reg; [OTC];",
"     </li>",
"     <li>",
"      Zantac 75&reg; [OTC];",
"     </li>",
"     <li>",
"      Zantac&reg;;",
"     </li>",
"     <li>",
"      Zantac&reg; EFFERdose&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F217322\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Acid Reducer;",
"     </li>",
"     <li>",
"      Apo-Ranitidine&reg;;",
"     </li>",
"     <li>",
"      CO Ranitidine;",
"     </li>",
"     <li>",
"      Dom-Ranitidine;",
"     </li>",
"     <li>",
"      Myl-Ranitidine;",
"     </li>",
"     <li>",
"      Mylan-Ranitidine;",
"     </li>",
"     <li>",
"      Nu-Ranit;",
"     </li>",
"     <li>",
"      PHL-Ranitidine;",
"     </li>",
"     <li>",
"      PMS-Ranitidine;",
"     </li>",
"     <li>",
"      Ranitidine Injection, USP;",
"     </li>",
"     <li>",
"      RAN&trade;-Ranitidine;",
"     </li>",
"     <li>",
"      ratio-Ranitidine;",
"     </li>",
"     <li>",
"      Riva-Ranitidine;",
"     </li>",
"     <li>",
"      Sandoz-Ranitidine;",
"     </li>",
"     <li>",
"      ScheinPharm Ranitidine;",
"     </li>",
"     <li>",
"      Teva-Ranitidine;",
"     </li>",
"     <li>",
"      Zantac 75&reg;;",
"     </li>",
"     <li>",
"      Zantac Maximum Strength Non-Prescription;",
"     </li>",
"     <li>",
"      Zantac&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F217373\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Histamine H",
"      <sub>",
"       2",
"      </sub>",
"      Antagonist",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F217326\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Duodenal ulcer:",
"     </b>",
"     Oral: Treatment: 150 mg twice daily, or 300 mg once daily after the evening meal or at bedtime; maintenance: 150 mg once daily at bedtime",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Eradication of",
"     </b>",
"     <b>",
"      <i>",
"       Helicobacter pylori",
"      </i>",
"     </b>",
"     : Oral: 150 mg twice daily; requires combination therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pathological hypersecretory conditions:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Oral:",
"     </i>",
"     150 mg twice daily; adjust dose or frequency as clinically indicated; doses of up to 6 g/day have been used",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.V.",
"     </i>",
"     : Continuous infusion for Zollinger-Ellison: Initial: 1 mg/kg/hour; measure gastric acid output at 4 hours, if &gt;10 mEq or if patient is symptomatic, increase dose in increments of 0.5 mg/kg/hour; doses of up to 2.5 mg/kg/hour (or 220 mg/hour) have been used",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gastric ulcer, benign:",
"     </b>",
"     <i>",
"      Oral:",
"     </i>",
"     150 mg twice daily; maintenance: 150 mg once daily at bedtime",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      GERD:",
"     </b>",
"     <i>",
"      Oral:",
"     </i>",
"     150 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Erosive esophagitis:",
"     </b>",
"     <i>",
"      Oral:",
"     </i>",
"     Treatment: 150 mg 4 times/day; maintenance: 150 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prevention of heartburn:",
"     </b>",
"     <i>",
"      Oral:",
"     </i>",
"     Zantac 75&reg; [OTC]: 75 mg 30-60 minutes before eating food or drinking beverages which cause heartburn; maximum: 150 mg in 24 hours; do not use for more than 14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Stress ulcer prophylaxis (unlabeled use; ASHP, 1999):",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     Intended for patients with associated risk factors (eg, coagulopathy, mechanical ventilation for &gt;48 hours, severe sepsis); discontinue use once risk factors have resolved.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Oral, nasogastric (NG) tube:",
"     </i>",
"     150 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.V.:",
"     </i>",
"     Intermittent bolus: 50 mg every 6-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Patients not able to take oral medication:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.M.:",
"     </i>",
"     50 mg every 6-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.V.:",
"     </i>",
"     Intermittent bolus or infusion: 50 mg every 6-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Continuous I.V. infusion:",
"     </i>",
"     6.25 mg/hour",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F217349\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/1/33815?source=see_link\">",
"      see \"Ranitidine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Duodenal and gastric ulcer:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Oral:",
"     </i>",
"     Children 1 month to 16 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Treatment: 4-8 mg/kg/day divided twice daily; maximum: 300 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Maintenance: 2-4 mg/kg/day once daily; maximum: 150 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.V.:",
"     </i>",
"     2-4 mg/kg/day divided every 6-8 hours; maximum: 200 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      GERD and erosive esophagitis:",
"     </b>",
"     Children 1 month to 16 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Oral:",
"     </i>",
"     5-10 mg/kg/day divided twice daily; maximum: GERD: 300 mg/day, erosive esophagitis: 600 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.V. (unlabeled):",
"     </i>",
"     2-4 mg/kg/day divided every 6-8 hours; maximum: 200 mg/day",
"     <b>",
"      or as an alternative",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Continuous infusion:",
"     </i>",
"     Initial: 1 mg/kg/dose for one dose followed by infusion of 0.08-0.17 mg/kg/hour or 2-4 mg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prevention of heartburn:",
"     </b>",
"     <i>",
"      Oral:",
"     </i>",
"     Children &ge;12 years: Zantac 75&reg; [OTC]: 75 mg 30-60 minutes before eating food or drinking beverages which cause heartburn; maximum: 150 mg/24 hours; do not use for more than 14 days",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F217327\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F217328\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 150 mg every 24 hours; adjust dose cautiously if needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: 50 mg every 18-24 hours; adjust dose cautiously if needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hemodialysis: Adjust dosing schedule so that dose coincides with the end of hemodialysis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Stress ulcer prophylaxis (ASHP, 1999): Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50  mL/minute:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral, nasogastric (NG) tube: 150 mg 1-2 times daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: Intermittent bolus: 50 mg every 12-24 hours",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F217329\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Patients with hepatic impairment may have minor changes in ranitidine half-life, distribution, clearance, and bioavailability; dosing adjustments are not necessary; monitor patient.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F217292\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral: 150 mg, 300 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed in 1/2 NS [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zantac&reg;: 50 mg (50 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution: 25 mg/mL (2 mL, 6 mL, 40 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zantac&reg;: 25 mg/mL (2 mL, 6 mL, 40 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Syrup, oral: 15 mg/mL (1 mL, 5 mL, 10 mL, 120 mL, 473 mL, 474 mL, 480 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zantac&reg;: 15 mg/mL (480 mL) [contains ethanol 7.5%; peppermint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 75 mg, 150 mg, 300 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zantac 150&reg;: 150 mg [DSC]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zantac 150&reg;: 150 mg [DSC] [cool mint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zantac 150&reg;: 150 mg [sodium free, sugar free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zantac 150&reg;: 150 mg [sodium free, sugar free; cool mint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zantac 75&reg;: 75 mg [DSC]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zantac 75&reg;: 75 mg [sodium free, sugar free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zantac 75&reg;: 75 mg [DSC] [sugar free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zantac&reg;: 150 mg, 300 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet for solution, oral [effervescent]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zantac&reg; EFFERdose&reg;: 25 mg [contains phenylalanine 2.81 mg/tablet, sodium 30.52 mg (1.33 mEq)/tablet, sodium benzoate]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F217276\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes effervescent tablet, premixed infusion",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F217296\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ranitidine injection may be administered I.M. or I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M.: Injection is administered undiluted",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: Must be diluted; may be administered I.V. push, intermittent I.V. infusion, or continuous I.V. infusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V. push: Manufacturer recommends a maximum rate of administration of 10 mg/minute (or over 5 minutes); however, may also be administered at a maximum rate of 25 mg/minute (or over 2 minutes) if necessary (Coursin, 1988; Goelzer, 1988; Smith, 1987).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Intermittent I.V. infusion: Administer over 15-20 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Continuous I.V. infusion: Titrate dosage based on gastric pH.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     EFFERdose&reg;: Should not be chewed, swallowed whole, or dissolved on tongue: 25 mg tablet: Dissolve in at least 5 mL of water; wait until completely dissolved before administering",
"    </p>",
"   </div>",
"   <div class=\"block uica drugH1Div\" id=\"F14473102\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Usual Infusion Concentrations: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Premixed solutions available",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      I.V. infusion:",
"     </b>",
"     50 mg in 50 mL (concentration: 1 mg/mL)",
"     <b>",
"      or",
"     </b>",
"     500 mg in 250 mL (concentration: 2 mg/mL) of D",
"     <sub>",
"      5",
"     </sub>",
"     W or NS",
"    </p>",
"   </div>",
"   <div class=\"block uicp drugH1Div\" id=\"F14473103\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Usual Infusion Concentrations: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Premixed solutions available",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      I.V. infusion:",
"     </b>",
"     0.5 mg/mL",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F217380\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, fat emulsion 10%, LR, NS, sodium bicarbonate 5%; for injection, do not add other medications to premixed bag;",
"     <b>",
"      variable compatibility (consult detailed reference)",
"     </b>",
"     in D",
"     <sub>",
"      5",
"     </sub>",
"     LR, TPN.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Acyclovir, alcohol (ethyl), aldesleukin, allopurinol, amifostine, aminophylline, amsacrine, anidulafungin, atracurium, aztreonam, bivalirudin, cefazolin, cefepime, cefoxitin, ceftazidime, ciprofloxacin, cisatracurium, cisplatin, cladribine, cyclophosphamide, cytarabine, dexmedetomidine, diltiazem, dobutamine, docetaxel, dopamine, doripenem, doxapram, doxorubicin, doxorubicin liposome, enalaprilat, epinephrine, esmolol, etoposide phosphate, fenoldopam, fentanyl, filgrastim, fluconazole, fludarabine, foscarnet, furosemide, gallium nitrate, gemcitabine, granisetron, heparin, hetastarch in lactate electrolyte injection (Hextend&reg;), hydromorphone, idarubicin, labetalol, linezolid, lorazepam, melphalan, meperidine, methotrexate, midazolam, milrinone, morphine, nicardipine, nitroglycerin, norepinephrine, ondansetron, ondansetron with paclitaxel, oxaliplatin, paclitaxel, pancuronium, pemetrexed, piperacillin, piperacillin/tazobactam, procainamide, propofol, remifentanil, sargramostim, tacrolimus, telavancin, teniposide, theophylline, thiopental, thiotepa, tigecycline, vecuronium, vinorelbine, warfarin, zidovudine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amphotericin B cholesteryl sulfate complex, hetastarch in sodium chloride 0.9%, insulin (regular), pantoprazole.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Drotrecogin alfa, TPN.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Atropine, dexamethasone sodium phosphate, dimenhydrinate, diphenhydramine, dobutamine, dopamine, fentanyl, glycopyrrolate, heparin, hydromorphone, meperidine, metoclopramide, morphine, nalbuphine, oxymorphone, pentazocine, prochlorperazine edisylate, promethazine, scopolamine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Hydroxyzine, methotrimeprazine, midazolam, pantoprazole, pentobarbital, phenobarbital.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Chlorpromazine, diazepam, lorazepam.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F217295\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Zantac&reg;: Short-term and maintenance therapy of duodenal ulcer, gastric ulcer, gastroesophageal reflux disease (GERD), active benign ulcer, erosive esophagitis, and pathological hypersecretory conditions; as part of a multidrug regimen for",
"     <i>",
"      H. pylori",
"     </i>",
"     eradication to reduce the risk of duodenal ulcer recurrence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Zantac 75&reg; [OTC]: Relief of heartburn, acid indigestion, and sour stomach",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F217370\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Recurrent postoperative ulcer, upper GI bleeding, prevention of acid-aspiration pneumonitis during surgery, and prevention of stress-induced ulcers",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F217382\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Ranitidine may be confused with amantadine, rimantadine",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Zantac&reg; may be confused with Xanax&reg;, Zarontin&reg;, Zofran&reg;, ZyrTEC&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F217371\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Asystole, atrioventricular block, bradycardia (with rapid I.V. administration), premature ventricular beats, tachycardia, vasculitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Agitation, dizziness, depression, hallucinations, headache, insomnia, malaise, mental confusion, somnolence, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Alopecia, erythema multiforme, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Prolactin levels increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal discomfort/pain, constipation, diarrhea, nausea, necrotizing enterocolitis (VLBW neonates; Guillet, 2006), pancreatitis, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Acquired immune hemolytic anemia, acute porphyritic attack, agranulocytosis, aplastic anemia, granulocytopenia, leukopenia, pancytopenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Cholestatic hepatitis, hepatic failure, hepatitis, jaundice",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Transient pain, burning or itching at the injection site",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, involuntary motor disturbance, myalgia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Acute interstitial nephritis, serum creatinine increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Pneumonia (causal relationship not established)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis, angioneurotic edema, hypersensitivity reactions (eg, bronchospasm, fever, eosinophilia)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F217299\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ranitidine or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F217280\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; B",
"     <sub>",
"      12",
"     </sub>",
"     deficiency: Long-term therapy may be associated with vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     deficiency.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Confusion: Reversible confusional states (rare), usually clearing within 3-4 days after discontinuation, have been linked to use. Increased age (&gt;50 years) and renal or hepatic impairment are thought to be associated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastric malignancy: Relief of symptoms does not preclude the presence of a gastric malignancy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Porphyria: Avoid use in patients with a history of acute porphyria; may precipitate attacks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Phenylalanine: EFFERdose&reg; formulation contains phenylalanine.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F217367\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (minor), CYP2C19 (minor), CYP2D6 (minor), P-glycoprotein;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (weak), CYP2D6 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F217285\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atazanavir: H2-Antagonists may decrease the serum concentration of Atazanavir.  Management: Specific dose limitations and administration guidelines exist; consult full interaction monograph or atazanavir prescribing information.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: H2-Antagonists may decrease the serum concentration of Bosutinib.  Management: Administer histamine H2 receptor antagonists more than 2 hours before or after bosutinib.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefditoren: H2-Antagonists may decrease the serum concentration of Cefditoren.  Management: Concomitant use of cefditoren with H2-antagonists and antacids is not recommended. Consider alternative methods to control acid reflux (eg, diet modification) or alternative antimicrobial therapy if use of H2-antagonists can not be avoided.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefpodoxime: H2-Antagonists may decrease the absorption of Cefpodoxime. Separate oral doses by at least 2 hours.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefuroxime: H2-Antagonists may decrease the absorption of Cefuroxime. Separate oral doses by at least 2 hours.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: H2-Antagonists may decrease the absorption of Dasatinib.  Management: Antacids (taken 2 hours before or after dasatinib administration) can be used in place of H2-antagonists if some acid-reducing therapy is needed.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Delavirdine: H2-Antagonists may decrease the serum concentration of Delavirdine.  Management: Chronic therapy with H2-antagonists should be avoided in patients who are being treated with delavirdine.  The clinical significance of short-term H2-antagonist therapy with delavirdine is uncertain, but such therapy should be undertaken with caution.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dexmethylphenidate: H2-Antagonists may increase the absorption of Dexmethylphenidate. Specifically, H2-antagonists may interfere with the normal release of drug from the extended-release capsules (Focalin XR brand), which could result in both increased absorption (early) and decreased delayed absorption.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Erlotinib: H2-Antagonists may decrease the serum concentration of Erlotinib.  Management: Avoid H2-antagonists in patients receiving erlotinib when possible.  If concomitant treatment cannot be avoided, erlotinib should be dosed once daily, 10 hours after and at least 2 hours before H2-antagonist dosing.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosamprenavir: H2-Antagonists may decrease the serum concentration of Fosamprenavir. Cimetidine may also inhibit the metabolism of the active metabolite amprenavir, making its effects on fosamprenavir/amprenavir concentrations difficult to predict.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gefitinib: H2-Antagonists may decrease the serum concentration of Gefitinib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Indinavir: H2-Antagonists may decrease the serum concentration of Indinavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Salts: H2-Antagonists may decrease the absorption of Iron Salts.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ferric Gluconate; Ferumoxytol; Iron Dextran Complex; Iron Sucrose.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: H2-Antagonists may decrease the serum concentration of Itraconazole.  Management: When this combination is used, the itraconazole should be administered with a cola beverage (8 ounces). Itraconazole oral suspension may be less sensitive to this interaction.  Monitor patient response to itraconazole closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): H2-Antagonists may decrease the serum concentration of Ketoconazole (Systemic).  Management: Administer oral ketoconazole at least 2 hours prior to use of any H2-receptor antagonist.  Monitor patients closely for signs of inadequate clinical response to ketoconazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mesalamine: H2-Antagonists may diminish the therapeutic effect of Mesalamine. Histamine H2-Antagonist-mediated increases in gastrointestinal pH may cause the premature release of mesalamine from specific sustained-release mesalamine products.  Management: Consider avoiding concurrent administration of high-dose histamine H2-receptor antagonists with sustained-release mesalamine products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: H2-Antagonists may increase the absorption of Methylphenidate. Specifically, H2-antagonists may interfere with the normal release of drug from the extended-release capsules (Ritalin LA brand), which could result in both increased absorption (early) and decreased delayed absorption.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): H2-Antagonists may decrease the serum concentration of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, the absorption of iron may be impaired by H2-antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nelfinavir: H2-Antagonists may decrease the serum concentration of Nelfinavir. Concentrations of the active M8 metabolite may also be reduced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: H2-Antagonists may decrease the serum concentration of Nilotinib.  Management: Separate the administration of nilotinib and the H2 receptor antagonist by several hours whenever possible in order to minimize the risk of a significant interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: H2-Antagonists may decrease the serum concentration of Ponatinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Posaconazole: H2-Antagonists may decrease the serum concentration of Posaconazole.  Management: Avoid concurrent use whenever possible.  Monitor patients closely for decreased antifungal effects if this combination is used.  Consider using a noninteracting antifungal as appropriate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prasugrel: Ranitidine may decrease serum concentrations of the active metabolite(s) of Prasugrel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Procainamide: Ranitidine may increase the serum concentration of Procainamide. Ranitidine may also increase the concentration of the active N-acetyl-procainamide (NAPA) metabolite.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rilpivirine: H2-Antagonists may decrease the serum concentration of Rilpivirine.  Management: Administer histamine H2 receptor antagonists at least 12 hours before or 4 hours after rilpivirine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Risedronate: H2-Antagonists may increase the serum concentration of Risedronate. This applies specifically to delayed-release risedronate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saquinavir: H2-Antagonists may increase the serum concentration of Saquinavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonylureas: Ranitidine may increase the serum concentration of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Varenicline: H2-Antagonists may increase the serum concentration of Varenicline.  Management: Monitor for increased varenicline adverse effects with concomitant use of cimetidine or other H2-antagonists, particularly in patients with severe renal impairment. International product labeling recommendations vary. Consult appropriate labeling.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vismodegib: H2-Antagonists may decrease the serum concentration of Vismodegib.  Management: Carefully consider the need for any medication that increases the pH of the upper GI tract (PPIs, H2RAs, antacids), as these could significantly reduce vismodegib systemic exposure. Vismodegib dose increases are unlikely to compensate for this effect.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Warfarin: Ranitidine may increase the serum concentration of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F217316\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Avoid ethanol (may cause gastric mucosal irritation).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Does not interfere with absorption of ranitidine.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F217288\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F217302\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in animal studies; therefore, ranitidine is classified as pregnancy category B. Ranitidine crosses the placenta. An increased risk of congenital malformations or adverse events in the newborn has generally not been observed following maternal use of ranitidine during pregnancy. Histamine H",
"     <sub>",
"      2",
"     </sub>",
"     antagonists have been evaluated for the treatment of gastroesophageal reflux disease (GERD) as well as gastric and duodenal ulcers during pregnancy. If needed, ranitidine is the agent of choice. Histamine H",
"     <sub>",
"      2",
"     </sub>",
"     antagonists may be used for aspiration prophylaxis prior to cesarean delivery.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F217334\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F10424156\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ranitidine is excreted into breast milk. The manufacturer recommends that caution be exercised when administering ranitidine to nursing women. Peak milk concentrations of ranitidine occur ~5.5 hours after the dose (case report).",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F217303\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Some products may contain phenylalanine and/or sodium. Oral dosage forms may be taken with or without food.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F217301\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Ranitidine HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mg (60): $91.27",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mg (30): $82.30",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Ranitidine HCl Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg/2 mL (2 mL): $4.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mg/6 mL (6 mL): $9.26",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1000 mg/40 mL (40 mL): $48.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Zantac in NaCl Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg/50 mL 0.45% (50 mL): $6.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Zantac Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg/2 mL (2 mL): $3.99",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mg/6 mL (6 mL): $9.26",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1000 mg/40 mL (40 mL): $60.54",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Syrup",
"     </b>",
"     (Ranitidine HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15 mg/mL (473 mL): $350.28",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Syrup",
"     </b>",
"     (Zantac Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15 mg/mL (480 mL): $411.29",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Ranitidine HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     75 mg (30): $4.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mg (100): $156.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mg (30): $81.04",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Wal-Zan 150 Maximum Strength Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mg (24): $8.99",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Wal-Zan 75 Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     75 mg (60): $14.99",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Zantac 150 Maximum Strength Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mg (50): $16.99",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Zantac 75 Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     75 mg (30): $8.99",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Zantac Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mg (60): $299.99",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mg (30): $272.27",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F217290\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     AST, ALT, serum creatinine; when used to prevent stress-related GI bleeding, measure the intragastric pH and try to maintain pH &gt;4; signs and symptoms of peptic ulcer disease, occult blood with GI bleeding, monitor renal function to correct dose",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F217304\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Acicard (TW);",
"     </li>",
"     <li>",
"      Acidex (AR);",
"     </li>",
"     <li>",
"      Aciflux (CN);",
"     </li>",
"     <li>",
"      Aciloc (BF, BJ, CI, CZ, ET, GH, GM, GN, IN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TW, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Acloral (MX);",
"     </li>",
"     <li>",
"      Acran (ID);",
"     </li>",
"     <li>",
"      Aldin (IN);",
"     </li>",
"     <li>",
"      Anistal (DO, GT, HN, NI, SV);",
"     </li>",
"     <li>",
"      Antagonin (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Antak (BR);",
"     </li>",
"     <li>",
"      Apo-Ranitidine (NZ);",
"     </li>",
"     <li>",
"      Arnetin (MY);",
"     </li>",
"     <li>",
"      Artonil (SE);",
"     </li>",
"     <li>",
"      Atural (PE);",
"     </li>",
"     <li>",
"      Ausran (AU);",
"     </li>",
"     <li>",
"      Azantac (FR, MX);",
"     </li>",
"     <li>",
"      Consec (IN);",
"     </li>",
"     <li>",
"      Contracid (PH);",
"     </li>",
"     <li>",
"      Danitin (PH);",
"     </li>",
"     <li>",
"      Eltidine (KP);",
"     </li>",
"     <li>",
"      Ezopta (GR);",
"     </li>",
"     <li>",
"      Galidrin (MX);",
"     </li>",
"     <li>",
"      Gastrial (AR);",
"     </li>",
"     <li>",
"      Gastridin (ID);",
"     </li>",
"     <li>",
"      Gastril (MY);",
"     </li>",
"     <li>",
"      Gastrone (PH);",
"     </li>",
"     <li>",
"      Gastrosedol (AR);",
"     </li>",
"     <li>",
"      Hexal Ranitic (AU);",
"     </li>",
"     <li>",
"      Hexer (ID);",
"     </li>",
"     <li>",
"      Histac (BF, BJ, CI, ET, GH, GM, GN, HU, IN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TH, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Histak (ZA);",
"     </li>",
"     <li>",
"      Huma-Ranidine (HU);",
"     </li>",
"     <li>",
"      Hyzan (HK);",
"     </li>",
"     <li>",
"      Iqfadina (MX);",
"     </li>",
"     <li>",
"      Junizac (DE);",
"     </li>",
"     <li>",
"      Locid (KP);",
"     </li>",
"     <li>",
"      Lydin (IN);",
"     </li>",
"     <li>",
"      Nadine (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Neoceptin-R (SG);",
"     </li>",
"     <li>",
"      Peptoran (HR);",
"     </li>",
"     <li>",
"      Ponaltin (KP);",
"     </li>",
"     <li>",
"      Ptinolin (GR);",
"     </li>",
"     <li>",
"      Pylorid (HR, HU, LU, PH);",
"     </li>",
"     <li>",
"      R-Loc (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Radinat (EC);",
"     </li>",
"     <li>",
"      Randin (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Rani 2 (AU);",
"     </li>",
"     <li>",
"      Ranial (IN);",
"     </li>",
"     <li>",
"      Raniben (IT);",
"     </li>",
"     <li>",
"      Raniberl (CZ);",
"     </li>",
"     <li>",
"      Ranicux (DE);",
"     </li>",
"     <li>",
"      Ranidil (IT);",
"     </li>",
"     <li>",
"      Ranidin (ES);",
"     </li>",
"     <li>",
"      Ranidine (TH);",
"     </li>",
"     <li>",
"      Ranihexal (AU);",
"     </li>",
"     <li>",
"      Ranimex (FI);",
"     </li>",
"     <li>",
"      Ranin (ID, TH);",
"     </li>",
"     <li>",
"      Ranione (KP);",
"     </li>",
"     <li>",
"      Raniplex (FR);",
"     </li>",
"     <li>",
"      Ranisan (AE, BH, CY, CZ, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Ranisen (MX);",
"     </li>",
"     <li>",
"      Ranital (CZ, HR);",
"     </li>",
"     <li>",
"      Ranitic (LU);",
"     </li>",
"     <li>",
"      Ranitidin-B (HU);",
"     </li>",
"     <li>",
"      Ranoxyl Heartburn Relief (AU);",
"     </li>",
"     <li>",
"      Rantac (AE, BH, CY, EG, IN, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Rantacid (FI);",
"     </li>",
"     <li>",
"      Rantin (ID);",
"     </li>",
"     <li>",
"      Ratic (TH);",
"     </li>",
"     <li>",
"      Ratinal (ID);",
"     </li>",
"     <li>",
"      Raxide (PH);",
"     </li>",
"     <li>",
"      Ribotine (KP);",
"     </li>",
"     <li>",
"      RND (TW);",
"     </li>",
"     <li>",
"      Rolan (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Sostril (DE);",
"     </li>",
"     <li>",
"      Tanidina (ES);",
"     </li>",
"     <li>",
"      Taural (AR);",
"     </li>",
"     <li>",
"      Tyran (ID);",
"     </li>",
"     <li>",
"      Ulcaid (AU, ZA);",
"     </li>",
"     <li>",
"      Ulceran (HU, PE);",
"     </li>",
"     <li>",
"      Ulcerit (BR);",
"     </li>",
"     <li>",
"      Ulcex (IT);",
"     </li>",
"     <li>",
"      Ulcin (PH);",
"     </li>",
"     <li>",
"      Ulcodin (HR);",
"     </li>",
"     <li>",
"      Ulcosan (CZ);",
"     </li>",
"     <li>",
"      Ulsal (AT);",
"     </li>",
"     <li>",
"      Ulticer (HK);",
"     </li>",
"     <li>",
"      Ultran (PH);",
"     </li>",
"     <li>",
"      Umaren (HU);",
"     </li>",
"     <li>",
"      Verlost (GR);",
"     </li>",
"     <li>",
"      Vizerul (AR);",
"     </li>",
"     <li>",
"      Weichilin (TW);",
"     </li>",
"     <li>",
"      Weidos (TW);",
"     </li>",
"     <li>",
"      X'Tac (MY);",
"     </li>",
"     <li>",
"      Xanidine (SG, TH);",
"     </li>",
"     <li>",
"      Xanomel (HU);",
"     </li>",
"     <li>",
"      Zantac (AE, AU, BB, BE, BF, BG, BH, BJ, BM, BS, BZ, CI, CL, CO, CR, CY, CZ, DK, DO, EC, EE, EG, ET, FI, GB, GH, GM, GN, GR, GT, GY, HK, HN, HU, ID, IE, IL, IQ, IR, IT, JM, JO, KE, KP, KW, LB, LR, LU, LY, MA, ML, MR, MU, MW, MY, NE, NG, NI, NL, NO, NZ, OM, PA, PE, PH, PK, PL, PR, PT, PY, QA, RU, SA, SC, SD, SE, SL, SN, SR, SV, SY, TH, TN, TR, TT, TW, TZ, UG, UY, VE, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Zantadin (ID);",
"     </li>",
"     <li>",
"      Zantic (CH, DE);",
"     </li>",
"     <li>",
"      Zendhin (HK, MY);",
"     </li>",
"     <li>",
"      Zerdin (PH);",
"     </li>",
"     <li>",
"      Zinetac (IN)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F217279\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Competitive inhibition of histamine at H",
"     <sub>",
"      2",
"     </sub>",
"     -receptors of the gastric parietal cells, which inhibits gastric acid secretion, gastric volume, and hydrogen ion concentration are reduced. Does not affect pepsin secretion, pentagastrin-stimulated intrinsic factor secretion, or serum gastrin.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F217298\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: 50%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Normal renal function: V",
"     <sub>",
"      d",
"     </sub>",
"     : ~1.4 L/kg; Cl",
"     <sub>",
"      cr",
"     </sub>",
"     25-35 mL/minute: 1.76 L/kg minimally penetrates the blood-brain barrier",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 15%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic to N-oxide, S-oxide, and N-desmethyl metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Oral: 48% to 50%; I.M.: 90% to 100%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: Normal renal function: 2.5-3 hours; Cl",
"     <sub>",
"      cr",
"     </sub>",
"     25-35 mL/minute: 4.8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: Normal renal function: 2-2.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: Oral: 2-3 hours; I.M.: &le;15 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine: Oral: 30%, I.V.: 70% (as unchanged drug); feces (as metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;ASHP Therapeutic Guidelines on Stress Ulcer Prophylaxis. ASHP Commission on Therapeutics and Approved by the ASHP Board of Directors on November 14, 1998,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 1999, 56(4):347-79.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/56/42888/abstract-text/10690219/pubmed\" id=\"10690219\" target=\"_blank\">",
"        10690219",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Balestrazzi P, Gregori G, Bernasconi S, et al, &ldquo;Bradycardia and Neurologic Disorders Associated With Ranitidine in a Child,&rdquo;",
"      <i>",
"       Am J Dis Child",
"      </i>",
"      , 1985, 139(5):442.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/56/42888/abstract-text/3984961/pubmed\" id=\"3984961\" target=\"_blank\">",
"        3984961",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Blumer JL, Rothstein FC, Kaplan BS, et al, &ldquo;Pharmacokinetic Determination of Ranitidine Pharmacodynamics in Pediatric Ulcer Disease,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1985, 107(2):301-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/56/42888/abstract-text/4020560/pubmed\" id=\"4020560\" target=\"_blank\">",
"        4020560",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chey WD and Wong B, &ldquo;American College of Gastroenterology Guideline on the Management of",
"      <i>",
"       Helicobacter pylori",
"      </i>",
"      Infection,&rdquo;",
"      <i>",
"       Am J Gastroenterol",
"      </i>",
"      , 2007 102(8):1808-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/56/42888/abstract-text/17608775/pubmed\" id=\"17608775\" target=\"_blank\">",
"        17608775",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cook D, Guyatt G, Marshall J, et al, &ldquo;A Comparison of Sucralfate and Ranitidine for the Prevention of Upper Gastrointestinal Bleeding in Patients Requiring Mechanical Ventilation. Canadian Critical Care Trials Group,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1998, 338(12):791-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/56/42888/abstract-text/9504939/pubmed\" id=\"9504939\" target=\"_blank\">",
"        9504939",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Coursin  DB, Farin-Rusk C, Springman SR, et al, &ldquo;The Hemodynamic Effects of Intravenous Cimetidineversus Ranitidine in Intensive Care Unit Patients: A Double-Blind, Prospective, Cross-Over Study,&rdquo;",
"      <i>",
"       Anesthesiology",
"      </i>",
"      , 1988, 69(6):975-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/56/42888/abstract-text/3057942/pubmed\" id=\"3057942\" target=\"_blank\">",
"        3057942",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dellinger RP, Levy MM, Carlet JM, et al, &ldquo;Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock: 2008,&rdquo; [published correction appears in",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2008, 36(4):1394-6],",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2008, 36(1):296-327.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/56/42888/abstract-text/18158437/pubmed\" id=\"18158437\" target=\"_blank\">",
"        18158437",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dellinger RP, Levy MM, Rhodes A, et al, &ldquo;Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2013, 41(2):580-637.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/56/42888/abstract-text/23353941/pubmed\" id=\"23353941\" target=\"_blank\">",
"        23353941",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Eddleston JM, Booker PD, and Green JR, &ldquo;Use of Ranitidine in Children Undergoing Cardiopulmonary Bypass,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 1989, 17(1):26-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/56/42888/abstract-text/2909317/pubmed\" id=\"2909317\" target=\"_blank\">",
"        2909317",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fennerty MD and Higbee M, &ldquo;Drug Therapy of Gastrointestinal Disease,&rdquo;",
"      <i>",
"       Geriatric Pharmacology",
"      </i>",
"      , Bressler R and Katz MD, eds, New York, NY: McGraw-Hill, 1993, 585-608.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fontana M, Massironi E, Rossi A, et al, &ldquo;Ranitidine Pharmacokinetics in Newborn Infants,&rdquo;",
"      <i>",
"       Arch Dis Child",
"      </i>",
"      , 1993, 68(5 Spec No):602-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/56/42888/abstract-text/8323366/pubmed\" id=\"8323366\" target=\"_blank\">",
"        8323366",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Freeman HJ, &ldquo;Ranitidine-Associated Interstitial Nephritis in a Patient With Celiac Sprue,&rdquo;",
"      <i>",
"       Can J Gastroenterol",
"      </i>",
"      , 1988, 2:35.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Goelzer SL, Farin-Rusk C, and Coursin DB, &ldquo;Ranitidine Produces Minimal Hemodynamic Depression in Stable Intensive Care Unit Patients: A Double-Blind, Prospective Study,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 1988, 16(1):8-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/56/42888/abstract-text/3276451/pubmed\" id=\"3276451\" target=\"_blank\">",
"        3276451",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Guillet R, Stoll BJ, Cotten CM, et al, \"Association of H2-Blocker Therapy and Higher Incidence of Necrotizing Enterocolitis in Very Low Birth Weight Infants,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2006, 117(2):137-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/56/42888/abstract-text/16390920/pubmed\" id=\"16390920\" target=\"_blank\">",
"        16390920",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kahrilas PJ, Shaheen NJ, Vaezi MF, et al, &ldquo;American Gastroenterological Association Medical Position Statement on the Management of Gastroesophageal Reflux Disease,&rdquo;",
"      <i>",
"       Gastroenterology",
"      </i>",
"      , 2008, 135(4):1383-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/56/42888/abstract-text/18789939/pubmed\" id=\"18789939\" target=\"_blank\">",
"        18789939",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kelly KL, &ldquo;Ranitidine Cross-Reactivity in the EMIT D.A.U. Monocolonal Amphetamine/Methamphetamine Assay,&rdquo;",
"      <i>",
"       Clin Chem",
"      </i>",
"      , 1990, 36(7):1391-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/56/42888/abstract-text/2372968/pubmed\" id=\"2372968\" target=\"_blank\">",
"        2372968",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lehmann AB, &ldquo;Reversible Chorea Due to Ranitidine and Cimetidine,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1988, 2(8603):158.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/56/42888/abstract-text/2899203/pubmed\" id=\"2899203\" target=\"_blank\">",
"        2899203",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lopez-Herce J, Albajara L, Codoceo R, et al, &ldquo;Ranitidine Prophylaxis in Acute Gastric Mucosal Damage in Critically Ill Pediatric Patients,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 1988, 16(6):591-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/56/42888/abstract-text/3371023/pubmed\" id=\"3371023\" target=\"_blank\">",
"        3371023",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Maack DK and Spiller HA, &ldquo;Rare Dystonic Reaction From Accidental Overdose of Ranitidine in a 3 Month Old,&rdquo;",
"      <i>",
"       Vet Hum Toxicol",
"      </i>",
"      , 1993, 35:343.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Miralles ES, Nunez M, del Olmo N, et al, &ldquo;Ranitidine-Related Toxic Epidermal Necrolysis in a Patient With Idiopathic Thrombocytopenic Purpura,&rdquo;",
"      <i>",
"       J Am Acad Dermatol",
"      </i>",
"      , 1995, 32(1):133-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/56/42888/abstract-text/7822507/pubmed\" id=\"7822507\" target=\"_blank\">",
"        7822507",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Morris DL, Markham SJ, Beechey A, et al, &ldquo;Ranitidine-Bolus or Infusion Prophylaxis for Stress Ulcer,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 1988, 16(3):229-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/56/42888/abstract-text/3277779/pubmed\" id=\"3277779\" target=\"_blank\">",
"        3277779",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ohsawa T, Masuhara K, and Hirata W, &ldquo;Reversal of Ranitidine-Induced Hypergastrinemia by Cimetidine,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1994, 28(11):1303.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/56/42888/abstract-text/7849349/pubmed\" id=\"7849349\" target=\"_blank\">",
"        7849349",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Richter JE, &ldquo;Gastroesophageal Reflux Disease During Pregnancy,&rdquo;",
"      <i>",
"       Gastroenterol Clin North Am",
"      </i>",
"      , 2003, 32(1):235-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/56/42888/abstract-text/12635418/pubmed\" id=\"12635418\" target=\"_blank\">",
"        12635418",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Roberts CJ, &ldquo;Clinical Pharmacokinetics of Ranitidine,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1984, 9(3):211-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/56/42888/abstract-text/6329583/pubmed\" id=\"6329583\" target=\"_blank\">",
"        6329583",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Romaguera C, Grimalt F, and Vilaplana J, &ldquo;Epidemic of Occupational Contact Dermatitis From Ranitidine,&rdquo;",
"      <i>",
"       Contact Dermatitis",
"      </i>",
"      , 1988, 18(3):177-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/56/42888/abstract-text/2966715/pubmed\" id=\"2966715\" target=\"_blank\">",
"        2966715",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smith CL, Bardgett DM, and Hunter JM, &ldquo;Haemodynamic Effects of the I.V. Administration of Cimetidine or Ranitidine in the Critically Ill Patient: A Double-Blind Prospective Study,&rdquo; Br J Anaesth, 1987, 59(11):1397-1402.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/56/42888/abstract-text/3689613/pubmed\" id=\"3689613\" target=\"_blank\">",
"        3689613",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Souza Lima MA, &ldquo;Hepatitis Associated With Ranitidine,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1984, 101(2):207-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/56/42888/abstract-text/6331240/pubmed\" id=\"6331240\" target=\"_blank\">",
"        6331240",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Todd P, Norris P, Hawk JL, et al, &ldquo;Ranitidine-Induced Photosensitivity,&rdquo;",
"      <i>",
"       Clin Exp Dermatol",
"      </i>",
"      , 1995, 20(2):146-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/56/42888/abstract-text/8565251/pubmed\" id=\"8565251\" target=\"_blank\">",
"        8565251",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9853 Version 48.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-190.92.87.115-BA28D9014E-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_56_42888=[""].join("\n");
var outline_f41_56_42888=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217321\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217322\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217373\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217326\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217349\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217327\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217328\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217329\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217292\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217276\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217296\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14473102\">",
"      Usual Infusion Concentrations: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14473103\">",
"      Usual Infusion Concentrations: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217380\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217295\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217370\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217382\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217371\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217299\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217280\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217367\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217285\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217316\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217288\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217302\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217334\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10424156\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217303\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217301\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217290\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217304\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217279\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217298\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9853\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9853|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?21/56/22405?source=related_link\">",
"      Ranitidine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/1/33815?source=related_link\">",
"      Ranitidine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_56_42889="Preventive treatment of migraine in adults";
var content_f41_56_42889=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Preventive treatment of migraine in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/56/42889/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/56/42889/contributors\">",
"     Zahid H Bajwa, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/56/42889/contributors\">",
"     Ashraf Sabahat, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/56/42889/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/56/42889/contributors\">",
"     Jerry W Swanson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/56/42889/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/56/42889/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/56/42889/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Migraine is a common disorder that affects approximately 17 percent of women and 6 percent of men. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/4/26698?source=see_link&amp;anchor=H21674074#H21674074\">",
"     \"Pathophysiology, clinical manifestations, and diagnosis of migraine in adults\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most migraine sufferers require pharmacologic treatment. A number of medication classes are used for the prophylactic treatment of migraine. The mechanisms of action for medications that have proven effective in migraine prophylaxis are varied; no single medication has emerged as a clear treatment of choice.",
"   </p>",
"   <p>",
"    The preventive treatment of episodic migraine headache in adults is reviewed here. The clinical features and management of chronic migraine are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/61/7128?source=see_link\">",
"     \"Chronic migraine\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other aspects of migraine are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/44/21194?source=see_link\">",
"     \"Acute treatment of migraine in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/4/26698?source=see_link\">",
"     \"Pathophysiology, clinical manifestations, and diagnosis of migraine in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prophylactic headache treatment is indicated if the headaches are frequent, long lasting, or account for a significant amount of total disability. The goals of preventive therapy are to [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/56/42889/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Reduce attack frequency, severity and duration",
"     </li>",
"     <li>",
"      Improve responsiveness to treatment of acute attacks",
"     </li>",
"     <li>",
"      Improve function and reduce disability",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following factors may indicate the need for prophylactic therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/56/42889/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Recurring migraines that significantly interfere with daily routine in the patient's opinion, despite acute treatment",
"     </li>",
"     <li>",
"      Contraindication to or failure or overuse of acute therapies",
"     </li>",
"     <li>",
"      Adverse events with acute therapies",
"     </li>",
"     <li>",
"      Patient preference",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based on expert consensus, prophylactic therapy also should be considered to prevent neurologic damage in the presence of uncommon migraine conditions including [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/56/42889/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hemiplegic migraine",
"     </li>",
"     <li>",
"      Basilar type migraine",
"     </li>",
"     <li>",
"      Migraine with prolonged aura",
"     </li>",
"     <li>",
"      Migrainous infarction",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/11/32953?source=see_link&amp;anchor=H12#H12\">",
"     \"Headache, migraine, and stroke\", section on 'Migrainous stroke'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/11/32953?source=see_link&amp;anchor=H25#H25\">",
"     \"Headache, migraine, and stroke\", section on 'Treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/4/26698?source=see_link&amp;anchor=H21674155#H21674155\">",
"     \"Pathophysiology, clinical manifestations, and diagnosis of migraine in adults\", section on 'Complications of migraine'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/4/26698?source=see_link&amp;anchor=H222097293#H222097293\">",
"     \"Pathophysiology, clinical manifestations, and diagnosis of migraine in adults\", section on 'Migraine variants'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Menstrual migraine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Menstrual migraine (also called menstrually associated migraine or catamenial migraine) is defined as migraine headache that occurs in close temporal relationship to the onset of menstruation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/4/26698?source=see_link&amp;anchor=H21674106#H21674106\">",
"     \"Pathophysiology, clinical manifestations, and diagnosis of migraine in adults\", section on 'Menstrual migraine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Short-term preventive therapy during the perimenstrual period may be useful for women who have menstrual migraine that occurs on a predictable schedule. This treatment strategy is called \"mini-prophylaxis\" and usually consists of preventive medication started one or two days prior to the expected onset of headache and continued for the expected duration of the headache. Hormonal preventive therapy of menstrual migraine is another treatment option. These issues are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/38/35433?source=see_link&amp;anchor=H4#H4\">",
"     \"Estrogen-associated migraine\", section on 'Menstrual migraine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ANTIHYPERTENSIVES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data from randomized clinical trials show that beta blockers, particularly",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/2/31776?source=see_link\">",
"     timolol",
"    </a>",
"    , are effective for migraine prevention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/56/42889/abstract/2\">",
"     2",
"    </a>",
"    ]. Lower quality evidence suggests but does not establish that calcium channel blockers, angiotensin converting enzyme (ACE) inhibitors, and angiotensin II receptor blockers (ARBs) are effective for migraine prevention. There are no clinical trial data for thiazide diuretics in migraine prevention.",
"   </p>",
"   <p>",
"    Blood pressure treatment appears to reduce the overall prevalence of headache in general. This point is illustrated by the results of a meta-analysis of 95 randomized controlled trials examining four different classes of antihypertensive medications &mdash; beta blockers, ACE inhibitors, ARBs, and thiazides &mdash; that also included data on headache prevalence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/56/42889/abstract/3\">",
"     3",
"    </a>",
"    ]. Patients assigned to blood pressure treatment had a significant reduction in headache prevalence compared with placebo treatment (odds ratio 0.67, 95% CI 0.61 to 0.74), and headache prevalence was significantly reduced in each of the four classes of drugs compared individually with placebo. One limitation is that the individual trials lacked information on headache classification, so the proportion of migraine versus other types of headaches among the subjects is unknown. However, it is conceivable that most of the patients had migraine, as the prevalence of headache among placebo patients (12.4 percent) is similar to the reported prevalence of migraine in the general population. (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Beta blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 2012 guideline from the American Academy of Neurology (AAN) concluded that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/2/31776?source=see_link\">",
"     timolol",
"    </a>",
"    are established as effective for migraine prevention, while",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/46/30440?source=see_link\">",
"     atenolol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/15/35063?source=see_link\">",
"     nadolol",
"    </a>",
"    are probably effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/56/42889/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Suggested doses for migraine prophylaxis with these beta blockers are as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/56/42889/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/49/8986?source=see_link\">",
"       Propranolol",
"      </a>",
"      in two divided doses starting at 40 mg daily; dose range 40 to 160 mg daily",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/31/39417?source=see_link\">",
"       Metoprolol",
"      </a>",
"      in two divided doses starting at 100 mg daily; dose range 100 to 200 mg daily",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/2/31776?source=see_link\">",
"       Timolol",
"      </a>",
"      in two divided doses starting at 20 mg daily; dose range 20 to 30 mg daily",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/15/35063?source=see_link\">",
"       Nadolol",
"      </a>",
"      starting at 80 mg once a day; dose range 80 to 240 mg daily",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/46/30440?source=see_link\">",
"       Atenolol",
"      </a>",
"      100 mg once daily",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It can take several weeks for headache improvement to accrue with these drugs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/56/42889/abstract/7\">",
"     7",
"    </a>",
"    ]; the dose should be titrated and maintained for at least three months before deeming the medication a failure.",
"   </p>",
"   <p>",
"    We suggest",
"    <strong>",
"     not",
"    </strong>",
"    using beta blockers as initial therapy for migraine prophylaxis in patients over age 60 and in smokers. Compared with other antihypertensive drugs in the primary treatment of hypertension, beta blockers may be associated with a higher rate of stroke and other cardiovascular events. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/29/36314?source=see_link&amp;anchor=H22#H22\">",
"     \"Choice of therapy in primary (essential) hypertension: Recommendations\", section on 'Beta blockers'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of beta blockers may be also limited in patients with erectile dysfunction, peripheral vascular disease, Raynaud's syndrome or disease, and in patients with baseline bradycardia or low blood pressure. They must be used cautiously as well in patients with asthma, diabetes mellitus, and those with cardiac conduction disturbances or sinus node dysfunction. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/39/3704?source=see_link\">",
"     \"Major side effects of beta blockers\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Calcium channel blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calcium channel blockers are widely used for migraine prophylaxis. However, the data supporting the efficacy of calcium channel blockers are weak and conflicting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/56/42889/abstract/2,6\">",
"     2,6",
"    </a>",
"    ]. Two methodologically flawed studies showed a small but significant effect of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    (in three divided doses starting at 120 mg daily, dose range 120 to 240 mg daily) for migraine prophylaxis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/56/42889/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Nevertheless, verapamil is frequently our first choice for prophylactic therapy based upon ease of use and a favorable side effect profile [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/56/42889/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tolerance may develop with calcium channel blockers; it occurred after eight weeks of successful therapy in 42 percent of those treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    , 49 percent treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    , and 4 percent treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/20/16710?source=see_link\">",
"     nimodipine",
"    </a>",
"    in one report [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/56/42889/abstract/11\">",
"     11",
"    </a>",
"    ]. Tolerance may be overcome by increasing the dose of medication, or by switching to a different calcium channel blocker.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     ACE inhibitors/ARBs",
"    </span>",
"    &nbsp;&mdash;&nbsp;A double-blind, placebo controlled, crossover study of 60 patients with two to six migraine episodes per month found that the angiotensin converting enzyme (ACE) inhibitor",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/58/937?source=see_link\">",
"     lisinopril",
"    </a>",
"    (10",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for one week, then 20",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    significantly reduced the number of hours and days with headache and headache severity compared with placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/56/42889/abstract/12\">",
"     12",
"    </a>",
"    ]. Another crossover trial of 60 patients from the same group of investigators reported similar results with the angiotensin II receptor blocker (ARB)",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/48/38663?source=see_link\">",
"     candesartan",
"    </a>",
"    (16 mg once daily) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/56/42889/abstract/13\">",
"     13",
"    </a>",
"    ]. However, the small size and single center, crossover design of these trials prevent definitive conclusions regarding the effectiveness of lisinopril and candesartan for migraine prevention. They are not widely used for this indication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     ANTIDEPRESSANTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a systematic review of prospective double-blind, randomized controlled trials of medications for migraine prevention, the tricyclic antidepressant",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    (starting dose 10 mg at bedtime, dosage range 20 to 50 mg at bedtime) was effective for migraine prophylaxis in four trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/56/42889/abstract/6\">",
"     6",
"    </a>",
"    ]. In other trials, the",
"    <span class=\"nowrap\">",
"     serotonin/norepinephrine",
"    </span>",
"    reuptake inhibitor",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/45/22233?source=see_link\">",
"     venlafaxine",
"    </a>",
"    (starting at 37.5 mg once a day, dosage range 75 to 150 mg once a day) was also effective as prophylaxis for migraine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/56/42889/abstract/6\">",
"     6",
"    </a>",
"    ]. Similarly, a 2012 guideline from the American Academy of Neurology (AAN) concluded that amitriptyline and venlafaxine are probably effective for migraine prevention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/56/42889/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The tricyclic antidepressants most commonly used for migraine prophylaxis include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/21/30040?source=see_link\">",
"     nortriptyline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/51/32560?source=see_link\">",
"     doxepin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/5/10327?source=see_link\">",
"     protriptyline",
"    </a>",
"    . Amitriptyline is the only tricyclic that has proven efficacy for migraine; insufficient data exists regarding the other tricyclics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/56/42889/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Side effects are common with tricyclic antidepressants. Most are sedating, particularly",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/51/32560?source=see_link\">",
"     doxepin",
"    </a>",
"    . Therefore, these drugs are usually used at bedtime and started at a low dose. Additional side effects of tricyclics include dry mouth, constipation, tachycardia, palpitations, orthostatic hypotension, weight gain, blurred vision, and urinary retention. Confusion can occur, particularly in the elderly. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/20/36169?source=see_link\">",
"     \"Unipolar depression in adults and tricyclic and tetracyclic drugs: Pharmacology, administration, and side effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     ANTICONVULSANTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anticonvulsants sodium",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/27/5561?source=see_link\">",
"     topiramate",
"    </a>",
"    are more effective than placebo for reducing the frequency of migraine attacks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/56/42889/abstract/6,15\">",
"     6,15",
"    </a>",
"    ]. A 2012 guideline from the American Academy of Neurology (AAN) concluded that sodium valproate and topiramate are established as effective for migraine prevention, while evidence is insufficient to determine the effectiveness of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/56/42889/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Valproate",
"    </span>",
"    &nbsp;&mdash;&nbsp;A review of three trials evaluating divalproex sodium (sodium",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    and valproic acid) at doses ranging from 500 to 1500 mg daily for migraine prevention found that the drug was significantly more effective than placebo as measured by the number of patients experiencing a &ge;50 percent reduction in migraine frequency (odds ratio 2.74, 95% CI 1.48-5.08) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/56/42889/abstract/6\">",
"     6",
"    </a>",
"    ]. Divalproex sodium can cause nausea, somnolence, tremor, dizziness, weight gain, and hair loss. It is contraindicated in pregnancy because of teratogenicity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Topiramate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several placebo-controlled studies have found that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/27/5561?source=see_link\">",
"     topiramate",
"    </a>",
"    is effective prophylactic therapy for migraine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/56/42889/abstract/16-19\">",
"     16-19",
"    </a>",
"    ]. The starting topiramate dose in most of these studies was 25",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    in these studies, with slow titration by 25 to 50",
"    <span class=\"nowrap\">",
"     mg/week",
"    </span>",
"    to the maximum of 100 mg twice daily or the highest tolerated dose.",
"   </p>",
"   <p>",
"    The two largest randomized trials of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/27/5561?source=see_link\">",
"     topiramate",
"    </a>",
"    for migraine evaluated 468 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/56/42889/abstract/16\">",
"     16",
"    </a>",
"    ] and 469 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/56/42889/abstract/17\">",
"     17",
"    </a>",
"    ], respectively. The following observations emerged from these trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/56/42889/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The mean monthly migraine frequency decreased significantly for patients receiving",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/27/5561?source=see_link\">",
"       topiramate",
"      </a>",
"      at either 100 or 200",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      compared with placebo. For patients receiving topiramate at 50",
"      <span class=\"nowrap\">",
"       mg/day,",
"      </span>",
"      the reduction in migraine frequency did not achieve statistical significance.",
"     </li>",
"     <li>",
"      Significant reductions in migraine frequency occurred within the first month at",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/27/5561?source=see_link\">",
"       topiramate",
"      </a>",
"      doses of 100 and 200",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"      The responder rate (proportion of patients with greater than or equal to 50 percent reduction in mean migraine frequency) for these doses was about 50 percent of treated patients. The effectiveness of topiramate at these doses was maintained for the entire double-blind treatment phase.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/27/5561?source=see_link\">",
"       Topiramate",
"      </a>",
"      treatment-related adverse events, generally mild to moderate in severity, included paresthesia, fatigue, anorexia, diarrhea, weight loss, hypesthesia, memory difficulty, language problems, difficulty with concentration, nausea, and taste perversion. Of these, paresthesia was the most common, occurring in about half of patients receiving topiramate at 100 or 200",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"      Weight loss is a unique side effect of this drug, and it occurred in 9 to 12 percent of patients taking 100 to 200",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      of topiramate.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Adverse events with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/27/5561?source=see_link\">",
"     topiramate",
"    </a>",
"    were more frequent with the 200",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    dose in controlled trials, leading to withdrawal of therapy in up to 30 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/56/42889/abstract/6\">",
"     6",
"    </a>",
"    ]. Therefore, some experts recommend using topiramate at no more than 100",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for migraine prevention.",
"   </p>",
"   <p>",
"    Data from one trial suggest that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/27/5561?source=see_link\">",
"     topiramate",
"    </a>",
"    has residual benefit for migraine that persists for up to six months after the drug is discontinued [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/56/42889/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/27/5561?source=see_link\">",
"     Topiramate",
"    </a>",
"    may be as effective as a beta blocker [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/56/42889/abstract/20\">",
"     20",
"    </a>",
"    ], but comparative data are limited [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/56/42889/abstract/21\">",
"     21",
"    </a>",
"    ]. No data are available comparing topiramate with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    for migraine prevention. Topiramate is much more expensive than beta blockers or valproate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/56/42889/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H158088962\">",
"    <span class=\"h2\">",
"     Gabapentin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/19/19768?source=see_link\">",
"     Gabapentin",
"    </a>",
"    was evaluated in a 12-week trial of 143 patients with migraine who were randomly assigned to treatment with either gabapentin (n = 98, dose titrated to 2400",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    at the end of week four) or matching placebo (n = 45) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/56/42889/abstract/22\">",
"     22",
"    </a>",
"    ]. The median migraine rate during the last four weeks of the trial was significantly lower in the gabapentin than placebo group (2.7 versus 3.5). However, the strength of this trial is limited by methodologic problems that include small patient numbers, a dropout rate of 24 percent, and further exclusion from analysis of 21 patients (15 percent) who did not achieve a stable gabapentin dose of 2400 mg or the equivalent number of placebo capsules.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     OTHER AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of other agents have been studied for migraine prophylaxis. Guidelines issued in 2012 from the American Academy of Neurology concluded that Petasites (butterbur) is effective for migraine prevention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/56/42889/abstract/23\">",
"     23",
"    </a>",
"    ]. In addition, the AAN noted that feverfew, magnesium, certain nonsteroidal antiinflammatory drugs, riboflavin, and subcutaneous histamine are probably effective.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Botulinum toxin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several randomized placebo-controlled trials have found no consistent, statistically significant benefits for botulinum toxin injection in the treatment of episodic migraine headache [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/56/42889/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. In addition, an evidence-based review published in 2008 by the American Academy of Neurology (AAN) concluded that botulinum toxin is probably ineffective for the treatment of episodic migraine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/56/42889/abstract/27\">",
"     27",
"    </a>",
"    ]. A 2010 systematic review reached a similar conclusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/56/42889/abstract/6\">",
"     6",
"    </a>",
"    ]. Given these data, the use of botulinum toxin therapy is",
"    <strong>",
"     not",
"    </strong>",
"    recommended for the preventive treatment of",
"    <strong>",
"     episodic",
"    </strong>",
"    migraine.",
"   </p>",
"   <p>",
"    In contrast, there is evidence that botulinum toxin type A (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/27/10681?source=see_link\">",
"     onabotulinumtoxinA",
"    </a>",
"    ) injection is effective for the treatment of",
"    <strong>",
"     chronic",
"    </strong>",
"    migraine (ie, headache on &ge;15 days per month for at least three months, with at least eight of the 15 headaches per month fulfilling criteria for migraine without aura). The utility of botulinum toxin injection for chronic migraine is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/61/7128?source=see_link&amp;anchor=H10#H10\">",
"     \"Chronic migraine\", section on 'Second-line agents'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Butterbur",
"    </span>",
"    &nbsp;&mdash;&nbsp;An extract of butterbur (Petasites hybridus) root, a perennial shrub, is an herbal medicine that is marketed as a food supplement in the United States and as a licensed pharmaceutical medicine in Germany (Petadolex). At least two small placebo-controlled clinical trials have found some efficacy for Petasites extract in migraine prevention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/56/42889/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. In the larger of these studies, Petasites at a dose of 150 mg daily (given in two divided doses) but",
"    <strong>",
"     not",
"    </strong>",
"    100 mg daily (given in two divided doses) was effective and well tolerated as preventive therapy for migraine. Gastrointestinal upset, predominately burping, was the most common side effect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/56/42889/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Butterbur contains pyrrolizidine alkaloids; these alkaloids are potential carcinogens that are removed from the commercially prepared Petasites root extract. No part of the Petasites plant should be ingested other than the commercial products.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Coenzyme Q10",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interest in coenzyme Q10 (CoQ10) and riboflavin&nbsp;(see",
"    <a class=\"local\" href=\"#H22\">",
"     'Riboflavin'",
"    </a>",
"    below) for migraine treatment has been sparked by the potential role of mitochondrial dysfunction in migraine pathogenesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/56/42889/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a small, randomized controlled trial of 42 patients with migraine, coenzyme Q10 (CoQ10) was effective for migraine prophylaxis; significantly more patients treated with CoQ10 (100 mg three times daily) experienced a &ge;50 percent reduction in attack frequency (the primary outcome measure) at three months than patients treated with placebo (47.6 versus 14.4 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/56/42889/abstract/32\">",
"     32",
"    </a>",
"    ]. CoQ10 treatment was well tolerated. Larger clinical trials are needed to confirm the benefit of CoQ10 for migraine prevention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Feverfew",
"    </span>",
"    &nbsp;&mdash;&nbsp;Feverfew has been the herbal remedy most studied for the prevention of migraine, but evidence regarding benefit is conflicting. A systematic review of feverfew for migraine prophylaxis found five randomized controlled trials with 343 patients that met the inclusion criteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/56/42889/abstract/33\">",
"     33",
"    </a>",
"    ]. While three of the trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/56/42889/abstract/34-36\">",
"     34-36",
"    </a>",
"    ] found that feverfew was effective, the two trials with the highest methodologic quality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/56/42889/abstract/37,38\">",
"     37,38",
"    </a>",
"    ] found no significant difference between feverfew and placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/56/42889/abstract/33\">",
"     33",
"    </a>",
"    ]. The review concluded that trial results were mixed and did not establish that feverfew is more effective than placebo for the prevention of migraine. The safety of this and other herbal products is unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Magnesium",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reports of low magnesium levels in migraineurs prompted the study of magnesium supplements as a treatment for migraine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/56/42889/abstract/39-41\">",
"     39-41",
"    </a>",
"    ]. Four small randomized controlled trials using variable formulations of magnesium for migraine prevention have produced mixed results, with two trials finding a statistically significant benefit for magnesium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/56/42889/abstract/42,43\">",
"     42,43",
"    </a>",
"    ], one trial finding a nonsignificant trend to benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/56/42889/abstract/44\">",
"     44",
"    </a>",
"    ], and one trial finding no benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/56/42889/abstract/45\">",
"     45",
"    </a>",
"    ]. Diarrhea and gastrointestinal discomfort were the most common side effects of magnesium supplementation in these trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Methysergide",
"    </span>",
"    &nbsp;&mdash;&nbsp;Methysergide is an ergot derivative and a specific serotonin receptor antagonist (primarily 5HT2). Its effectiveness for migraine prophylaxis has been demonstrated in open-label and controlled studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/56/42889/abstract/46\">",
"     46",
"    </a>",
"    ]. Some experts believe it may be most useful in patients with refractory migraine who have a high attack frequency. This agent is not currently marketed in the United States.",
"   </p>",
"   <p>",
"    Contraindications to the use of methysergide are numerous and include pregnancy and cardiovascular disease. Methysergide use is also associated with a low but real risk of retroperitoneal, pleural, and heart valve fibrosis. Thus, it should be reserved for severe cases in which other migraine preventive drugs are not effective. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/21/34136?source=see_link\">",
"     \"Clinical manifestations and diagnosis of retroperitoneal fibrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who use ergotamine-type medications such as methysergide should",
"    <strong>",
"     not",
"    </strong>",
"    use serotonin agonists (eg, triptans) within 24 hours due to the potential risk of myocardial infarction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/56/42889/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H179289492\">",
"    <span class=\"h2\">",
"     Nonsteroidal antiinflammatory drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of older randomized controlled trials have found that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/43/43705?source=see_link\">",
"     naproxen",
"    </a>",
"    , a nonsteroidal antiinflammatory drug (NSAID), is moderately more effective than placebo for migraine prevention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/56/42889/abstract/48-52\">",
"     48-52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Guidelines issued in 2012 from the American Academy of Neurology (AAN) concluded that the NSAIDs",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/52/27464?source=see_link\">",
"     fenoprofen",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/36/43592?source=see_link\">",
"     ketoprofen",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/43/43705?source=see_link\">",
"     naproxen",
"    </a>",
"    are probably effective for migraine prevention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/56/42889/abstract/23\">",
"     23",
"    </a>",
"    ]. This AAN assessment was based upon an earlier systematic review and meta-analysis from the US Agency for Health Care Policy and Research (AHCPR), which included 23 controlled trials of 10 different NSAIDS indexed from 1966 through 1996 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/56/42889/abstract/53\">",
"     53",
"    </a>",
"    ]. The AAN identified no newer randomized trials of NSAIDs for migraine prevention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/56/42889/abstract/23\">",
"     23",
"    </a>",
"    ]. However, the AHCPR report noted that the evidence was strongest for naproxen, with multiple placebo-controlled trials showing a moderate reduction in headache symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/56/42889/abstract/53\">",
"     53",
"    </a>",
"    ]. Only one trial supported the efficacy of ketoprofen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/56/42889/abstract/54\">",
"     54",
"    </a>",
"    ], while the evidence was less certain for fenoprofen. The AHCPR review identified no controlled trials of ibuprofen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/56/42889/abstract/53\">",
"     53",
"    </a>",
"    ]. In the earlier AAN guidelines from 2000, ibuprofen was included within a group of medications considered clinically efficacious based upon consensus and clinical experience but with no scientific evidence of efficacy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/56/42889/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of NSAIDs for the treatment of acute migraine headache is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/44/21194?source=see_link&amp;anchor=H4#H4\">",
"     \"Acute treatment of migraine in adults\", section on 'Nonsteroidal antiinflammatory drugs'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Opioids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of opioids for frequent or refractory headache is controversial, as frequent opioid use can contribute to development of chronic daily headache and can interfere with other preventive therapies. In addition, frequent opioid use increases the risk of dependency and dose escalation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/2/35879?source=see_link\">",
"     \"Medication overuse headache: Etiology, clinical features, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24812537\">",
"    <span class=\"h2\">",
"     Pizotifen",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systematic review identified five placebo-controlled trials evaluating the serotonin blocker",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/15/40181?source=see_link\">",
"     pizotifen",
"    </a>",
"    for migraine prevention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/56/42889/abstract/6\">",
"     6",
"    </a>",
"    ]. Although the trials were heterogeneous and could not be combined for meta-analysis, all five found that pizotifen (in three divided doses starting at 1.5 mg daily, dosage range 1.5 to 3 mg daily) was superior to placebo. Weight gain and sedation were the most common adverse events in these trials. Pizotifen is not licensed for use in the United States.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Riboflavin",
"    </span>",
"    &nbsp;&mdash;&nbsp;A randomized, double-blind, placebo-controlled study of 55 patients who were suffering from two to eight migraines per month found that the administration of oral vitamin B2 (riboflavin) at a dose of 400",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    compared with placebo resulted in a significantly higher proportion of patients with greater than 50 percent improvement in the frequency of headaches (54 versus 19 percent), headache days (57 versus 15 percent), and the migraine index (headache days and mean severity, 39 versus 8 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/56/42889/abstract/55\">",
"     55",
"    </a>",
"    ]. The benefits only became significant after three months of therapy. Riboflavin was well tolerated. Additional studies are needed to confirm these results and to determine the optimum dose and patient population most likely to benefit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     NONPHARMACOLOGIC THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of nonpharmacologic therapies have been used to treat migraine headache. This section briefly reviews recommendations from the American Academy of Neurology (AAN) regarding cognitive and behavioral therapy, and presents evidence regarding acupuncture and closure of right-to-left cardiac shunt as migraine treatments.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Guideline recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recommendations from the AAN practice parameter published in 2000 regarding cognitive and behavioral treatment for migraine prevention are as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/56/42889/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Relaxation training, thermal biofeedback combined with relaxation training, electromyographic biofeedback, and cognitive-behavioral therapy may be considered for migraine prevention. Specific recommendations regarding which one of these to use in individual patients could not be made.",
"     </li>",
"     <li>",
"      Behavioral therapy may be combined with preventative drug therapy.",
"     </li>",
"     <li>",
"      Evidence-based recommendations regarding the use of hypnosis, acupuncture, transcutaneous electrical nerve stimulation, chiropractic or osteopathic cervical manipulation, occlusal adjustment, or hyperbaric oxygen could not be made.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Acupuncture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical trial evidence suggests that classic acupuncture for migraine headache is more effective than placebo treatment, but not more effective than sham needling or traditional medical therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/56/42889/abstract/56-59\">",
"     56-59",
"    </a>",
"    ]. The following reports support this conclusion:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized controlled trial with 302 patients found that acupuncture was",
"      <strong>",
"       not",
"      </strong>",
"      more effective than sham acupuncture (needling at points distant from \"true\" treatment points and using fewer needles) in reducing migraine headaches [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/56/42889/abstract/60\">",
"       60",
"      </a>",
"      ]. However, both acupuncture and sham acupuncture were significantly more effective in reducing days with headache than assignment to a wait-list control group.",
"     </li>",
"     <li>",
"      In another randomized controlled trial with 794 patients available for intention-to-treat analysis, the reduction in migraine headache days at 23 to 25 weeks for acupuncture, sham acupuncture, or standard medical therapy groups (mean reduction 2.3, 1.5, and 2.1 days, respectively) was statistically significant when compared with baseline, but nonsignificant across treatment groups [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/56/42889/abstract/61\">",
"       61",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although the explanation for these results is uncertain, headache improvement related to nonspecific physiologic effects of needling is a possible mechanism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Results from a single-center blinded randomized controlled trial suggest that surgical removal of muscle or nerve tissue from headache \"trigger sites\" may be an effective treatment for select patients with frequent migraine headache [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/56/42889/abstract/62\">",
"     62",
"    </a>",
"    ]. The trial screened 317 patients with frequent moderate to severe migraine headache (with or without aura) and found 76 who were eligible for inclusion, which required both identification of the predominant \"trigger site\" where \"migraine pain started and settled consistently\" and a positive response to botulinum toxin injection at the trigger site. Eligible patients, who had approximately 10 migraine headaches per month at baseline, were randomly assigned to treatment with either actual surgery (n = 49) or sham surgery (n = 26) at their trigger site.",
"   </p>",
"   <p>",
"    Actual surgery involved removal of glabellar muscles from patients with frontal trigger sites, removal of a segment of the zygomaticotemporal branch of the trigeminal nerve from those with temporal trigger sites, and resection of a segment of the semispinalis capitis muscle (under general anesthesia) from those with occipital trigger sites [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/56/42889/abstract/62\">",
"     62",
"    </a>",
"    ]. The sham surgery group had exposure but not resection of the muscles and nerves through a similar incision.",
"   </p>",
"   <p>",
"    At 12 months, actual surgery was statistically superior to sham surgery on a variety of outcome measures, including complete elimination of migraine headaches (57 versus 4 percent), and a reduction of &ge;50 percent in the migraine headache index, calculated by multiplying the headache frequency, intensity, and duration (84 versus 58 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/56/42889/abstract/62\">",
"     62",
"    </a>",
"    ]. Confidence intervals were not reported. Improvement with surgery was independent of trigger site. The surgery was well-tolerated.",
"   </p>",
"   <p>",
"    While this type of surgical treatment for migraine seems promising, independent confirmation of benefit in a larger trial is needed. In addition, only a minority of patients with frequent migraine &mdash; those with identifiable trigger sites and a positive response to botulinum toxin injection &mdash; would appear to be candidates.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Closure of right-to-left cardiac shunt",
"    </span>",
"    &nbsp;&mdash;&nbsp;Migraine with aura has been linked to right-to-left cardiac shunts, usually in the setting of a patent foramen ovale (PFO) or, infrequently, an atrial septal defect. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/4/26698?source=see_link&amp;anchor=H130649662#H130649662\">",
"     \"Pathophysiology, clinical manifestations, and diagnosis of migraine in adults\", section on 'Right-to-left cardiac shunt'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, there is no good scientific evidence that",
"    <span class=\"nowrap\">",
"     PFO/ASD",
"    </span>",
"    closure is an effective treatment for migraine.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The only prospective randomized controlled trial to evaluate PFO closure for migraine is the multicenter double-blind MIST trial, which enrolled 147 patients with a PFO who had frequent migraine with aura that was refractory to two types of preventive medication [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/56/42889/abstract/63\">",
"       63",
"      </a>",
"      ]. Patients with prior stroke or TIA were excluded. Enrolled patients were randomly assigned under general anesthesia to either PFO closure or sham treatment. During a three-month healing phase, patients in both treatment groups received",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      . The following outcomes were reported:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      There was no difference at six months between PFO closure and sham treatment for the primary end point of headache cure, which was achieved in each treatment group by three patients (4 percent).",
"     </li>",
"     <li>",
"      There was no benefit for PFO closure on any of the secondary outcome measures, whether analyzed by intention-to-treat or per-protocol populations.",
"     </li>",
"     <li>",
"      The PFO closure group experienced more serious adverse events than the sham group.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A systematic review published in 2008 identified six retrospective studies with 194 patients that evaluated the effect of PFO closure on migraine [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/56/42889/abstract/64\">",
"       64",
"      </a>",
"      ]. The quality of these six studies was considered very low for five and low for one, precluding definitive conclusions about the effectiveness of PFO closure for treatment of migraine.",
"     </li>",
"     <li>",
"      In some (but not all) relatively small and largely retrospective observational studies, improvement in migraine had been noted after device closure of a PFO or, much less often, an atrial septal defect [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/56/42889/abstract/64-74\">",
"       64-74",
"      </a>",
"      ]. Most of the patients treated with shunt closure were selected because of prior cryptogenic stroke or paradoxical embolism. A majority of study patients were treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      , which may have reduced migraine frequency.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In summary, the observational studies that reported improvement in migraine with PFO closure were flawed, and the only randomized controlled trial found no benefit. Ongoing clinical trials of PFO closure may yield additional evidence regarding the utility of defect closure for migraine. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/0/25610?source=see_link&amp;anchor=H3#H3\">",
"     \"Management of atrial septal defects in adults\", section on 'Indications for defect closure'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/57/35731?source=see_link\">",
"       \"Patient information: Migraine headaches in adults (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?41/59/42931?source=see_link\">",
"       \"Patient information: Headache treatment in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prophylactic migraine treatment may be indicated if patients are having more than four headaches per month, the headaches last longer than 12 hours, or they account for a significant amount of total disability. Additional considerations that may weigh in the decision to use preventive treatment include the patient's own opinion of disability, contraindication to or failure of acute therapies, cost of both acute and preventive therapies, and patient preference.",
"   </p>",
"   <p>",
"    Prophylactic therapy should also be considered to prevent neurologic damage in the presence of uncommon migraine conditions including hemiplegic migraine, basilar migraine, migraine with prolonged aura, and migrainous infarction.",
"   </p>",
"   <p>",
"    The choice of prophylactic agent depends upon the individual situation, associated medical problems, and presence of conditions that are comorbid with migraine such as depression, mania, anxiety, panic, Raynaud's syndrome, epilepsy, and stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/56/42889/abstract/14\">",
"     14",
"    </a>",
"    ]. As an example, either tricyclics or other antidepressants may be considered in patients who are depressed or prone to depression. On the other hand, beta blockers and calcium channel blockers may be preferable in some patients with hypertension. However, we suggest that beta blockers should",
"    <strong>",
"     not",
"    </strong>",
"    be used as initial therapy for migraine prophylaxis in patients over age 60 and in smokers. Compared with other antihypertensive drugs in the primary treatment of hypertension, beta blockers may be associated with a higher rate of stroke and other cardiovascular events. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/29/36314?source=see_link&amp;anchor=H22#H22\">",
"     \"Choice of therapy in primary (essential) hypertension: Recommendations\", section on 'Beta blockers'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prophylactic migraine medications that are effective in controlled trials include certain beta-blockers (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/2/31776?source=see_link\">",
"     timolol",
"    </a>",
"    ), antidepressants (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/45/22233?source=see_link\">",
"     venlafaxine",
"    </a>",
"    ), anticonvulsants (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/27/5561?source=see_link\">",
"     topiramate",
"    </a>",
"    ) and other agents (eg, butterbur). Approximately 50 to 75 percent of patients given any of these drugs will have a 50 percent reduction in the frequency of headache, but the doses required may lead to intolerable side effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/56/42889/abstract/75\">",
"     75",
"    </a>",
"    ]. As a result, we often begin with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    (a safe, tolerable, and easy to use drug), particularly in young patients with new onset episodic migraine, recognizing that the efficacy data for this medication are weak.",
"   </p>",
"   <p>",
"    The prophylaxis of menstrual migraine is reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/38/35433?source=see_link&amp;anchor=H4#H4\">",
"     \"Estrogen-associated migraine\", section on 'Menstrual migraine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Prophylactic principles",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regardless of the drug chosen, some general principles may improve the success rate of prophylactic migraine therapy and reduce complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/56/42889/abstract/14\">",
"     14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Start the drug at a low dose. Increase the dose gradually until therapeutic benefit develops, the maximum dose of the drug is reached, or side effects become intolerable.",
"     </li>",
"     <li>",
"      Give the chosen medication an adequate trial in terms of duration and dosage. Clinical trials suggest efficacy is often first noted at four weeks and can continue to increase for three months.",
"     </li>",
"     <li>",
"      Avoid overuse of analgesics, opioids, triptans, and ergots. In addition, patients who use ergotamine-type medications such as methysergide should",
"      <strong>",
"       not",
"      </strong>",
"      use serotonin agonists (eg, triptans) within 24 hours due to the potential risk of myocardial infarction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/56/42889/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Women of childbearing potential must be warned of any potential risks. Avoid",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"       valproate",
"      </a>",
"      for this group if possible, and choose the medication that will have the least adverse effect on the fetus. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/63/5114?source=see_link&amp;anchor=H5#H5\">",
"       \"Headache in pregnancy\", section on 'Prophylactic treatment'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Address patient expectations and consider patient preferences when deciding between drugs of relatively equivalent efficacy. Discuss the rationale, dosing, and likely side effects for a particular treatment. Discuss expected benefits of therapy and how long it will take to achieve them. Prophylactic migraine therapy requires a sustained commitment on the part of the patient and physician to achieve benefit.",
"     </li>",
"     <li>",
"      Migraine headaches may improve independent of treatment. If the headaches are well controlled, slowly taper the drug if possible. Many patients experience continued relief with either a lower dose or cessation of the medication.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/56/42889/abstract/1\">",
"      Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000; 55:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/56/42889/abstract/2\">",
"      Silberstein SD, Holland S, Freitag F, et al. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 2012; 78:1337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/56/42889/abstract/3\">",
"      Law M, Morris JK, Jordan R, Wald N. Headaches and the treatment of blood pressure: results from a meta-analysis of 94 randomized placebo-controlled trials with 24,000 participants. Circulation 2005; 112:2301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/56/42889/abstract/4\">",
"      Linde K, Rossnagel K. Propranolol for migraine prophylaxis. Cochrane Database Syst Rev 2004; :CD003225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/56/42889/abstract/5\">",
"      Limmroth V, Michel MC. The prevention of migraine: a critical review with special emphasis on beta-adrenoceptor blockers. Br J Clin Pharmacol 2001; 52:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/56/42889/abstract/6\">",
"      Pringsheim T, Davenport WJ, Becker WJ. Prophylaxis of migraine headache. CMAJ 2010; 182:E269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/56/42889/abstract/7\">",
"      Rosen JA. Observations on the efficacy of propranolol for the prophylaxis of migraine. Ann Neurol 1983; 13:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/56/42889/abstract/8\">",
"      Solomon GD, Steel JG, Spaccavento LJ. Verapamil prophylaxis of migraine. A double-blind, placebo-controlled study. JAMA 1983; 250:2500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/56/42889/abstract/9\">",
"      Markley HG, Cheronis JC, Piepho RW. Verapamil in prophylactic therapy of migraine. Neurology 1984; 34:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/56/42889/abstract/10\">",
"      Tfelt-Hansen P. Prophylactic pharmacotherapy of migraine. Some practical guidelines. Neurol Clin 1997; 15:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/56/42889/abstract/11\">",
"      J&oacute;nsd&oacute;ttir M, Meyer JS, Rogers RL. Efficacy, side effects and tolerance compared during headache treatment with three different calcium blockers. Headache 1987; 27:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/56/42889/abstract/12\">",
"      Schrader H, Stovner LJ, Helde G, et al. Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo controlled, crossover study. BMJ 2001; 322:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/56/42889/abstract/13\">",
"      Tronvik E, Stovner LJ, Helde G, et al. Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial. JAMA 2003; 289:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/56/42889/abstract/14\">",
"      Silberstein SD, Goadsby PJ. Migraine: preventive treatment. Cephalalgia 2002; 22:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/56/42889/abstract/15\">",
"      Chronicle E, Mulleners W. Anticonvulsant drugs for migraine prophylaxis. Cochrane Database Syst Rev 2004; :CD003226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/56/42889/abstract/16\">",
"      Brandes JL, Saper JR, Diamond M, et al. Topiramate for migraine prevention: a randomized controlled trial. JAMA 2004; 291:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/56/42889/abstract/17\">",
"      Silberstein SD, Neto W, Schmitt J, et al. Topiramate in migraine prevention: results of a large controlled trial. Arch Neurol 2004; 61:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/56/42889/abstract/18\">",
"      Diener HC, Bussone G, Van Oene JC, et al. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia 2007; 27:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/56/42889/abstract/19\">",
"      Diener HC, Agosti R, Allais G, et al. Cessation versus continuation of 6-month migraine preventive therapy with topiramate (PROMPT): a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2007; 6:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/56/42889/abstract/20\">",
"      Diener HC, Tfelt-Hansen P, Dahl&ouml;f C, et al. Topiramate in migraine prophylaxis--results from a placebo-controlled trial with propranolol as an active control. J Neurol 2004; 251:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/56/42889/abstract/21\">",
"      Topiramate (Topamax) for prevention of migraine. Med Lett Drugs Ther 2005; 47:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/56/42889/abstract/22\">",
"      Mathew NT, Rapoport A, Saper J, et al. Efficacy of gabapentin in migraine prophylaxis. Headache 2001; 41:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/56/42889/abstract/23\">",
"      Holland S, Silberstein SD, Freitag F, et al. Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 2012; 78:1346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/56/42889/abstract/24\">",
"      Silberstein S, Mathew N, Saper J, Jenkins S. Botulinum toxin type A as a migraine preventive treatment. For the BOTOX Migraine Clinical Research Group. Headache 2000; 40:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/56/42889/abstract/25\">",
"      Evers S, Vollmer-Haase J, Schwaag S, et al. Botulinum toxin A in the prophylactic treatment of migraine--a randomized, double-blind, placebo-controlled study. Cephalalgia 2004; 24:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/56/42889/abstract/26\">",
"      Elkind AH, O'Carroll P, Blumenfeld A, et al. A series of three sequential, randomized, controlled studies of repeated treatments with botulinum toxin type A for migraine prophylaxis. J Pain 2006; 7:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/56/42889/abstract/27\">",
"      Naumann M, So Y, Argoff CE, et al. Assessment: Botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008; 70:1707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/56/42889/abstract/28\">",
"      Grossmann M, Schmidramsl H. An extract of Petasites hybridus is effective in the prophylaxis of migraine. Int J Clin Pharmacol Ther 2000; 38:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/56/42889/abstract/29\">",
"      Diener HC, Rahlfs VW, Danesch U. The first placebo-controlled trial of a special butterbur root extract for the prevention of migraine: reanalysis of efficacy criteria. Eur Neurol 2004; 51:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/56/42889/abstract/30\">",
"      Lipton RB, G&ouml;bel H, Einh&auml;upl KM, et al. Petasites hybridus root (butterbur) is an effective preventive treatment for migraine. Neurology 2004; 63:2240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/56/42889/abstract/31\">",
"      Tepper SJ, Rapoport A, Sheftell F. The pathophysiology of migraine. Neurologist 2001; 7:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/56/42889/abstract/32\">",
"      S&aacute;ndor PS, Di Clemente L, Coppola G, et al. Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial. Neurology 2005; 64:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/56/42889/abstract/33\">",
"      Pittler MH, Ernst E. Feverfew for preventing migraine. Cochrane Database Syst Rev 2004; :CD002286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/56/42889/abstract/34\">",
"      Johnson ES, Kadam NP, Hylands DM, Hylands PJ. Efficacy of feverfew as prophylactic treatment of migraine. Br Med J (Clin Res Ed) 1985; 291:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/56/42889/abstract/35\">",
"      Murphy JJ, Heptinstall S, Mitchell JR. Randomised double-blind placebo-controlled trial of feverfew in migraine prevention. Lancet 1988; 2:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/56/42889/abstract/36\">",
"      Palevitch, D, Earon, G, Carasso, R. Feverfew (Tanacetum parthenium) as a prophylactic treatment for migraine: a double-blind placebo-controlled study. Phytotherapy Research 1997; 11:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/56/42889/abstract/37\">",
"      de Weerdt, CJ, Bootsma, HP, Hendriks, H. Herbal medicines in migraine prevention: randomized, double-blind, placebo-controlled crossover trial of a feverfew preparation. Phytomedicine 1996; 3:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/56/42889/abstract/38\">",
"      Pfaffenrath V, Diener HC, Fischer M, et al. The efficacy and safety of Tanacetum parthenium (feverfew) in migraine prophylaxis--a double-blind, multicentre, randomized placebo-controlled dose-response study. Cephalalgia 2002; 22:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/56/42889/abstract/39\">",
"      Mauskop A, Altura BT, Cracco RQ, Altura BM. Deficiency in serum ionized magnesium but not total magnesium in patients with migraines. Possible role of ICa2+/IMg2+ ratio. Headache 1993; 33:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/56/42889/abstract/40\">",
"      Mauskop A, Altura BM. Role of magnesium in the pathogenesis and treatment of migraines. Clin Neurosci 1998; 5:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/56/42889/abstract/41\">",
"      Mauskop A. Evidence linking magnesium deficiency to migraines. Cephalalgia 1999; 19:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/56/42889/abstract/42\">",
"      Facchinetti F, Sances G, Borella P, et al. Magnesium prophylaxis of menstrual migraine: effects on intracellular magnesium. Headache 1991; 31:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/56/42889/abstract/43\">",
"      Peikert A, Wilimzig C, K&ouml;hne-Volland R. Prophylaxis of migraine with oral magnesium: results from a prospective, multi-center, placebo-controlled and double-blind randomized study. Cephalalgia 1996; 16:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/56/42889/abstract/44\">",
"      Wang F, Van Den Eeden SK, Ackerson LM, et al. Oral magnesium oxide prophylaxis of frequent migrainous headache in children: a randomized, double-blind, placebo-controlled trial. Headache 2003; 43:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/56/42889/abstract/45\">",
"      Pfaffenrath V, Wessely P, Meyer C, et al. Magnesium in the prophylaxis of migraine--a double-blind placebo-controlled study. Cephalalgia 1996; 16:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/56/42889/abstract/46\">",
"      Silberstein SD. Methysergide. Cephalalgia 1998; 18:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/56/42889/abstract/47\">",
"      Liston H, Bennett L, Usher B Jr, Nappi J. The association of the combination of sumatriptan and methysergide in myocardial infarction in a premenopausal woman. Arch Intern Med 1999; 159:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/56/42889/abstract/48\">",
"      Lindegaard KF, Ovrelid L, Sjaastad O. Naproxen in the prevention of migraine attacks. A double-blind placebo-controlled cross-over study. Headache 1980; 20:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/56/42889/abstract/49\">",
"      Ziegler DK, Ellis DJ. Naproxen in prophylaxis of migraine. Arch Neurol 1985; 42:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/56/42889/abstract/50\">",
"      Welch KM, Ellis DJ, Keenan PA. Successful migraine prophylaxis with naproxen sodium. Neurology 1985; 35:1304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/56/42889/abstract/51\">",
"      Sargent J, Solbach P, Damasio H, et al. A comparison of naproxen sodium to propranolol hydrochloride and a placebo control for the prophylaxis of migraine headache. Headache 1985; 25:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/56/42889/abstract/52\">",
"      Sances G, Martignoni E, Fioroni L, et al. Naproxen sodium in menstrual migraine prophylaxis: a double-blind placebo controlled study. Headache 1990; 30:705.",
"     </a>",
"    </li>",
"    <li>",
"     Gray RN, Goslin RE, McCrory DC, et al. Drug treatments for the prevention of migraine headache. Rockville (MD): Agency for Health Care Policy and Research (US); 1999. file://www.ncbi.nlm.nih.gov/books/NBK45457/ (Accessed on April 30, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/56/42889/abstract/54\">",
"      Stensrud P, Sjaastad O. Clinical trial of a new anti-bradykinin, anti-inflammatory drug, ketoprofen (19.583 r.p.) in migraine prophylaxis. Headache 1974; 14:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/56/42889/abstract/55\">",
"      Schoenen J, Jacquy J, Lenaerts M. Effectiveness of high-dose riboflavin in migraine prophylaxis. A randomized controlled trial. Neurology 1998; 50:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/56/42889/abstract/56\">",
"      Diener HC. Acupuncture for the treatment of headaches: more than sticking needles into humans? Cephalalgia 2008; 28:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/56/42889/abstract/57\">",
"      Linde K, Allais G, Brinkhaus B, et al. Acupuncture for migraine prophylaxis. Cochrane Database Syst Rev 2009; :CD001218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/56/42889/abstract/58\">",
"      Li Y, Zheng H, Witt CM, et al. Acupuncture for migraine prophylaxis: a randomized controlled trial. CMAJ 2012; 184:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/56/42889/abstract/59\">",
"      Molsberger A. The role of acupuncture in the treatment of migraine. CMAJ 2012; 184:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/56/42889/abstract/60\">",
"      Linde K, Streng A, J&uuml;rgens S, et al. Acupuncture for patients with migraine: a randomized controlled trial. JAMA 2005; 293:2118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/56/42889/abstract/61\">",
"      Diener HC, Kronfeld K, Boewing G, et al. Efficacy of acupuncture for the prophylaxis of migraine: a multicentre randomised controlled clinical trial. Lancet Neurol 2006; 5:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/56/42889/abstract/62\">",
"      Guyuron B, Reed D, Kriegler JS, et al. A placebo-controlled surgical trial of the treatment of migraine headaches. Plast Reconstr Surg 2009; 124:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/56/42889/abstract/63\">",
"      Dowson A, Mullen MJ, Peatfield R, et al. Migraine Intervention With STARFlex Technology (MIST) trial: a prospective, multicenter, double-blind, sham-controlled trial to evaluate the effectiveness of patent foramen ovale closure with STARFlex septal repair implant to resolve refractory migraine headache. Circulation 2008; 117:1397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/56/42889/abstract/64\">",
"      Schwedt TJ, Demaerschalk BM, Dodick DW. Patent foramen ovale and migraine: a quantitative systematic review. Cephalalgia 2008; 28:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/56/42889/abstract/65\">",
"      Wilmshurst PT, Nightingale S, Walsh KP, Morrison WL. Effect on migraine of closure of cardiac right-to-left shunts to prevent recurrence of decompression illness or stroke or for haemodynamic reasons. Lancet 2000; 356:1648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/56/42889/abstract/66\">",
"      Schwerzmann M, Wiher S, Nedeltchev K, et al. Percutaneous closure of patent foramen ovale reduces the frequency of migraine attacks. Neurology 2004; 62:1399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/56/42889/abstract/67\">",
"      Post MC, Thijs V, Herroelen L, Budts WI. Closure of a patent foramen ovale is associated with a decrease in prevalence of migraine. Neurology 2004; 62:1439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/56/42889/abstract/68\">",
"      Reisman M, Christofferson RD, Jesurum J, et al. Migraine headache relief after transcatheter closure of patent foramen ovale. J Am Coll Cardiol 2005; 45:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/56/42889/abstract/69\">",
"      Azarbal B, Tobis J, Suh W, et al. Association of interatrial shunts and migraine headaches: impact of transcatheter closure. J Am Coll Cardiol 2005; 45:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/56/42889/abstract/70\">",
"      Giardini A, Donti A, Formigari R, et al. Transcatheter patent foramen ovale closure mitigates aura migraine headaches abolishing spontaneous right-to-left shunting. Am Heart J 2006; 151:922.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/56/42889/abstract/71\">",
"      Anzola GP, Frisoni GB, Morandi E, et al. Shunt-associated migraine responds favorably to atrial septal repair: a case-control study. Stroke 2006; 37:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/56/42889/abstract/72\">",
"      Mortelmans K, Post M, Thijs V, et al. The influence of percutaneous atrial septal defect closure on the occurrence of migraine. Eur Heart J 2005; 26:1533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/56/42889/abstract/73\">",
"      Yankovsky AE, Kuritzky A. Transformation into daily migraine with aura following transcutaneous atrial septal defect closure. Headache 2003; 43:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/56/42889/abstract/74\">",
"      Rod&eacute;s-Cabau J, Molina C, Serrano-Munuera C, et al. Migraine with aura related to the percutaneous closure of an atrial septal defect. Catheter Cardiovasc Interv 2003; 60:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/56/42889/abstract/75\">",
"      Goadsby PJ, Lipton RB, Ferrari MD. Migraine--current understanding and treatment. N Engl J Med 2002; 346:257.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3345 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-655B890CD5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_56_42889=[""].join("\n");
var outline_f41_56_42889=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29\" id=\"summRecButton\">",
"      <span>",
"       RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Menstrual migraine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ANTIHYPERTENSIVES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Beta blockers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Calcium channel blockers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      ACE inhibitors/ARBs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      ANTIDEPRESSANTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      ANTICONVULSANTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Valproate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Topiramate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H158088962\">",
"      Gabapentin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      OTHER AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Botulinum toxin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Butterbur",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Coenzyme Q10",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Feverfew",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Magnesium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Methysergide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H179289492\">",
"      Nonsteroidal antiinflammatory drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Opioids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24812537\">",
"      Pizotifen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Riboflavin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      NONPHARMACOLOGIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Guideline recommendations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Acupuncture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Closure of right-to-left cardiac shunt",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Prophylactic principles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/44/21194?source=related_link\">",
"      Acute treatment of migraine in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/29/36314?source=related_link\">",
"      Choice of therapy in primary (essential) hypertension: Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/61/7128?source=related_link\">",
"      Chronic migraine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/21/34136?source=related_link\">",
"      Clinical manifestations and diagnosis of retroperitoneal fibrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/38/35433?source=related_link\">",
"      Estrogen-associated migraine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/63/5114?source=related_link\">",
"      Headache in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/11/32953?source=related_link\">",
"      Headache, migraine, and stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/39/3704?source=related_link\">",
"      Major side effects of beta blockers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/0/25610?source=related_link\">",
"      Management of atrial septal defects in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/2/35879?source=related_link\">",
"      Medication overuse headache: Etiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/4/26698?source=related_link\">",
"      Pathophysiology, clinical manifestations, and diagnosis of migraine in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?41/59/42931?source=related_link\">",
"      Patient information: Headache treatment in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/57/35731?source=related_link\">",
"      Patient information: Migraine headaches in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/20/36169?source=related_link\">",
"      Unipolar depression in adults and tricyclic and tetracyclic drugs: Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_56_42890="Erythema multiforme acral";
var content_f41_56_42890=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F62370%7EDERM%2F72055%7EDERM%2F65570%7EDERM%2F80715%7EDERM%2F57894%7EDERM%2F54232&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F62370%7EDERM%2F72055%7EDERM%2F65570%7EDERM%2F80715%7EDERM%2F57894%7EDERM%2F54232&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Erythema multiforme",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFEAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5WpKWkFUAV7h8H9J8jTBNIMNJ8x4rxfT7c3V9BCP42AP0719G+FoxbadEMbRgVE5WR1YWN5XOtnmCWwUHA61Da3qWVwGJIRjlhnr71UubhWkIBygGBms3W8XG1FHJUdPWuVzaldHr2urM9f8AD13bu6SWzqxA+6DzXR6jIPsgwSC2ODXzjaf2vYshgaSNt2FOc/hWzP4o8UxRLG6NLER8sikkH1HtXdHEXtKUXocM8NeWkj0nVvL2szMqkHgniubspYHvJV85WZwBkD5Rz0z61y6a3fXyEzRGKdeqklsj1qXTmm+1gnKjJZgOM1E8QpTTsdMISUbXMz4mEebYqCOJ9+M9cZrHRN4yp+f+dTeN5xNrljCw4ClvpT7eJnKmPAYdzXLVleRT00J7RsiJLiPCqePx68068tY3Lw3Fuzn/AJZs3BIznj8KmtYpR/Dkddy1NZ29wshdoo5FbIILEYJHr2rSm7mEtEQ23h6NPMZYZJGjG9CsrLkAc5HermlaETB+8vrt1YbjFnasee3v9KIJJ4IJBeLIAibY2ALKufUj+daWmTlbaPy/MmJTA5Uj8utdEbdUY8r7kMumwwSKsVqFkY4QkEkEdSSaqSQrHPKHyP3ZMa5wOvX+daySGSILKVjm5G0Ngmsy4hO6RpCxKRkoWPvWEmr3RstjkICsviQJjKxx5I9ea1Lm9mSWJAPvHcDnqKxNIkDeIbve23Hyhvwq1Bbt5wkaQyeWwxjsK57XZtSdjsdEjuZZzjMgRSzDHGT3rU0XVYjcpZ3JWKUHC5BGfaq/g++htrtZp22JICjZ/nWdIj6hr99LaoXjUFQzsFx7j8K60lGKaeonJybUkdTetth3hl8hGKI2OrVmW82N+6UNgMMjqapJc3UmnxssYit1YhZB85bsMD0rMtpzvUFm25wTjB96yr73Q6L0aE10j+z7tSx27cDvXncMoiZlB5PA9Sfau512Rn028ZFLZh3EDnn0HrWDong/XtTjSZNOeJeqGZgufw61jClKekFcVWrGEtWRRFTFtbh26+9FlaIl350YYMo5x3q3qmh6ppUBF5Zyqo/5aqNy/mKqWc6uVUE7sc89amUXB2kjanUTV0bumTnIGCCSTz2rfs7g7GabPt2FcvbYDh9xAIxx3rVsZi2PlGBwfWoZV7nQWAVckvxyQe/NakDcksT/AI1gRTbJdpx61q2kqyoU3EnPLelEXbQcld3NO3Yyk8sMDg9+tTSTMpBbHPTB6VAhESqAeBwT60yaQeU/zfKAPzrfm01BJE7z7omyDg/r9KqSlHgYhtvIGM8fn3przmWBQ7bNq8HOSBUSt5gQkHH8A6fiazk02NRM3ULJLmGcSAFGRlyy5wcdq81NpPo120EoCgfOpJ6qa9Yk3ldsbZZecmuc1nSI7uNFeNVJIOQPm+pNOM1sxTpOWqMyxujsBwVHcYPy10FjNbvgkqSD0x+tcqYLuCVYwxlQkjjqfwp32i4VRIUZNp2srHkH3qlBPVMwldfEjt3ubeFNpfaijaW/iGT2rkdft7C8nWKxTckahTIVwWPXp29Kw768v7iVo0TYqfxdc1o6JFJsQzOS2ckU22lYcYxkVj4Rt1lCtGA4PIGP1xV+70CKO3hKQou1cScH5j6j04rq7UFnHyFFZApIPJ9a6TTbS3Fq5uIY3LZAD+pGOv8AWqiruyHOEYxvY8f0VH0s+XEw8rqYz1FdJb6iWQMNpwMgHpXUa/4bt5Eae22/JwGAwW/2T6ketYI0jYV+Rh2Axj61pNuDszBQ5tijcXnyrwGZupBqKCwa+eSSQltowATwK1odCeSfaBtGQdx4C812CaOtraxoPljKgZxgk/8A66h801poUqaT1dz5r8VeGSuqRuqFAxwR261t+GPC3nfZxLCQrFhux9416T4g0qJwWcZGcgkZ6d65uHWbrTY10wzBbKSTzdpAwHHoe1P2ja95kewUHzIi1HwnbQLkx5LZU7en50zQIbmxuIx1QcAegroTfLNEGJ3Z4BJ61D5kUWcHPrWLb2NFBLU3WuXeAJIwx9awL8i4vIrZTnc+D7io7zUHX5VzyOwrQ8O6cZY/t05JDsUAxyCKaTWo0uZ2R8t5opKK7jwjofBFv5+uRnGQgz+Ne62QP2Uhjjb0A7mvJPhpa7pZpmHBIANerO21UIJCKe3rXPiHayPQwaJ380dDgcbjW5Z26bLeSZ02EsGI5I71zN/fD7M8cL7mZgv1FamnX7z2qwXIhaFQPlJ2O59jWVK19TvqN2OluUkini3SmO0mXCsyrkODnj61kvDNDqVwsZkZZV3Zbna3qB2qrf6k93bW9pEswkgkAUOuGb0zVrXnld1ZMxFkAZF5OD/I13OV02uhzLcisLe4MLTThBIWxweTzzV+KLypXOednNMSN2FogKx7Bh/mJLHr/Ko727Uw3TLgEEBR7Z5/pXPKNjaDurHE+IGEni8gf8soFB/GteyO1F2k8Hg1zHm/afEN/MRz5gQc+gwa67TFIZTg+WBn1rmk9Stzat43SMnCtzuUHjH40sTPtz9mRpAw3R7uT71Zt4w+zBYNjI46irZt8MpMSsUA5UYNaU79DKVkQR3SrHj7LPEDjlvnGO4OKlNvbuPNIEfoy8ECrEUygPGsm0N/Cw5FSTiSON92xh2PSui7tdkW7GTOg3SME4jIIfOS3vWNqU48qR4yfmG3PtW1KzIkj42bjtwOcn0rl9WmdbOZwvG0nH4Vg2aNWRymklp725lj+XdIwAFa0IO0KysCzYZt3TB5OKzvBkZkU5wCzBlB7H/CukurRnvJ7jekTONwZR9/J5GKzW4k7JNFjT7OeV2czeZEi72eNQWUe4NaCQpFpd0yzyKWI2gFdzDODnjOOe1Qi21TyyLae2wDnPk53DvuPepYdH1VLgpPrCRKcjy4oV+8e+D0z7elddOKWpnKbfU0LmVxbwWYhjhazAdjK5GeOCPXOa5JrmWW5csSGJ2sfUV0Vxp32e5E95qVzNOAWeV8NgjsBismdGuLneq/OwyXNY1tdDakjU0lVTUtP8zDR5ycDO7k8V6dZSO3+qhVR2ya860eAfaNOO4sU+8PTk8V6Vp88aDp8o4J7V6OBjPlaRx4hx5k5Ed0rbmSeFWX0FeJ/EfRo9J1NNS05CtrIcSxD+BvXFe/3SK2OhBHBrltW0+GW7jM8KSxNlGRlyGB9aeJhzpJlUGt46Hien3hl+7ywGQQMitGGRt+SwTNZWs6c2ja7c2wBWIMWQL/AHT0H9K0LeWNYcHKyFhgseMen1ryJRtoztT10LUbvNMiIxHfPrXV6UnkW6r/ABMed3OawLGPdJ5hIbn05roIJuQCNo7Vl1N73NJpwEfoCBgVmtMZM7TgBuM8ZNQXlzsmIB4IqvG5iiYqST/nk1EpXZaWhpIw53NgjhRjioRcbDtwSTyaoG6ZW5J4Hy+9NSdifmbGew6mlcqxpo6iMZc8nkdsVFLIIySpJ3HrVdW258x8r39RVeW4jUH5WJJwD7U4q5SkkJMAVwxAx90Dg/WqjsHjw4BzkEt3+tOnlL5CckcY/wDr1Snm2QjcdzA8ketaxZlOaYgiAc8oc8g9eKlgG1SFJ3A5+gqnLdEqA2Qe2RxTIrs70ULyfX+dVfoYcyTOs0zAVUQlixDBieB6112mOuAinkHC4/i/ziuD0+4Z1YBjhe5HA+ldJbXwJEK+WMkfOcjHvj0q6UuV3CWqNnUZvLZDtbAbdtI6f/WqCJbXyre4BUTszF4/c8d6zbq5mUlZpRIUBG7rn6VPa3cTxRqJELuOcLlhj3rVVPedyZRsjcWcImdgVTwwXofb61Snvk8so5zgY3Z5A9xSKrTWjpG2GUnJJ24X1rm5fPtLmZJ5Y5VAzuQ8EfjTqVHHZaFQgmrj9WkDcgAjd0HOOPSuG8S2CXoMf3ZFOQR1zXV3l4gYnaYyxwCw4yKwLxXMplDfNnGfauZS1HJaWMOOyu4YoUwWB5y2Vzz+taMK30ke1I4xjO4E9h6e9WEdlcFmyAMfWtTT2TeGjA2nrnsat1WtiYUVLdlXS9OYTxzXDsVBBGVyPyrqLO3ijWLy2KDjcvY+9QBdxG0D8KnhIibA3D29aydRvdnRypLQ+QKUUlKOTgV6R8wen/DyHytPVyoIYZJ9K6m9vvLBCAlT1xWF4WiMVtChJChM89MYq7fB5Y1bI2Z6dK5K0tT1cNHQtQyTMSUQLuPAx0rp9LsJUi+03Vl9pjU/xMR+vSsfQ7i0R186J5iQMIvf8a20122ht5Y5Ib2EpIAjNgqMdQ3Y4qqUFa7Z0Tk3pYparO9neRTQiRIn/eKueD9K1rXXHuUW4nsQFEm4PuBb6bc8isie8glRJUIDeY2AM4K4/h9s+tWLCOMWU/l3FqisRIrOQzMCv3R7iri2tmYNJ77mv5v2rUIJraU5G4NxggYzyKyb2faLhgR5aRlmP41PYQukbyozZDYIAyDjBPP41h+LJjDp184yC4wwzjJPSlUd7Di+W5keHF+0tJcY/wBbIWAPua7qwwFAwCe/tXJ+FbfZZwZUjAFdlaoWX5AOD1zXM1dm0Hpc2IE+QE4cL0weTV6GVn2/KDgc4ODVAI0UY5GWG4YNWxJHblmBB4/i4P1rogkjKWpaSNCUD71bqdwBBqG6SWBhg/u2HKrk1PaTCVPMJMZHOB3+lMc7HbO14+OnXGPStH8N0SrozLx2KNtAwBnJ4rjfFEjQaRcyHnMZ57jIrsb0KUbLbj2/+vXCeNNyaJdEN6Lj15rneho9jN8Ix/uYWLYGBXaLbI7xK6JhRkfSue8HwhbKIHqAOK7vTUMkZGCQpJwe1ZwTbLatFMW222wEkFsGQ/K8fmcH3HGRVhioEE/kTxoFGXKhgWz7H8OavWcRXD20m04IwVyMVZ8qZSNogfIGcDbg12wu0YtK5g3SRlP3Ji2ct8wIYN75rLv4gxQRtuCryVGM+tdHcWv7xnaJcdfWsu6QeYNiKD09K5qzu9TemrLQrg+TPasAWV3jTjtkgZ/WvZrOyiSBdwASPH6V41An2q8hBO5QoYgdjXounXV21pHDJMWiGOo5P416OEvKnyp21ODFUnN3RvzLZz3QUtIrN1PRT+dc7fbBIoPIV8fka3tY2S2qMBh+DwK5yUlSCOxrSXwIMNC12eZfFq1Eer2d4i4jkyhA7ntXLW0m4A5GQeh5r0b4s2/2jw60wBDQsJAAOeK8v0wN94ElWPf0rzq6tJ2Omm72R1emStEucBverjTsqFmIC46VjwSgDZk5A4pkkpkcc+3Ncj3OuLSNJ5AThepyTjtTgxYbOcAcnNVbZhGxywLnqRT/ADGGAzA5PNZ2ZfMTOgUZQ8niouiN90AHrSy3O1MKrMexHSqLThwynjuwHAo5Re0L0ci7Du2gHuaqXMi787mU9jjNQvcoYgoPHQKeM1myNG0bRoTvz95j0rSKM5TLhnJIDStgHqvakZvKK/8APQnOfWsS6c2xQiZ9+7nK/Kw9KgW7Zy2JXzk8HtV2aMOdmxcOqSLJITuaoYbppJj8qqucgg9PrWJJdONwjcyAHGDzUsMd3JKjhCCBgj2/rSsK7k9DqbC7EZHmSbQDwygEMfx6V09lLGBlrmFpTxhjyR6DtXnyxzglvmXgYA6A+9SCe4i+aXOMZH1oTNFdHoE1y7M5nkwQNoyuAasW8scUOI22sT1UjJrz8a7MXw3zr29qkGukhthcAD5V2/mKVne5TkluenpqCRW7xSbNz8lj78CszVbqJo8iVcg7VPO38u9cJFrzqW82XP8ACVz0pzax5rAF/k64Hp9apzlJWZKdndGpcSyB8YTac9sZ96z7yfc+wsvup4NU7rUMkeXKGQAjmqE1+m3a7YPvStqKUzQW6BkPOATjn0+tXY7ohv8AZHQgcViRS71/d7cnqg5/GrkUcjukjHc+Oh/h/DvVOxMZtHT2d6SoHmEj19KvLOWCHBLDtmuZjfBBEhI6nkcVoJOCMhgFPQ1jKNtTojO58yVa02Lzr6BOuWGaq1teF4TJqG7so/nXrLufPRV3Y9KsBtsQqgb16GtFY1njC7RvHrVGyjKxtkZwfzFba2its2JkdcZ6V51R8zuezRVh1raokSiQEOpOSOMV0lvYva2H+lRzeVJ+8iw/yS9uFPf6Vl2KF5ykkbMp6gEZB9RniuqcWT2KEW13HNFHvCxMBn3Xnj8q2oJNajqs5aCwEl2HSIQ5c/whjkDuKmTQYGvPOELLGx27ujKQeuBWw9rNujMYd3Q+YFKgkfy55q6LZikf2l2jkfDFSu3I9citVojHqV7uJBbhIzhMcd8AfeP415945mQpDCvLyMA3Poc9K9HvQY7GQxHETnYnHQZryzxBi88UQw7spEM5x1PSsqjbkNLQ6LRY9sSqW+cDBwf6V09jHsWPZyCerVz9rtjjC/xAVrWpbPXhcEjPeoii7tRNRXmVN+xF44O7tUyTyNndAXB6BGzmsW4umTYHhDruz8rc4P1pgu3KoyvhMnBQ45rfYm9zpEmVl+VPKK8FuwPT86naQNEWixlQFwTnnHY1z0M90ryqW/dYDHI+9z2rRt7p2lUuQwKg8c44pqSaDlaY29AaDdkD1HTNee+PJcaXJGuPndcnPvXoOoMZocqRu/iHf8a8+8brvsovlUZkUYH1PWueW5e5c8NErDESdwCgfhXbQxuE3Ry+WRzx0Psa5Pw1GDYRsi5bOOa6+23fxDKYBYjkVnBO5r0LVlv87fIJWwPlQHbWir3EWJA8pGeRkEelVoUJYOrSMOqsBzjvV6VnEW4iQqRhWAyD7kV1wTSMHuU3YNhfMbcPwArOuiHJRcjv071pzZcbsjcODxgVUcK5Y/dcj196xrK5vDYxNLwdTXe+z5flz3x2r0PT3xEhHT1ry7UHMV5tXAAy35Vr2XiSe2hijSIuwHzHNb0MVCjpITpSqK8T1e7ctZg5BO0fhXPXUuzIPfge1Yya9f3MQxFsRhjzCM7RVdIroTl5pRIGwwI6VtVxScfcRFKi1pIseJovtmgXED8MYyM14vp8jLGEADMDjI7c4x7V7dcv5lu4cZOK8SuB9h1m9ixhFlboeMHoK5ZS52TKPKzThn2gscdcDvU0WQQx5NYdrOS4HQ56mtRJ96kRsFZetc8omimaAkDMoYe3/wCql+VXIB+QHkkH8hVWFpBliw2n15pZApTb5wUcnOQMU0mJzEluzLiNN+c8DGAfpTZWKR7S539flpofdCVQMVIxnHNIU8uIu8TAHgEHJaixPMyK5kYQkLEmOpJOcmsqe7dG2iNAoHHOTU0zSO7bypAAwnQ/Sm21jLcMxjVVTIwSMmkK1yi6PcqBsZm/KtLTfD01wjZ4HUqOn510lhp9uNqsVMvC/N0rRtpI4XV4lUsvO3+62ecj6Vok2axpJblTR/DcMM+yUKBtJ55y3p7d+a0HtbaCQOzqUIQKpAyFLdT+VWmkj8qU7S+/5sKMDk9qxr+V2na0hy0bIMFsAg5z/StlCKRrGLWg42XnbUjmiSN3KZc4wwY96s2ehTXTzLFET5Zxxg7hj3rLvWW9Nq9pG5ZV2XCMMqGJ5YVpeH7+RV2M+GT+PHXspx75/Sj2EL6jc3bQr3Hh+e3iMtxAAn3iRjgZx/OqEOnRsSYsZJ7H9K7v7UzyMt15THIJBJIJxnpj/OKuMI0tleKGNZJRsY7cAAn6cH3p/VE9Ysz9tZWa1PPzo9vsw6JuC5JYcn3FVoNCV8eXGzMTtKg4564NdpdzQQybDEAcDG7G0H0qtqN5H5UkqsDLJwJezY6j8qx9iluzWyf2Tk5vD6BcsrKSxG0jnPHaqt1oMRDFCu5ASeM4+tdTfy/avLmhYmfO3gfMMdPyrNuLZYIyZgzSBCWRiQCT3yKn2dtg5I21Rxd3YTW0ZeLceeDjg0+wvnWQb8BwOUOa3447kTIhTgDLI3RcjNZmp6fFMjS25wzDOCMUvU5qlFrVBDco92CSixn7wx+taiSMpKx4APQdsVxSXM8VwuUDY+8GPBroLS6M8yq0WxegwcgihxsjKMjwuur8HRkI8n+0MVyld54St/Lsom7kZruk7RbR5lL40dlYhjwBlgchfaujtt/ykbQ3qT/OsPTxhgVG5sc+ma1rZXkRHJUEn7vevOkz14G1AG81DGpyg5YLuGPcdxXQxq0dmE+yCUbtyfvBt2keh5FUdKsD5DO1uzTjncsmMfhV8NNBHt86KRgcCKU7WHurDrXRSXKtSZ2Y2UCLaI7Z4JUbO4Ngfn3p5jaaNSySK4yeZNwB/wD1VLAyfOm2TzOrKWDdvyqRE2DnaflydpwDV31JsZt+AkGQzARj7p6Zxx+teV2Si58QXlw2Wwdg49P/AK9el+I5hHZO/HQlvfHevPvClsTam6YjMrls56c9azerC1lc2JJGjVN/y7jgn1NT2svmI7o+XOCASF4B6fjWPqMpuplt8EjJBYnaPbFSaakxm2N5WVAGSx59qpK25NzZmN00gQqivvHJflR9aLeS6VVLRyFGbBYfOqj6CmwyhJxIwiO3O4AkD9etaVnOGdQECgfMBIMqPUg1cdXYNtTc022gu4DJKTvRc4Ax+lZk0ohZ/LySvIdcjAPap11C4890Vt2WyrRENx3yOCayJ5xLPI00bRuM5GCAPQY96qpZJJFU31ZdupmgeNXEh6APnKn1rj/FwZip3cM44PYV1cJM9uElUBH/AIeuQelcprsahUALMqSBcH+dc0tijofD8ZFtFFG2MA8Y5PSuks4yDgfdxzk8/iK5jw/KJGAYckjaB2rqYRbRsfNAxIcEFj19qcEnqW5aGpaKyyM9vKyhCCSoz29D3qwpuYn814t6tn5kOM59jWZClp5q7XMQyeFlIrUM8saKiX0bg8jftYDr1IrrVra/mZNu9kU5LsO7R+XycnDDGRVSQpjIxyOPrTb0vI5DKrNjqp6e4qu6n7OMsOOOBmuKbbdjeG1zFudrawu7ocj8cVtWen7yAUXf93B71g3ZKarA2DwfSuvhl5wgw5wctwOlTFJvU0jJxWhp2FvDHax+XuL5ww7DHtUUqEPnYAAOgqWxSR7mUM7GPaucDaMnvU00caqgz5bZIZweDxXbJXhdGKlaWpmNzG2D8xrxvxgrW/iCfK48wA49TXr2+VVZXRCVLY2nPFeW/EYJ/atuznYWBXPPPvXHGXvWLq7XMSEu0nykBl/SrnlyBCZGwvUnOSaz7UlSR0XPXB5q/u8yZQwO1BnOMVTRzXNe02lOFZePukYAqw9qpjIdUw3P3etVobeML5kzHc2BgtitSCEMU5PsBg4oSLbKZiwVCxhWXpzgVLyWJKknrjtmrIhjbJKnKfNnPWoL2YIVJKgY5A70mNK5UuLXc/zbXHfAyasJJGUaGMBWI2jPQH61SkumlYhTtHYD2oh+XiTdtbgn/ChK50QikaMAUbQinbjk45BqxJ+8UFB+8kTcAp4yDz/Wslp/KbKcHHXPWp7C6XK5++DuBP8AKtOZLQuJtWDebcpGjgFgzOckgADt71JZW8VyrNcuPPD4KrxznIPHtVTR22SyOMNgbAWOMZ7/AK1qWd2kToHweeAOMHPr+tbU5K1zSSZR1OyVVXy8AbysZOAwPQr/AFqfT7IPZSSQvE7qqkA9cA557/jWpIbe7AdwPM3E5AzjntSRqqzNGzBeqjAC5GP8au+pkw8pkulYzvLhQ52YI5Xt61qBnmlt9j71A3nvkDpWBeSmGbBPAQJ8vOcCrmn3YN2T5qwsQBknge4ohNRdhThdXHanYvl5EUMXXCgDG7B681FdaIt5pLyb4IZIojJsk+Xcw4OD61r298LkSRllwBgsT78YNY+qLBdB45pCUVQCQcZPU/maqahvvcKcpLTsYXhs+bbzLtJlVvlUckH1zVO6E32+SKRWQjjk5qxr03/COaEt1boSzNuEaEKQo75rg/D/AMRrQXLRavE88MtwJgz/AH14wRn0qfZKMEpGdTFL2r5fuO0tSpZ45W69COucYqN7Rykk7qqqv93knt0rLXU4L2586wc+S74wRyp6/wAq6GeRBbPEgO1hkljzjP8AOuecOUvnU9UcdqlklwDJEP3i8lc1UtGJYIFYDPGwnIP410V0ioySqu1RkNznJqnLaorGTGVZQRnsajTY5qsbO6R4NXpPhxT9kRVHRQOvevOEG51Hqa9L0NRsUZ2gYrpqaRPMofEdRYL5eD95x0QdzXRaVEjuhPOOx6/gKwbJ1DbQMn1xya6Kykt0Ik2bSq9cZ+Y9641G8rHorQ6MXHlxkxmJnKhFDIVPXufWq8l66LteLYGBUsp8wdeo71RmuAQhBZsk9CQetVjqiiVgss/mAbULLnjHfitmx3OjsLqGR98PkkKNpjZQGcdK05UDRHaQCvVelcraXkUqCJLiGYBx8rLyCfQ1rxyyKgRN2U6p14+tVrbURgeMHWLTLtmLL+7PA7CuT8NMY7ONcjau3k9PXFdH45m83SLrkBhGcqe4rkLAudNhEX3hjK5wPas4LUVSXQ0IJ1k1Oed1VcscDrj0rVs/JaTzAgGACzdPwxWBYyFtQDYCK5+VRziuiis5mIiWVoyBn51AHrk5p6tkrzOjt0XyY1eONgBnH3jzntVPUNJs/LElu7PKEAypIWNj79M+1UVjvIZ2VkLAfM3lnGauR6gksKiApGjFcxEYVuevua2WmjQNX2FurC4hI+z3Czqy4i3cMpPXBHcVn6o93EvmTO7BSB8wBPPHUda6PV7KWyZHLRAuu5AyhS2e3Bx0rKkmLSSeZHtUqPlxwcHpSmrOzFF6XRJpMbTO6TLgxqdrY7VzfiiH99ESDsMgxzz9a3rYStcucttxtKlsEZ6H+lYWruC6JO21kDEEdAfT6VlPsXF3NSyjWKAMh3luCq8Fcc5rTgMktzbxhwiN/F1wT3rmLOaURARkkPjadtdDaGGK2jYXU0U4Ofm459hjHNKCLc7I6F0nhlaONvMIBywkGGx04NMe7T5TdwBMDc7PFgE9AARwaovLcBmxeF8KG+dMD6ZFSw6g+3Y4aMyAZYsCv69q6HbYzvfUSWWIs0sAV4ucjdyMdx602GV8MUA5HVvSsy/W3VWyyqMfMyHADE9PpUkDOY4trAuy8MBxnvXJPc3jLQoalKFkRi2DkZ4610enTh4oXaOUlTtf0I9RXK3W6a4QNjLnB/xrpNCSHyYzM4QqGRt7cbh0qYpuSLvozobSeVZpoP3yDaNpC5JXtmpbRHaWeV3Uqh2nfkmql1qq201rKZ4hgGMsrZOMdc/WnLfWz24S6uoVEx3H5hnJNdaSvy3uY83UhvZ8K4QEk9CnTFeV/Ea4EiwsygOH+U+xr1G71Ozjd4I2Mo2EKFTocV5p8RofM0x5VUq6kELj3rmatO5tJ3jqctYNN5e8gEgYA6jNa9vgyrE7s3APA4J9KxNOkMm0biBjOAOPzretMo+8kFmXAyen5Vbtc5UdDBsijDyc8dT2+npUN5fQW6ZSQ7iQTWPe3Z8tw2QeijNZF3cuAULqB14NTHUbZ1E+qRFUwzqmMHK9RWW9w0sx5JzwB7Vjw3AZhuY471fidRk55Ayvsarl1NIy0NWHCopTc4yD+lOaQIgaPgdz1FY0Vy3nE/MSOcg96uW83nOFIzH3xwc1TVylJsnuJQyKcBVzkbelVvPaPGW+UnArQSOOT5flRiMfMODTWsMQt8qlM8p2+uaXJc1UrF/S7lJMtKcA988Vo37eWqvFkjuVFcmoks2wiu8RH3Twy1f/ALftms2jnlVZRxg9auMHazNfbqyNXT75luHdSRnjGa0Bd7pGLAAY5I7157a68sF7L5vyRtkq5P8AP0rYsdYhuYQ6zx7uRjdg1NmgdRNnRXUxKkKw6cZqtFdMoJCg5GMe9ZzXtuVy84VhxtzWTb63LBL5THcA3AUZ49alq2rH7VbI7Oxv2RWL4wc57YokuvPfbGypuIzjgCuUbVBIMAEn1Ixj8KItejjA2xhnUnc2eKamtrkzbtobfiXw4NV1S3+2agwhhj4gDBQw6kkntXini1I4fEDqU80JKVCoQodc8AYH6133iPxfJcsEt1nkdVIQRkEE46nIrD8N6Nm8F5qGy4uCDhOTszzknpmuz2iT5keTVpSm1A3PCmmLbaZbMGdXkIlbdxj/AGfyrqBcHzP72e7dKzTvUDzBtUfgaswBnG8AY965asuY9ClDlSRavoFMSsSfNIyEXGAPU1jwPid4piNhGBn61qrMY4nAI5/M/j6VhXG8z72wBntWTVyp66M8Vs13XUSgZ+YV6XoYMYBGMnqcZ4rznS/+P+HAyc16VpkggiXpubuegrrqfCjxqHU6W35kRImZSepPT2qyb+BZJBI0ZUYXLEn8qyoJYpCWdnfaMBz8oBqRPKZg4cNz0SPJx+ArmWjOzcuXd4fKKxSMoPAUZ5Hp9KfDp4aIS3FxIGPIUEk49OtU7yRJJlEpdQexTB//AFVs2scN8IpFlbBAXHr/AIVfK2y00kVIFj89NrMOcK7g/KRXT6PdHmKR1DqAC/Qsf8Kx9Q0Y6ZKskFyZY5V3Be6//WqzbgPAGZXZx95umfpRG8ZWYSs1cZ4wKyaPOGOT5bAcdBiuD0w7bGASsVBwWweSMcY/Cu91fy30mUNux5Zxnkk4rzewJ+xRls7R2x/KiPUzqaWOg06MzXKMgLRE4O7jBrpfNurYf6NdJMueY5EIJPoDXOaPMPtYQFjFje/H3a6S8tQfL+coZCDuzuXqP4fX2pxT6ClJFeDWpQ8rXFpPLvO59hwSRzg4HQU+41xLm4eSWwnhZ1xGkY+VOM5x359KVLRw0ktozyJuIOw7OOetbum2jExu0piRztwT6DgBsZ+taWbVmxGGs5kt0zFNvAKkytggdcgGnC6keOaPMx+b93kjJ6dcdua3LpPNkhYIh2jaGBHP0qr9nijiclYwx4wB2x0+vvUO9zQZY7VS7iZdsjbYznksCeuf89K53XcPelXkVchn3Bcjjpx74rpYJfLSWRAFl2n5xzt9BzXIaoSNTSN4g8mzqvqamWqRHNa5f8O3ltuKyq28D7pPUE8flXRQWkd/KhE0hAO0KvysAOnNcX4fYGSVpWy2NqkrwuDyPavR7WK0S3hWa3XexwTnaFz0+Yc5yelVFcysNvS5l3NpMVto/tUqtlgVYbyvPp3pn2TUoyNklpPHjbh4+a0p7qbTbx5owJCoaMF8ncfVcelK2waXDcSbwqjKhT/EeSx+p6elU9BrUyNXhUoySWIikcAfK/OeucelMWVraCBR80R+43IKnvV+5ke7kiS8UtIeN7MBn0OfWqExXzoomcsp6KRt+orF6u/Q0S0sypdkvdKhIwG7Guj0+2kuGO5RJzwehz71ytyQssKhcKDjGa7PRFIVd7AKwBzms38SRpFuxLNoltJGsgtWKE4KhiOf8aZb6ZZrJslhjCseC5LAelah2RMrx3RVifm3thQPWoxNGGcvdR7+ScKG3enPpWr0sSrplt9OggiRoY8pjJODgj1zXG+PNLW80qXaQCEIGOh7/jXd2hma2MKZMPBwcYB9axvEEIe3ZWHVTnBzRUSdpIuPZng+lKPIGcBwO54rWibdIAMlfes6RTbaleRj+CQgDFW4+fLJLLjnmol3MCy0kaeYz5Z1+hzWTPbm6Zntyu48hW4/KuhhhikyZ9r8dAKitbMPOypt2nvzwKdNrm12JnFtaHLeXd2Nz/pNvIqKwVn6qCc4BI78HitOB1nb90R24rrdUsUksWCQQs8oXqdoXB67e7deTXNiyW0vYZCnmIG3Og+62D0zW8lBy0CnCo9GiP7KRKwDrn1BzV60R0jO4hWHB9DXVXK2UTpPBaqlmRuLINxBIztOeciqF3qX2uBjbJCix8kKvLH61b9jHd6m9OlOTuQW0ZkjJXLkAkjrVd9X+zhlMixxr0Urmp7C4mF3G0oaKORSDtOOMd6eLWGS8F5bSRYiPyxSplW+tJSpv4XZm8qc1eyuYks76oQIxcykcDyYj1qXTvBGp6xMPMP2aMH71wfn/Kuuj8YzWJCtpcLRgfeSXAP6UqeO9KudTge7iktxGOcfMAT9K3UaD+KRyzeNs+Wlp95Y074T6YsY+13c90T1AOwfkK0W+GHhYROn2OVpCvyss7AqfXrXQ6f4q8PXKAR6nAOACCdtbZktZ7Um2ljkB5yhzXXGhh91ZnlyqVr+/dHltn8MLOS8mimhlit1x5TrMfnXHOTWk/ws0p41jtXu7dVGC6zZJ+uRXpdtEjwqrde9EtuEDeW2P1pLC0WthPEVe55e3wdgKSOur3WQMplVx+NcH4j8FXWjW01wLtZLdTukZhg49a96glmmuJYiwCDAOOpqLU9CsLvT5oLuJrkSAAhjgY79KcsJSmrRQLE1Y/FLQ+XfLNreo1ypkRxncDwwI7YrpNBw8P7hQAvJwQK6Pxh4AttOtLibTpJPLiBkEMhzt9QD6e1cRpN7bSgxMWjkHXBIP4151ShKjL3kexh61OvH3XqdbKqyH96+5cfePB+lRySBABFxjpVQTsI13Nv7dhTHldmCpGc4POc1jKNzV3iTicYLTSAc8DvVaWUSfT0qi5kXLOSqjqxFMNyAGG/a23OOpNZqNzGdQ8v0Uf6ehGOMnmu/s5PKgRyCAAACehPeuC0PP2wAdxXd2GJFywDGMbgu7rjrXVPZHm0OpsCZWDM2X5+7jg1r6VcQ7QJDJEqc4wRkVhvJmePYysXJIQHhK6nTGiWDdcSuwTJMakAA9q51udnQivDbyCV1uMBlBKhi5x06etWNBhuLd91lbTSRlvvsMD8s0tpBFOgEloElmcsHXkFcdfXOa7XT1jW3tGid1kz5bjoMVaeujNFHTUxrnUlmUI0AinHAA5Vv8DWbPLKdRRUHlRZyGYdSe1db4jjtFhOwIGDDDL3P19a45ixuEdmZk3c7V+6SarmctyGkvhLeqMo019gO8Ic4PfFeeaDIZbUwfNySMAfy/Gu31K4VLScjIdQwx6+9cT4fYCyDlNo3naxPHOKiC1uRV6GpbELMQmVHtxn3zW8PNS2hxMxcfMgKEH8x1rKjjMx2ADevO1h/Wtu2tkWIFZnhxyVboD7e1VezbZKXYr/bbi2me1kV/Ln6KqliD159/atmyv0nUrJOu0DJMh5B6HApuIJExLNIQwyCmRhj0ye9SPBGmA80jiIbGzgr0xx+NNuxaix9viNUIZ2WPIV8DGM9x/WmXa4t5HYSEMwBye/t9acLcLAskscnlA5zKdo9Dhe9Tssfm7A2+UZZm4woPYD8azvcqxSjdAkkTKcbMnAwD7VyaMX8Stklog3lZzjBwf1rs7+2KxvgBFDh1Hc/jXnNpcSXN1qLPtRfM8zJ4OenHvninG91czqeR02gwxmFXcbRuKhf7w759/51u3crNbm2tTKBJyoZv3a+h+vFc1ZxXEiGPKNGrZHO0knrg9K3vsEqQA6ffXFjcAF9kmJFcdCPY01rsU3ZaiPZq0EYnubppnXKyCX92oIycEd/amWelw3Wn5iku2BUEx+YcfiKzfsmohkiub6FR5iqPkycHuB0GKv6ZDfxQv5Oot5hznCjYq5/XPpVNXd2SpWRZudPgs9giln8xV6M+4A+lNuJk822Zizu7B2YH8+tJC01tcI0gkufl6nBxnpx2qpcqj6lGsjGMs/TO5VFZ7GvNdWGXqotxE4BAY4IJrsNDWRIU3ENEeR7Vx90A+ooCBkux45xXa6aoa3QZCsO4PGfesZfEaU37ptW8ixFd3lnOSMjOKVWSVtqKshY8qqgE/jUEUapv/5Z/wB75sgZ74p7xSSOsRETjcDlcEfnWsW7WKSTJxKqSlEE0ZXj52qpq6tPEWPBx0AGasalYLDGj78Ej1PSqUMhMUkbjK9mBzUzvF2Zairc0Tw/xKnk+I7ngneMj1JxikjPyrnqB1JqXxvEY/GDqzfKUyD6mmRN5f3lAJ6ZpPVHM9HY17Wd5GULlU29sc1r2pQEbUAOw4ZRWJZcyrsO0Yxx1NaskjxHaHBTuV/lWctdjWBPDfxuD5ykj7q8bSPqao3yKko8tlTdzkD+VQ3csM8BJDBR05/nVGV2QRuGyEGATVQlY6qT94v3lxBDAYJBLtdcE9y3qa2dE02W609baI28aF/MDsuXJxjjHPTtXPQkXmXZg7Hnn1qxoOqT2huzny4Y1CtNg/LjoFHqTWkkm7y2LlCTi+Q1JoIgrWkOwPg7pZvlU4+vf2rPhSKNMIysBwSTWbEl3cuGtSXlckNk5x7muij0nZYxLCsjSqxErsAc8dPrmsYU5z95LRG8H7KNm73MG7/fNiNRs7N61CNCluJU+RUznBLVvPaKXSOUNHuAOCu04+lWY51tYpo3jby3UqrYJB+lYyb5rS2NViZR0iY8Phm8WJovssIIGQ6vtYj+RqE6ZqOnENBezI3UGNiv6V0Szz2yKUfIx0fkiqlyxu5syThP77uTgD1o5lH4bpg06vxWaEsvGHiWwXbHqEc4TqtxHn9a17D4lasC/wBvs7aWM9DE20g0R6SsE8UVvdW86SruA3Z3qehGarTafbLKyyeUuCQSD9010xxFel9o4p4KhU+yWk+JPkNI8enF3Y5w0mMfpVS++LWohSINNt1OeC7E1mXdhaod0b5xyT1xWbqSRTqF37GGAScYqnmNS1kxwyvDac0bk134o1vxBG0cjQLHJ8rJEvJB9zVG18MrHcEyKFm/iGcml0jT4Gk/cyYYnBAfA+tWJre+UE28zLIh4DgMrCp+tTkrzdy3haNB/uopF2XS/OukE1xMioAARHnjsMVbXQ7aZvMiuJV4wVxg8eoHSsxp7lArZRJWB3Mn9RVvSHWfULdJpRBKzAB3J8s9cgn8qarSk+VGTSlq2JcaIFtZZvMVY0byixcHJ9MVzusaDPC6wgzQCNf3vnAL8+TwvfGMda9T1uzF/oEFra3MNmkDMZldcKzn+IEA89RiuS8Rzy6hcwxGR5nggSJ7gDCzkEk5HXHIGfat0qqaWh58482p4RofM/HXB/lXdaK0al2kQswI+hz2NcRocaks56jNdxp/lnT5ByJGZTnHQD3rWpqkcNF2TJrOMmdD91jyq4+8PSuktrS+Qk/ZvMeVuXi6r/SuYsjLJc7Bl16DA6H+ldlp8lz86rFtXZ/f6+ox6f1rnUddTtT0C01S5t7kvPZeapOCFJHA/hB5xWtPrhnSJLO0uYFRg213yoPoDWc6jENqylWk4SRNw4z9xgR29afFbzQ+W8k20xSkL1MasD19zVWkP2ttC4980z7sMWVskdvpSXOyEfaDlXDcxkZGMdBUMr7julCNuJJZM5xnr/hT2SFocSFyirtXPXeTjP609tjLmb3MjX52i0eeUKOYTtB549q5fwkvm6enPyng56AkV0HxIJsvD0kSkMqxFcZ5XoK53whueyjWQMU4BPT6U4Q3InLVHTWLTebHKsZZx8uzb9411GlyRyRsCJWUrglccexrnoHP25/LB2AjBXOVbHT8a3LaRFjM8EkcEuAWx/F/hQrLcpF/zIS0qW8sGwt8wmj25I9D606a5htVSNbuJMgFzHHkk49fapYb2YRGSaAsneYIGHJolvXkVhFGqRKf44wevcCk7f0i47lIt586KlxJMr5zhtx47egrRso4oo1Ds6lvvZ5IPf61XtI2ZZHzgZ+dguGHoBWtbNLKuUQKCpADdT/hUbFvc5/xRcGC0lUZVYl57ke9eV6cpmSeUSHDsxjLdyTXpXxAn8jR53VFG2NsnqMkV5r4eO61j3Bs4IGOg46U07oyl8SOo0K582MBlZBEu8qQc8f0rs0ikFvCYJQ7/fCyKDtzyec/pXH6VAk7JHvLFV2qykjJPPX1HvXV2qSNb5vLEybACHh6qc98VVNNCbuQai7yZjkhPnsCm9Ux9M/571c0W5tpt3nwIr7VQNLMFKY4yPpU9ulpPHuF5MpKhAX+YE55yD2P9KkFkksODcwTBWOMxjnHvmtddwir6FK+aMSY+VccLtPEhBFU71Y2lRpUJLjIaMYABPep54oonAUo0jLztHXnPB/SoRGkJZZj85PLZ4+n1rGWt7l6lGZUa/t/JOQmeB169Diu3sZohaoQm3aOQeprkLNfN1V3QgMcAHpxXURTwQwjeSB13delc0371zeC900ZJYVCsLWc5wAQuc01L628v5rSeNlOCTDwfxFUI9VtTId0z4XlgWxmrUN7FdFYYZstn77TAfh0rWEk9mU423GzajbMSgZ1HUFkI/CpoQjxExSBh3xSzWW0b2jdgT/CwYD+VZzt9ivVXBCsOD71nVhNO7NVJNWR558SrZo9es7gLy2UH86oQx7kWQjdkkD3NdH8U0DWNtKoDSJIAT259K5OzkO1dhyc9af2Tke5vQwR7wQBuxniryxqVYoRnHzA96z7TLJlSM9Mn1rRt5MFS3QcH3qGaR2KF/B5i7Vk4Azx61jPIfMKEfJjiupuADGfLwoB6nv61gTxKkhyVJIPBGMUIqMrFXTpjBO24fuya1Z7WCaMSsSMtkop4b61kqF27SRxyRVyOLbg/MeM4JrSMujPRpSUtUzTsrqG2AWJQNp5GOtbtpqRvWaJsbM5Vc4APtXOWkYC5wSG71cjXymE0fDKOvbNUqzVkdioQkmupr6F4dafVZEkmAgkBPzElw3bFbFzpE1hJBFHDtZTyzkcMOhGeufSqFjLc+dbSyYQMQwOOa2tUjczxPfM7jOVBJGc9s+nvXRam4Npann4inU5029DA1GFp7wzSKkbH7+1ePTNY+qQLAyJEwkRjglTx+vevVrnRDLYW95OAnmoNiBcgcdTjt0rjL7RLqISFbfJUkfMvGfb61wYnBzWq1RlQxVuuxzctqHG0I0S4wNrVHcSBXRI23qRtO4d61GtJoyFkilRscgjG3ipItFub0Si3gllC7QzKpP8q5aVKc3ZI7o1lu2cxPlFJKkdhj19x6VUzh28xPnJGOc5rs4LS2lDQRW/nS5KpGysGY+4HNYuq+CtWlvXnhgeBI1PyMcEY9utbPCyteKKWISdpaHP+UguW2OyYJGRnt2re0i3unj3SLuTG8E8EL71B4f0maS9ZSPMYHIyOR/tY710ureVFJDAEMAjUiVcnDk9x7V0UaOnNLYipN1HyRMDVbaAW/nWTE7gOP4kPfIxyPesUiSYCGRsbDuUr65rcm3Qr8gODnp0NZj3KROkhhRyjBtrdH9jWnLG90ZzoOnpudvouq6svh/TI7Ge0h+eRZ1lmRWfng/N2xWLr+sXlrdodUaK4uSmP3bow2ZPHy8ZBzWRca9Cdp/sDSTg7gSjf41Sursaneb47G3tEC4MUAIUnJOee9W6rsec4csveR5l4cRTBOHHVcg9wa6+zTzYFSPhueveuX8NIGiJkwoK8H1INdbYxCOeN+QCc/Qg1vUPLor3R+jIsdxKssZyV+Vgf1967MJhYmM0qEDgIBwPxrnbO0AZ2Jy+eGHp9K3rNmDhi0bbSAM9D6E1judKHyW7vKsjSXD5z96UL+lJDbTQJmQzQtjfgkPuz3xViONnmLSSFCxySoHcYPtVlLdXUKwZVQbXJwB65znmncVru5HDCZYSY1G5MZ3MCAT9Ov0qSyUKo8wlEhJJL5Ic54PtSSzFi4MmVPIVBtUnsR/9anvCpheZ2BjwAyjueflUVN7A0eefFC4KaM28t5s8gVSTjcvXpUGhMV0yMRF2UsMhj6DmqHxauzJdWdrwduWwPwH+Nafh7c1rHyRCq+n8XT/6/wCFax0RzttybZ1di6jyni2i5fsDgHHetRIPLuJZUlVY87QrLjOevSuVVRGTKGA+X64P/wBetqyne3LC4ZMtgxOBjbxyPes5OzudNNHUQ2kbWOY0QgtjAcgA9c4pkUVsjBWmYJ1J5/LJq34agFxZmV5H8pQMsCemakuJ7C3uXww5Byd27NX7O6ubK17DYRGioyykgFvvjGSP51e2ZY+W/wA64xWZ9otfMjGFAU/xHgZqza+Wl0ckAP8AMSOM1lKOpdktTm/iQFHha+yfm8o/KD2rz3QI/Iit4nQjKAnJ6nsPyNdr8ULiGPw1eTk4dlCDPfJFcVoqq0UW4OXC7sZI4Appe6zkqP30zrdOttk8kaDG5QySE5xxnkCuosbq5S3AUIcEYnhOfwYGuZs5CscSyZdeTtB59cg/Wun01d9qr27hmb5miJAJPrWsEuoncka8UCS3EkDMMYEwIIPqMjvTzHHswttbIx7q3y59qR3jnkXzZ0SRTj7md34VK8cRhdYjbxknJZVyVHaiXkaRXUixvcvIsS9gYiP8+1U7qIQgk4dQvQ/wj3q+EEUSiEbic5duOc8cVlXrsEcn5h90+3rmsZbFkOiStLeXDxYyxPPZKnkuI94ij8ySLqewLVX0dG/sfUJI0LrHG7gqew9a1/DVtHJAsuFVnXox4FYOm5OyN6ckldhBeBIVRrJVUHIJfv8AlV+xHDFEtZAx/wBVImAfbcOtLYStcMbdXELK3JKBuPUH0qfUPDd39nSaS/zETkN/D3IraFCdrrX8BSqRvbYjW8u44WXzEIjOFQMTkemT/Wsm6eV3a4mdgoOCCOB9DUUtncwzNEk7nHJDDNNubiRbLEyg44DA9PqKwlKTdmW1y6oo+OV+0eGJ2IOVUMD9Oa4TS3QxpvHJHc4r0PXwJPDUyE/K9vu/nXl2mkiOMp0xwMVS2OaW519sy7VC7VJ/WtSNVeMuAN49K52ykJUK3Uc4xxitNZ2Z9qqwQYPFSzSJbyZFK4DY69jWa9gI3kfDHcORnt7elXZZgrFg2SOciozOjP1B9Tmhbg9THnj8t26g5zmrNmzSN15zg+1WJ4o5lK5zGvQ4x+lY5k+yT8scc8Y6H3q+XTQqlVcHY6SB0z93GTxWpZxx+WFYq2TurmrW6Vvutk9cVrWc2CCemKhxPXo1uZHRwiRyi7iApyAT0Fa0Ui3kBWckunPXrjpWBYXGxiWHB6GtNJCDmLJJ61dKpZ6m8oqasdPo/iFrKy+wyEsoUqpcZ2qfStOPXtOit1eVJLiYAqyFsZJ6n0rirsqzDcuWPU1V2bV2Kp3HNdEa04aJnnzy2E3zbHTXviGCS/a4a2jj3JgjhgwAqTQNS/fTCxUQx3BVmKN0wMcHtXLM6WkwEkRkQfrWjp10JXASMRxZ6DjitIVLO8mVLARUWkjq7S1jhu2kmuBtHIPcfjWR4pWW5mNzZyBCiYXIzk4qCWLcp2yvtPQBqD5scIC/MSeCTya2liIyXLYSwqU1O+voYGmWU+mwNPKIjMed5Ubkz6HrWLqu6aYyuDtxjJ71093GzIVkbAB+YZrF1IRqgVCCQOlcNSppyxO+mowfN1Me4+aEIc47YrDuUx8q/MCcg1qXcgydrE47CsC6u1SI5YcfzrOCuc2JqqK3ILmOaZ40hikkZn2KEUnJ9B7+1bMdtBZ2ywyW95BfKAZxMw+bk9FxkDHvWp4Z1FP7Jhmzcm4sEmKwpCWVnf7spYdMDI5p+rzwr9kijeW4eC2Eck8qlWc5Jzg84GcCnJWPGlUdSR4/4fCraISCQQOP6108ELI8asGITLBzwCDzXOaMwWwiVATIVIyecDrn+ddRYukj4AfCqB83QNjkfTvXXUOCjojZ0xR5W4gEAkgd8H3rQMQ8xcoxQ9COv04rO05hHu242nOB13VvRSbcbIY5FHPX+VYo6UQhQ0xiWLYjHpI2APfNXTBsMagb25G0fMB+ZqzHbswI+yxRjAOCxYL37etRRQqsu6ZkKjJ2IvJHpV2sJ3QsMTzsXdQWOI8Y4jHpmrd/C1vC4DKzLnG0fKM+g9qjtrx5HLBDvC4SMdB7tUVy7TWzjzGwvy5U5Jb0H8z9KnS4m2eI+OJxP41iiwrxRBFC9hnk/wA66LTUjitFcknY2zA9+Rn9a5DWF+0+OblUDPGku3K9gOM12+kxvJDNGF+ZVXaD2IOM/ka2tdHNF3bNdIUHyMdguOVbHUhuPwpYHdpw+Mx7ypUnIB6flTliPmWbNGWHkmRVJxkjOeaLCB0V/JxtYh1Vx1BHOD655rGotTsos7jSSh0vNq0iBeJFB6tWNquWkkzJszzGAozn+h5q/o95st2h1G3Y4OBNtxvGMDpTdQithGhZ2YFsrGnp75rTmThuaq6kZen75LhfMAcAgYUYAPfmt23dp3aQYxGnI6DJ4H41kWpCuxskDTk9znrWtZ25gjP3WmAO5mJxn/62awk76FydjgfikJZNBZVYyKsicHtzWd4diV4YdjliVx0yVOe/tWp8SUcaXkEtGr5KjjdjqaqeGYo5YcwPtkwsgXH54rSKXKcVRtzN+CSR7WCEhGljyqHGAw9PrWtaWUs7qWJVzgFkYgrn1HQ9KxE8xZWSJAmOSCPukc5/GtywuJcZaYssiAtuGRj2IpQ3uzaOxcaS6g3CaLzXGcOvysB9OhFXw/n20cX+sYHJIwPzqpayxTK1uZHWROdsmMAY7etOii82ZgSSEwdwbAJq5NdAj5k80TLFH/GoOWQtmsvUI0SEryeCQB61tmNNivC4ZuoGMc1jayz+QWkVfl67eM1jIsyvDbl9Pu9PLfNKjKnzYyD0+tS6dqN7YoIgyZByGZfTt7EEVQ8OyiWN1JG9W+RvYH9DWlFHiaUsBJGWLMOcqfXFZt2Y46oni1JryZDLYyvJkjfC3LljyMelWDruqLHNHJaXH2cErnHTGcfrUc2keYkM1gpkmXG5QwIPGRg9/pSXT6pdaaqwxwPEXLFUJV1bvwa2u7asTavoTW7XAHmaml1C0qg7sfePvVXULaWKylmVpow2Sof+IVas9VnuMx3NjK7RKEjj3YCsOhNN1MtNFm5dUcceUDk/n0rHkS1NOe+hUc/aPDbFC5VImVmfpnB4FeW6TuEaruC88DNeowKf7Du94Cp84wPXbmvLtPI5KDn0quhl9o3IJdoIHDd60Elcgljxjt1rNs2YdQQcd6vKMtnKqQMjJ61mxx0Lcb5DHrntUbxE/MWC46+tReaVOVGCPTpSvIJgPvD1296SZaZE1zkbsbmUcVBLKkigYzu68VZ8ldwIJweB71VlthnK4BPHWrjJGcoszpZHtnxFKHxyP8K0bXWFUqlxmN8cg9qzZ7UgMjkjHQ46ms+QyqH+TPIXL+la8qkKFedM9Csr+NkDJID9DW5p96yRKfMzn9K8Zi1G5tj8mVXOelbFp4waLakqH6gVk6bR6VLMItJM9bivGkyZSAo6CrMN9HsDEjPSvLYfF9q/ymYox9eMVox+JLR4yEnjx3+ap95HbHFU5dTubq7hmfIHYZOetOgn2t8hxk4HNcSmu27LiOZcexFW4NXQgMswI6kZou+pusRC1kzukvHjADNxjFE16wUASYxz6VyDavkfK4wRUFxrKFPmkCkD16079DOVWG51N3fx7M78561zWo3i7uuWrEuvEEKgkMGAGRgE1i3WsmSXbH8nOCxPSnGm29EclXG04LQ1tQvERm+br271lkefMHY4Uc9Op96qo+WBzvkIJJJxVuLLKzAkk81ry8qPJq4h1Xoei+FJ4Z9Fit4ru3hIhuEnhklEe9mHyNz94Y49qx/E06Sy2UAuUuLi2t1innRsh2yeM98DAzVnTo518NafJpmkWeoSl5BPI9qJWjOflUjr05zV/XIIJdNu1m06zs5ILSOZ2gQIYpy2PLJHXcOcdqzepnF8p4tp0QSFBk/d28V02iMAERgenJ/ka57SlfzYhtPOTwenHNb1kH3CWHbwvGT1/wA4rslsc8VqdBBGyDan33GWcHGcdqtsZBG23AdSM9g3PeodOyNsrdWJLLjjp6VYjVJYgVJIzgZPQ1gdUXZm0msRJoj2qxjznfcz5547VBZkzFz5jbX4UDjjvmqDQGBOHHlk427ckGrmnqhcySozEHIUjaG9vetE29yZtLY041AhCq6xQYAYBcFh9fequpyNFC6geWwBwgH3c8Z/KnggzNLM6nadzFDjLdlUd8Vl6zJGv2gGYNI52nLZ78j2oeuiMW9LnjmiRTP4r1AxBs/vCVU/eXOT/Ku9svMe5d1KwhrZZFXjkjt+n6Vznh9DF4ruZID5YE7Rjac8YPA9q6ogwRxnKt8jxtjkA7/5cmteljFIcssgjuZtmWgTylGD0c559Ku6TIiTtA8xmjB3Yxnb0wAfxrOnM0NrIUkfzZiqsg6syMP0NFjcBb2fgYaXaVIzlT3zXPU0Z10tjtrSCN4XCmRXUndk8AfSqslpDLMNu915PzNwD9BVy3Ltp6p5TkxnCt0BH1qIK63BTASTB+6e9ZSOhXsWNPskhZXUeUF5+bPJrUQEKPnVgCS/pkDJqtEyI8eWLlDnBPtTpWz5m5st5QwB0BY9adrIhtt3ZxnjbBsXWWPKSYVdvYk8E1geEXJLI6ALGPLYkYMZBwCP0rqPFAjjht/ODOPkZsH8hiuT0WX7Pr0iyI3k7DKe2cmuiMfcOWUvfOqlCwBbsN86nB259ecg+3SprJI0usTSMbZgSidF+b3HSprkBriSNcGGeISFV7EDH+feodHeFnkhk2dgG67mHp6Gs2rGsfM1Hj+z24Lbtuep5Ib6+lW7UOqKHVs4wVPTFVlDKAkrsiLghsYBrSjCqw8uUZ2E7TzUyfVGqJCUEIjI2jbztHQVkamTHC0SnchXAJFbTBliDBRnBHArIuWK7lL5w3Q88fWpQ3qcX4ezHPcJM+xTKcDrzmuj8hLqdWmke1mBysq8hzWFZqj6heRSOAVwY8L0/wAa2UmJTyyDyAdjDjNRLSQQV9h073mnM3lRSygjd5kY7jvj9DV/TtRs7qMF41guQQS5DZJJ6jtmtLTLCaOEXZ2SW2MqN+0r9Pz6VWk09o3M1s8oG4lQhDYz3wa25Xa6FtoWrWIiS6uIHAjGAcr2OeOe9VLqJZFVgS0irkD+6e9Nn+1t8k8sgXqCsRGT781IoUwxJCryy7SJGJxj8ayauzSFjNvZHj0C5jbAGHcAeuOa8o08fLv6Fhg16vrp8vQrlVG0iI5Puf8A61eSWZLPHz8pp9DN6SNuM4UbcselWoiDkfKuBkE1XRQpG09OcZq5AA7cj8PesmxkgTKEkg5529qkiBUEg4z1qVVG/EanaR368U+KEb8jO0enQ1JaRE0mVA2557jFOjTht5B7fSrJtxtBwQSec9qeLJJVKHNFy1G5SS180p5ZyN3zZFI+lISweNS/TJHSt7S9PhtmC4Ijz0PJHHetO3sA0m0yHaBkr2Jz61STtoxOC6nGf8Iut0AmCpYZUKM5x1p0Hw/M7ZVSm3IVcglj1r1GxtYoE3BDvJxnAwWHYf41rG2jMsQt1Kg4JVjkjHUD1ropwurtmclbSx44vw0hmOBIiliQvP3iOo+tRXHwnYJJhiCMkEcivanEUcsu2NlBBG3GGDZpjqqwEfMjv1DZPHXp3+tdUacTB3seCv8ADK7RmKuEhVdwfrk/SsyXwVqkOUiebGchgTivoeTE0W2SH90OCT3P09KhksQlv5jBgchFUc7c9z+FRKmlqikmfPB0DVoiP3s6sQcqSelRSaLexKDI8vXhjzXul3YCbfNO5CoVRWLfMw9KwtRs4ySwhUqcgAHGP9og1hJuJpGFzyuHQ5xli7HHbmrI0xosMykZXHT0rvfs0ccbFIzuPRhVKayXyvmDKcc5rH20g9gjm7e0A+Z+QAOO5q0kSjDKMKOCM4q08WFJHPYGqsqByQx5pObe4ciR2Xhy3sI7WzdoLma7vY55BJHO0QzHnCfL1JxXL+MJYkbTpdPga3t7uATiN5C7b9zAls9+OvpWxYNaafodjPcXep/vZnliS0ZQsLKduST/ABEH8qwPFGoQ6nqCXMU19MDHtJu9m4EdgFAAFUmZSRzWmqFbIYgjv6mt22iEP7rI2nOOelY9rbeYVw2078kentWpY7QSGJ3Kdi/U9a7ZbGEdzZtHc2xDgmTAJYH/AMeFaqpG0RAwjYGGDfL+FZVo0rSESR+ybew7VrwR8sFjDLnGQuB09KxOhEjIjgYHmH+I5zgepqdZmlC7AxOcKfRe5xVVyQQnkpxyxHUj2xTllEhkTeY1Yctt59gKqJMhzXMkdurKgaOP5U7OT64rI1mR4rGd3iywIY89D71oEIkjN5h8vbgKOSNvf86z/ELr5cxUEEqWO/09TVrU521axyng2A3J+2KSGe63LxkD5j1rodSja3S9VXDo8mV2L3xmsz4fw+Vp9rM7Ahps7fYZJx781vXcRXVg0SMQX34zkAbjgGrW5KKdwxW1YsDu3Iy4PI+Xdx+NV7CXbeAOC4ADA5znjmrlxDDMYlUuZGGJMfwsvf8AQ1HA2+7+WImPceB/IVzVzrw71PTtP8q20JLh8yBwMjd09q5+7dbi53rkc5BA+vX8avrB9s0EFSrMpyFNZMam185rxkAfO0NnI+laVLcqN4aNmrpz+ZDJJNnccBQD71eL/vrjbtC7lXPoPf8AKsGwY/ZUVgcszYH93kGtFZ2Cy4G5VlBAHU1iiHuzl/GDL5ZZXDykLsA7DnjNc3ckLe2hdVWQwlSytjknIx/hXW65bx/Zp1Ls1yqDaMgYO7pn8a5a/QSwxyNbiOQncvsMYx9faulaROOXxHZgm9sre5VvNn3bV28HGOcj8az7aAQnzx8kysFZexHqPf3pdDU3GnWwhIjkZvlycjdjnPpWlJGp8pkx+9BZlPBUjjg1jK5vTLLOPs4dAxRzl426gdv/ANdaCsAqhCqnsQM9v/1Viw3DyTp5qqMNsY9wuK10MabDHLtYrk5Xjdnpn6VMmrGyRcjCyIkcjHcN3JPBOKqzoAWUbHVBuyBjrxzT42Z5FDElQclsYGcVLAoDcEMpj5CnrUx1ehMnZM5C8gMWvSCDYHkUMjBcbuPu1ozWy3tkJYUfzk+b3A7g/wBKdrZFprMJIR4h8vAJ5/8ArVGYLm1ummId4XXLeWeV9/pTqRSkRSm9y3pN0gaNBMwbJBUnaR+fFa4uZGMge3RQSAXKjgZ6j3rBvbX5UurOSO4R/vxsPmPuDVuzngntfLjmG4dEdeQfTmqTa0Zq5c2poyP5k4VkLOOnzZzSMh+V5QUjLbTtGPrTRcMsqgxqWGON2SP0qTBl2tIQGD/MAemTUyCBj+MAE0a628hgxA9gMD+deIWF3yAOOeO9e4eIh5tnKq8lt6+2K+doJ/IvJomJG1yAe/Wqpx5kzGtLlaZ3to3yAvgg+/WtC1xISAQD1+tcxpVwvLO4x6dq6DTpFSVXLZB4471hKPKap3RqpuU5KspGDgVeRdxO7GOvHWmKVbDINue2acrbefm29/UVm/I0Ro26Bj5aMOR3FSfZ9kgYfMw5qpBMFOeMDHIrRgmDuSByoyAwrORtAGYyKiBcEMOfb6VuWKRx3C7/AONecjHH1rMCiXYSgAHJ4q6rsI8AcNhdo59/woi2VoapmRVZl2ZU8pjggHkj1q+t0JyFSFlYMCPLOcL1zWFE4I2jcyqD99TjH+TTrW58idSqEcYBQdvx/lXRCrYlwudI80coLyozqCVO4/M46gr7iqU8gjui0aStIScCRf0OKhFwoTeFXc/Hbv8ATpVJ9SEYEbmUkDDFidoB/rXQ6y7mSpvY1Y58yB53AJXG0LhQfx/Oi7ikjVkIRnYZOQcjP045FUjdM0R3AJHnarhclvaqU87CEQlMlc7VjPDccsxz1p+2vow5UiS7XhSURQ+F2pnOcdc9ves/apdUDsVAITvk/wAzT0leQYgjYAkKGkJ+QKPqQBUgGGOScqv8P8OPc81zzfMVsUJkKA7lB2Z+ZuAe3FZt9IjZCL1GGJ4rQvo2corCXaPft1HFZU+wMUcnJz/nFZlLYyZ1LDcoGzGRisyZmXkAe/vW7II0hYuOfUdKwpn2XsbMiSopBZGzhh6GgykdRo092vhyyXTNU07TpRJIZopnTdISflY5B6DjFc74pa6fUIzqN/bX8qxABrYqVAyeDtA561oNrmmtknw7poxxu3P/AI1i65qEN3ciS3sLeyAXaUiJOT689/8ACtInOzOiUqqjGSQSMc+wrRjt9joU2s5bIzz+P1qFIZEDbONvzHP5Yp9tE8f+uf53OcgZx9K6mzKK6GvaB8ZVlKFcEEdDWnG+2F5AZC5PyjaVz65rPhQlU2BzE2NwHB49q1ZZdsarl5MHG1lx9azNr2QFmYosSFC45EfNTJBaiUCTZlBnawzz/WqapJL8oPlIMsXbOcdhU8MEUZA3eZjqAMEj61rFdzObB8q5W0jUOMdRxzn16Vy3jCUpp5VZhISmwuPx6etdLMjoSrmJABkKWLZz04Fcz4klgk32sEe+RkWPJGCORkjt7Vokc0maPguLydIthICwXHAH3eeoFWLhkZroZw7TIpx6bjxWlpyraW9vHI4OwI5A6tzgAfQVg3Mm9rjylKj5SynnPzEjr35oejGhksUv7yYtJ5m8J7BSDkGrFmrregugRyoOMYDCppYY982XPz/NhsAAnjP51IPmuI97gqgCrg8D1/CuatqdVDQ6Wxubm1jATbt/uBxwfYGsXUJZLybfKzkc4GP0rqIRZLZvMZYlmA5UqSG9x6Vz13MobIBIbcAcfzrNt2Orm6klpgHCGQMRkZI46frWkHZIisKoE+XOerEHmqWkET3O8gKgXcR6eo/Wr8toyo0cL4lU8Fh0FaxRhK5ka7aJs2u6mVjuBHQdeM1hT2q3tmqSE+ZGd6yA8KfQ/lXR61EiwJ5kLSBTg7c5PNZdxELWS5kj+aMhcg9fy/Gt5bWZydSLw9dF9OMny+ckhyyjDM3cY9KveZKhjRo8sw3KxPVT0IP1rL0O3Ae+j8tjCBuQBvlBP6mtG2jlaQQLKHjICjI4QfWpkk1c1g7OxZiAmh85wNzDB9atxsFTcfMXHOMcA4qGKBp7YrgowXORyOPT3qxDI7oTcKqoeNxHfHPFc7R1IesrLMyqTyOOeCSM1qaXhooTIMs67T9QT0rB3M0zK5ICcjjqf8ituzO6KFlI+/nHXGRkUqa1IqGX4vNxE1tJj/R1kyyjt2OaktIvtKJCtycFC67euO+Pam+PZUjsG7OMHB52DHJNV9FuGksoLiFoyigplG52nBwR2romveOeL6EVrLPZSplR5RfazD1+lXZbWGZGfdtuwQBIqkcc/h+dLq3+kQlVUtCPukEEg+xqravOJ1QSsybdpBwWA+ves3vY1jqXrYyrCrTbXZT/AAMM7f8APpWlAnnlAFKuDzuGAax7a4USZQHk4dewOewrYSRzKkkYwd4BB64+tTJG0UZ2ox5gWNu24nA9T/8AWr5q8TRG08RXiYwRKTX1Dd4kt5OPmOD79a+d/ijbfZvErMANsqZz6kHBqqDtLU58UvduU9K1ElgmBxxiun024JkPmYx6/wBK86tpDG25Tgg8j1ro9N1EPHmQgdutaVad1dGNGr0Z6fps6MgVAM9h61a5kfecBc4welctpd+DGig4x37kVtRTiQ+mMcGuJxaZ2xlc0UIVdwUrk9qnjlLljnPqc81lJKoSRn4XB71NHLD5Y8shSPzqGrlpnSW9xlAo5x+Qo81wzc7iOeapWrB48Kwyxwexq+VAwG2lVHUVGpspCxXr7zvUqTwfQCrn21XwyEgL8rbeM1lyAJGxDYAXGfc1XJEcSmRhtAJJ6HNWhuSNSW9UHMYVcNjPTNSNcMICQ+d4JOazEdWD7kG4plc+h4J+tVNQuAZ/JVySAGA9sfpTsZuaNn7XK2CzKsg53jPB6cCor29H2g+bGCPlZo1JXPv65rEa+2SfOwBRT19etaFvI08G+RnAOMsF/M+1Gq3C6ZorflpuAERR8qbuN30qPzgm9Sc7vVulUItkcjBSqFTtQbefqaZeXKIXbAO1duAMAkUNthc1bi6acbWLDB5BP3h61nXTI9wxjJyOOf4jVWC4dz5pQhyM9aieYxuDH97kbifaglyK2qgshCEbVznnrWLFIIpY5JY/ORWBaPdgsM8jPatK7kMhRGIHJyV71Rv4o4gwJLHH5UJX0M3JHU2enWup2bXFj4VZ4dx+ZtQKAkdcZ64rlfGtr9ivkhOnpp7eUrmEXHnHknkntwOlamnazFHpmkyXcF00Ns0trMyLmORJQc8/3x6d65zxxdQpd2tlELovYwCB5bmMpJJySPlPQAEAewrppxuc0pGhG4XLbUJwfl9PxpYpS9ztKbpCSOvANUZZyoEgPzkkY9MDir2jKzKHYjO7Oe9Wy4R1Z0VhZ3MkRGWiwO3zHFTSW0sWVMztngNnmtvw/cQ3UzoRmRRtwflP0qnqSGGd1QRxEk985qnDS5e+hm28dzEGHnuEHUuOf/1UksyO+XG5m+Y447c1I3pcNsXPJPBPtj0qMGOWVfLDSuehBwB+PtVRMZiXM8MUZCoIn2DCg/M2aw7GzDeRcyYbFwApzwMckk+pNat88VvEysVMir82B0+p/pVy1tVjCJEisR+9+ZuVdv0rbQ5txZAlulzDcNxEofJ75yR+tcvbzlhJDKqeeTxkcknnmp/Ft7Irfxb5pcAjoVXtVrw3aROjXMshMxyORzkjrWcnrZbmsI3V3sSXC4WfGQuVjK9S1V4b4x3RRh5bZ5A/wq/eboNPljKljEFJcDIBzxk0mjWW1GuriMuM5yOTWEk5SsjrppLU3tNlmmtSSsrr12qnUd+e30qrcPGYFLA7GOATyRWpY6za26qIkWYMCXRBhl5xyewpniix+zMLqLDCRdxHBUA9vf60502ldfM2STdtijpRRQxbOCpBGcZx/iK2dQGxI5fM39AQo48sjrn2rB01lWRcbVt3wyt/db0zWmCzyE26qqkbHB+YD3+hpQemhhNWeo51Plui8iIE4xnjFZk2nebGwQlHQZ81T1B7EfjWzEGJUjJUnt6Ed/yqFX3NNE8Y8uXqSMsD/SujeOpyvRnN2kRS0uJo2CIwLbD3wehPvVxHLZIHlFgMrjGP84qR4naFLWMD90hJdhjfyef61agSMLGVMioq/wAR68e9TLYunuWrULJCxlZQxXYdp5Deo/Ske2KsUZMSY3Egjn1x74xTrZGRACmHHAH17kd6I5TsZEUbnIPPXOOv0rDyOpEEaxmZgCVAwCefnHFXtPHlhW7ljgZ64Y//AKqzrhhIEO3yoyuSBzkeoq1YyuhbAPUMoHQZ7n8j+dNKxnLzIfFqtJZ3EkYw7REDjpn/APWa5jwFqMdxpElt5ZaZXZdxIXoMYrq9YkMkJBDNGhYkg4OewHsK8rhgfR/E8xw7QXC+YMttIbHIz3Oa3Ubq5yylyysemyzPLbBPLUBl4BA4HY59aookYWPCYdOrA/rUemysdODtE6qn8QfNDYnEjn73KkqvGP8AGonqbRZpKpfyfLkAPQ7hg8/zrcVzFEd65VCCSOh7VztrKsTx7mZW+XA5Ix3raeVJCEjAz6/3l61kbondP3Uh4wQF9++a8b+NWm/uYLxUx5bbSfY//Xr2SzDTQqAc5I5x161xvxF08ahoN/GF+bbkZ7EdKS0kiKseaLPnMGpoWAkGPlHrUBBBIPUUoPrXZF9zzDrNI1MQ481wT3Unr7VuWeoyNNlWwM8nOQorgopohIny5AIHI6e9advqRidoMdyNxP5VnUop6o3p1mtzu47jezbCGXb1/rWnbTxqXkdv3ZC8E88VxFrdiNkRZch/Q1ak1BDMsQbC9+eCa5XRZ1e1TO2tb/DFjzhskZ6Z6CtCO9WOBVDkr1IPr3rgLW/EbmQfPvPQ1dTVAbvaW3jI2L0575qHTNec7d7obFdnJ43Y9Aar3V15lnOCfmCg9KxEvYg+VcNgEdd2T9KtxXEEtlIA3zSjPqOn+NJQ7A5mlBcsZSHB3KMDavUf4VmQSM+uSysT5UgIQ4645x+tNOogzSJHxtTdgiqFncfbriWVUVQhYqR68c/SrUbbkOV9jVguQtx5hQM8jkYK54A6/wCfStSKeSQmNNw2HBx0PvWPZIst1vMquiJtz79/1qdL3a0mN2xRhvUEf1qWrlc6NGaZkSWZsbwM4I5IB71QBaQKJGH95h3yailuGmDqWUsD8/HQDmqcd6qyMc8Y656+9LlFzmhdTMhRQ4yiknBzkdqbHPyXLbVA4J7msmfUQQzZADY3P7elUbm9adXMXAJCqp/lT5GLnNe4uYyok3qpXnGfWsi6vjcyMV3EDcM+tQz3aqfJLDOPnbsMelZa6jJBOslq3lyRsHR+6kdDWsKZnKVjpo57TVvDljYT6idOksnkwkkTvFNuOd2VB+YcjmszxZew39xYW9vPLcJZWwgNxIpUzHcTnB5wM4GfSt3Srqa08P2V1d+JNTsRcySMtvbwCTd83zPksOCT+dWvEGhi7tft0et3Gp3EdqtwouIdm6AuR8pz2YnINb3UdjKzlucvdyZijZAPlwCfX3rqdBaOJFLsmSNzZ/pWBAiytEihWj27Cccgk1q2tqOFw/yHbgVlJnTDXQ7HTNSt7bcyLH5h7Y6iq0ktxdSMYohljy2OAKrWqeQwkkCKcAY3cmtSEPJA7rFKY0JBkJ2rmmpOWhc7R2M5kjtpWkmKtIMFl9fbmq8ku0l2LRoSMIvce1WLlUZ2EEZeU5y+cgfUnrWY2UceafMXYduezdeBVxdjCSuOnzNKiSr+6J3N8vRa1I5URfMVyFlJ9zsHf2rMtyzKxxIwJ+bIwFPpmrF0cZAVgxHLDsv+FaNnPytM5jxGf9Js1XOxNxPOSSxzmum8GTwWau00qu7DjPOKwtYiiaUzSBo4y208859qTSU8uVlk3HByrg8MfxrOcuSfMjekuaHKdFr9yZ4JQm1ImG7g8s3arlhdq+liIsUaRgMKefqKyW3XDMCpbZKpGOw6CtNYglxFiNNgBC5Pye/PUVk6j5rnVGCasacOiXFhCbgW7u44jKjOd/U/X2rT8UJBHoiRxo6kABiyhWz7ioNK1TU7O5gSdDcfZH4VfmyQOM/rU2sXUutXa3F5DKsRwVAU4J9c9PwrSVSHK0jVRlz3kzn3t3gjCqCf+Wqr6jHIx9KsRXbCPcp3Akj72D7DFX9ShKxyNC/mGDDBm4OB/hWKGD3bKGUROokBz91+eo/A1lDTcxqam9byRkghdwCnJBzn2ptxsjhwA+5/7p/Cs2Gco8UmcE5wvTv0xU05NwhVpCrHLbn7Y7flXUlpc4m9bFaZo2JU7gBySM8k8CrFrEGuIIlBaVMySBQeMf41mx3UcpErK2EckgDgL0/+vVtp5kZ57OcB2UMZM8H/AGT+lZN3epujWafzoGlhDrKHzhumOvX61BCdtjcXS7hMjbSx69OmO4qhHM3nqxZI0mjXnPHT5vxyK0okheG4jxkMuISRgn8fapi05aG62MTT7qWEeYArROu35jkBs/4ZGKtoRFfyoszpAyhhxziqdrZu8EtuXaOcvyCMgjPGKkZGF9ZpkiUEiTd2A6E05fCTNovaw32iErCFEu3zACehHvXC6raTyeW7hHgOd6544P3gfUZrsrhgLeVicIGGQACTnI/wrKvbOM2UkO7azMBHIxICH0GfXvXRT2POqfEiPS1EMJWKNNgwMlywII7H1q3BPtna2R8Kx5YEDk+tU7OLyLn7PNGomDEhAcZI7gd6smKNb2HzgwMgPzEY5+grGcktjemnpc1bc/v0Q5jVD5YYdCSM9avw7o4HIQHgYPp6mo7R4YbdoWkMkjMQSR3HTNWrQNEY4XVcYPzA5zjNYt62OtXLenMqKhRvk3AisrxEhNtODhwGOfetVF2q6qpCqoOMZ9sZrO1j/j1lXBErAAH1zUyG9j5l12wa21O4RVIUPkD2PNZhBB5616V4v07bq7hQMYFcfeWOCcDmuqEk0ebKnYxKXOetTzQlM1XIrTbYxaJ0maL7jE9h7VOl63lhS21h0NUamjiMkLvvQbMfKzYJz6DvQtQu0adtqQiC7jkgYA98dat29+bYhmZXZBvJzzk9hXOujIxDqVI6gjFISSec5osuxSmzrH1ZXZGUvvByxB+7x0q3Y6okf7pZFGXUuepA9q5CGSQlYtyIrfLlhgDPc0xMxnIcdex60ezj2K9rI725vXMkpidmkPyGReFK/j7VN9sitbIxwOY/l+Zj1fPYVxMF5PIdzyYSMDqCf8n61YkuWQrK77zgElx1Ppj0FDoJ6oPanb22r+TAsYAaYrlmzgKAOBVfSdSmuLG5mjdHMAMzlnGT0HHr16VxtzqSyLsUkL3K8E1A2oSCFYlJwvcd/Y0lSSeo/avod3/akSwLI8kvmuxd1AG3b0AznPXNZetauZrnEQ8pWADewFc3JqDSBERdpH90dTSW8zu4MiFlBydx5NV7KN7idWR0TXO5lDFizgDOe30oa9WLzEhXJ6YUdTWSkc15cH7GrCHGQNwLY98VuaZok0bFpG+dhyB2qHGMdWy4uUtitDFNIpyCf7zH1qaKzUSfvCSoHbvWx9nQL5aBi392kEaK+AOB1GKylUvsa8iOl8OKi6HANbfTP7OaR/siXUUkkmeN23YQQueueM1b166vbXzreRrJ0vII1imtUwotwThI/QZHIPORWbp99YTWFvaavYzzJbsxt5raUI4DHJUgjBGea0tdZ5GsMWyW9n9nUWsQfeQm5uWPqTk1lJ6FpXdjmrMsLpUkACrmTnjOa3tN2hcSS8kgkdOcVzkcgkmQOduPlGepNa8MjW63KuWVmYdexFEka01qdRpiPPIFjESAc72/hrXu4nhtUKvI6s5JD8IWxjpVPwXqtraA+cFK4OSeasXl5HqF28yEmMjBUNj6c+tWopRunqaPV2aMq+Z7ZGjRkd1x8iL0Of0rCuVlEvzAls4VdwOM+tdFMRFbvEIFB3YMgPA749zVeSBbeeWUHzEcZXcPmkyOoHUYPapIaK1vE6xLA8i7GJZuMYAqMHzZd7fMoH3QTgIB6Ulx886wRttDD94zHsPSmtGfs7FDhi+C2Mce1axfU55q7sUNWZpfLRVyHDOARzkciqkGfKEgBVyd5Tt6HFa2pWr+XbzCExq7bVJOcLnv6Gs4qywKQUdlUofbJwKUyoK2hesboiacE4XJbIOBx0FdAlxE9jBuClmjKsvQlf8AGuWE5jeYCP5y23BHUEc/y61u2jxlba2kjGwDAIPLbjgGsXI6Y7GvFKkskc0Tb0IVZEc7WwvTn3rRbUWMUfmO0LqW2oRhceo7GsKO6W0jMMqrI8TsqtnLgDoD2/GrMEhu4USViMDKrztAPXJ9fao30NbFmaZZLUSIrLAuSUzgtkVlFSl3OW+VVXI477eBVpZZXldGQyqWJ+XgZxjr24FR3b/umlKRq5chcDpjg/U80LczktB1msMhWWWQZ2Z2HqDT7qVgD5hLAEjAHT/IqjayAHG0krgDPc4zVuaRpYIiBvck5HbNdl7ROO2pRVrdJ2YOyoT5qJ7jrnNOlzDbqXXbFK+5l6Ad+vvxTLi3ASR2AKDDrjj8P/rU9oWZCqYYbcn5sqP9qsW7mqSGqqyXzR+eRGv70FOSue3PfNXiz3U8cflG2k28jGfM46geh9KpaYg810cblQgbskcDkfzq6b8Wdm7TEsc9NvzBweOetCSbNlJpNktu6RTN5joOPnZuPp+tZ84SPUi4Yt8hJcZ+YmsN2uNQurhnuVa4PSHPUjtnpW1obi2sPMmZXVl55yBnufcVaV3YiW1yWaWExyKNyKgO1jzuOAcfmKzNWYyxgQB5FUgszdRx2HTNWcmWFofKCytuZSTz69PcUy4dYoFuYk3IfvrkgnPGcnqRWy0icTj71zBinBuJDK3mIG/dOvT8fSuggnlS6DHzJFUD5iu/ANMXT18g3FukTtEfni7EY+8PfmrOkHy5pmtCXj2bcdSKxqK25tDcvpKstpNNIN5EgLMo6CtW0/eeU6nDRR7uOeDxzVFUieGVF2wsdq4Jwd2etW7RUJuS7qpx17YFYbM6lsa0mFk2DkyIxzjg4IrMvkMiDIz8mR64rSLeYsLtwXBGPasy6kZQX6YX8MHtRIRwHii3WTUgcbSy9RXI6hZAEkAFgefQ13HimPE0bI2fnP5VhzRiTJRckdvWiMrGDSZwl9aKBjbzmsSeDGSox7V32p2gf7q8965y5tcuSOCPauqE+5zzpnNlCOtG3jpWzJaDbuAHvVY25GcqcVpoZcpR+aRe5x3NCrkgE4XPPNStA+/5QSfalS2dpApyvGc7SafmTYjmfeR87OFGFz2HpUZOanMEzFtqFjjJxUtvah1JdXA/3cmnuK1ius8qwtCrkRsQxX1I6U+aTe64RYyABtBOOB7mtSPSDcxsySqmwfKH4Lf/AF6hGkyy3CRBlYtnJUdPanzWW41BszFyz4QbmPQAU3a3YHjrxXUReGyhDPvOSQNh9q29H0L7Mojuot0ZwwYLkYPb61i6qNFRZxNnYTzNuVCenT0rpbTTUnlitCUijLYLYwcd+a6Wy05rSIxAqqO2YpIYwx2jtnsa1rWyyGLRMEwWIkOGY/1rOVVvRGsaKW5TtdIs7VgsCfLCo28ZyT/WnmHaSDj1bmrhUW8YWECND1GMVSmcMewwc1lq3dm602IJNp2qp2EdWqKARG8iF08hg3DzDGBux7Z4zSTLkkNkcZyO9TadavcXEFtGpaSVlRQO5JxTJsdJCvhWEkxvrZ9OIjS6zcWd6bJNMjuBBawCEGcDcTuJ7cd6VNI0i1maCfW8zRkqRFas6K3cbs81Je6f/ZzwgTpPFOnmwyxjh1z6HkdOlRzMqK6nAb/mjD84JGR1resZJNwyFaTduPOcjHTFc1pv+kXUgclVBO0dceldTbxIhXdypHOOaqVy4s2rWxtpCUil2Soed+cMDzx6VoW00VsnlQoDPngkEk/iO1YVvPAsLCUuNqkqVOM/WrMNypRWSPbFjB2IePfmiKtqatvZl6ZcTB5njkcnIVfujPoKiug8atiNWdjw5znpycf1pTLvjdrVWSNF5fgkk9qjcNIBK5AcrhjnAVcdB6mixm2PaFVuzmVZNkYZ/m+9x93Pv6Vn36SuIsZAjPmZK8EnrV6CKMoUYbcYb5jjAHT8TQkYni2ZZlYngdQTnBrRSstTJx1uVLjUHvYYYJkEaxIykqv32x1rNcoJY8B2cMS6gdRnOf1rXvAZpEj34jAIVWHOcY5NZ48xXil24BbajZ6YGNpqb82o1uCLEJwXcYDn7w4IzwfwqzHGcLJA+JXJj2lslT1BH602ZnVN0QCknIXHCnvRbt86so3qARyejf05zUPQ1Wht2k0KystwGWBlLM64LZ/wJq1pzDyRJazGN8g73IGDmsWNPkDqpzgjLKMrV6JRiNREsj7cn58K3vxUq7ehqnYTUL0LJhWbcpyGVerHrionbbaqDHtVT8pbruI5psxYpksE3gYQNx6du1LDIjZ3jdKDgbuRjvxTUdSJDY3UqC6MM4ATptx1rVt4lacmPoOBnp0zx+FZwDBIztYTu/INaNtJGrYfd97cMcEn0rVvSxgldlfYS4XyxkAume5z0xVYRnyLiOTCydUP3QMnnn8elazoscUcknyhTuHbHqKyZQZSQBkOcgnovPWpSsX6BxI7qwC3CSZwDwOKlvp90CRswVnXaRxkYpGjIVJIQvCbWI5PHtVC9tWMvmsrlSAIwD0pPqapXRB/Z8sDsdha0J+ZEPzLkfezU7eXbNCuAbUOow2eMdzTgJk3B3UxjqcEnp0qW3jS7jlD7cDOMnBz/WtYO5jJ2H6fNBPd+YJMCFmyOnGamhie80tooWLSLIWXGOSc5GPcVTlgEAkc+WkacCIffLYOc/pTdLlkV98cWQcoR0xjvWt1HQxceZ3JreCXS7K7uLZswOQWRwDg46fhUfhws8E0oK+XK20oOp70t95t0Dtb7x2AL0//AF1EtsQ4ktztwdn7skcgck//AFqxnLmZrGHKblxK0961ywT5QcD+HPTipbVsSMqlizkZB5OMZrNCXSssbyL5RUhW24+UdaXz5CWlbAwu9SB68D+VYyNonRx3P76XkhBGTnPTjFRXbb0Krtwu1SapWkjPCqH+N1zz0AHNPlkBb5PmXOWINCVwkct4q3bFZOMNiscFi6sMA+3rW74qIKuUBIyuAfWsP/VSnepA757GnZI5+o24jFwCQAJO49a5++tu5AVlrp1DPwjDI6e9UtQgWSM7vlkHt1qk+qEzlJIv4sZ7kGmrbq+Tg59K1HjDIRgh89O1RLCc91OMj3q+a5PKjGnsgMNn7pBNXLa3B+Zhg4xkelXo4wkgEi9qsxWwLfuTnPODQ5aWBQ1uVYtKLSA8hMYBxzV+w0RwxMLDJOSFHB/wq3a7g6gkqwI4rpLARGTfjL9COgNZyk0Vyo599IdowFjCk9cjr+NT2/hwrHG0bbZM7t6qc++T3rsGmUPhIQI1HABBGaptKHcFmVVPUDP9KhzbKSRnQadMItglG4ewA54qWG2LQ+SZ5HdBtdAAcY96vG4jjiLs6oP7wUnFZct2C8hQOM9SON3vSuxpE6CO2jMSyy+U3LgsefbNQXFyjNvRzgD5uOaqm6jcExE7AcZc4Ofeod42jaDgnnBqkmJk10xDBiAiY4Hr9aoEM3zuQEHc96sXG1GBeTdn+Ec1Wdl3Ag5HpTERtGxZcZGegNWLNpYbqJ7Unz0cFHHXcDxSBd5zgjj1p1szCdJYy0bIQylTggj0NO66BY663nS4lM934bUzuSzvG0sas3rtHAz7U/UZJbqaF57YWyRIEjjClVRQTgAHk855rZabxJeQW9xFFqKSeWFfaxAcjo209M+1c7qdzdy3LR6jJM10nysJicr3xzUGkTyxJWgvHUnCvyCPWujs7pvKRmdlG3HHb1rnpoPtAIBAbrgcflTIZriNdpZinbI7V0yRjCTOzs7vdNsDb17Lxj8av26EMCxZwVII+6PpmuMsbjbKoaLJJwSSR+NdVE5MYUsAByVHOfrWLdtzdvXQ07ONZLmPdh0AIH8KjjrV+eFSgcqpUKG9ASD1qjFdloQgVI4SQfcH+tXshyAQ2AB9/jIpcw7XJraL7Qknm8LN+8ZsfMSOgB9KsW8SmMeTGVZjuVemQM4+lIi+aoLMW35UMB9wVO8IaDCN8m/l3PPTj+Rq1ruQ9HoZDKiXMrRB1kQhSrDrxnNVJY1kAJRiTyy9gfWnXt06SvAw2jqcdc54OevSt610oukbQsUSQHryrDuTRCPNsNxtuctcRyy23D7uNwGePofeoUQ/vAoKMQFK8cH1Oa1L5ZEmMAjWRUO0tnaGB6fQ1mSIBcbmcEHIIJ3bSOmfb3qJDvYvWvMfYhh95uowfStG0UOpRmcxsNpKkDHtk1n2EahVcK68YG7nr7/41qoJFdEYg8n5VQ4+tSmarYzLmLy/vAgHgDuamtYXdDMpXIOSB61YZdzIojXJIy7nP5dhT4rWVm2wkDkk88EeppxJkxjRlNroWVjnAz+tPBPm54xwevAFWG+eNsFWO7DbTz+FQLnCLsVFXr6t0q79zO2o+QF3dWzJGeODx0pYBG6qwfDRnIXH8OOv+fSpniCwk8hRjHPNVS/GNuw9s0LUo09Mtorl4ciPoQ6yHG70rM8RfZ7Z2it5I5fLYLlcqRz0+lSreRfJ9mQp2ABPHvmqK20styjMQu47iDz+NW37tkhtdSEAMd/R3JC9hjuBU1lDG6lwGe5J6E8AA8ECpp7UQquAzGNQcs3Ge9aFrAkkrNIeBglV4AJ7ULRmL11OevLR7idprgKqj5hznd9cVZgDGNp2YplgF2j7ox1qzqUXno4ikw4AyBxzxkU6KFY0AckIo7HGPxqNW7BYpSQMJWSVc8fKAcA+4Pr9aW0RmkzGxhUA844xjpx1zTIriG4E9qLiMF2HTovpg+laywvC4hlciPBK8DGB6+lKSdjWEdbMqAu8IjViNo2Ebfur3/EmowrGaZ26EhEAGAcDAq2u5t+UZeh2cjgd6ntogvzzHcoOeBkfhUa2KtrZEcERibypDgKu5j6j0/OnYXKBRyQCox2p1xOGdVP3n7H09KImDTLghsHB/kKa2M53Of8AE64tDnIYdazn2zEMQSHrZ8RREW8oHORwD3rKhn3WykgfKo5PrQ2ZrdkQXy2woBx0IHIouofMQ7lwcd+M1ZTZIpOATmlnhG04OVPJWhSsBzstsqIWGcniqs0eeMHpwK3JoEkU8lSPWqflkKd3P93HWrTBqxmCNV2llyMdM09P3J68dcVP5ZGX4z3B7ilYLhW2gr3A60CHpOxb+Anua1NPuNhCMAAeemRWRHJHIpCDaN3THNENx5MxX5sZ6dKLDR1sc5YDaiEAY+Wo2uSAqSbGyMAL/WsyKaIlWDOuRycdKk3QRKdkhBIyCR1NRysq4jkM7byFAYcA8Ukk0TjYrkYPLY4qncbNwZ/09aAWdiI0AC8nNCVhNiziJ/mSMF/727BpkECctK7ZHABfio3Lh8v0Y4AFPbGCSd2D1PTNUmIlCEfKMBfbvUZjUSnd0HQU7IA+9+dJt4zgCh+QrXHOQq5PJPQelaOjOIL62uJowyxSrIVPcA5qpbxxllMgJHX8K1dOMb6nbNdRAWiyKZPZM8/pUbDN6dbG81GW5j8QoBMxfE0cm9c9uOuOnFM11oJ3tBFJLcCCERefIuGlIJOfpzgZ9K0rm7P26az1vyJLKQ5hlhC/uFP3WUjtjGRUPieFYTpaNKkgiswu6M5V/mbkGky4ni1pIrrGJCODkHFS3FttlIzu9AvcVVtwFbHRTkCrscS7Vx97tg8/Su2Zzw1I4VYMpJByeBnP6V0Gm3KrkgN5hP3WGKxipYkMDu9QOPrV+BWIVgxY9vUVzzRvFnQ2dzvMaDaHLHJPGfTitRkzxJIjNgfdJP8AOuZtiykuZFAB5B4JrpLK4jEIBVM9VbGTWJoa9uXiiZgyonZF70sqlkWFABkbzjoPaoLWXKlAcgknLjj8BTpJUAMa4DcgtnGB61V7BuctrXmLfmRwSJG6r0PtV7SdVvEshZq26PcQgYZKfSrN7Ak4DOcIODkdfcVDZWYt386ECSJs7H8zDD6DuaceZbbA2mrMtFpZbcLKfmU7iGIBrNul2XJYAB+GyRnd6gitO/klwrbd2cMcndtHT65rKnJKADAZeeO/PWqYt9zSslBnXzOdwwNjDP0rZXyjAxBEZ6MAOfyNYOnyEgmTYRnGR1+tacIcQIzgP6FyD39KzNIkwUws4X5CSMtjOBSqyOhRZyduRv46/SmMzFWYFfOycljlV9vrSR28iYWMA5JwAvHP1px0CZalkiVtvyKCCNp5GfXiqEisW+bnC5BJxkfSrBP7rAizg8yNwWPt7VFOWEgO0DcOSMNn2FVdGdhtrJI42bgXOcZ5AFEqBQFzyMkuQefwqVIgEJbEfoXPQfSlkjVU2OVC4znufT8aYyi7FpUMgCDIC45Jq4CEOyNnCkYbb71TCkhd3DHkDOSB71chcSKMZJOBjHGPc00wepYUhi4mfbEg/EnAxx3qaFXZD5S7QpHmMf6UrZC7huzgsOBjHuPSnDYEBywXGDgf5z/Om1qZLQzbg78siKSCduB1xWTrQluNGZsGLa2MdzW5fkxuRGVPlr6YwT6etZdzHKjrHcrE8LDOHbofepTs9TWLOTs57dbmBI4SRGqnoSS2eprt5ZTOlv8AJudnA2gnp6Vj3en2m6OdZ48Lnd5Axj05ra0iNQInKs8mCERTyB6n0Jq5yVrFo0YIRK4bnYSc5Gcnv+Ao1m5isYSAwBY7APYdeKnsDII1LrsQEfj7CszV4Vu5isjqEX5nZeuPSohbdgrIqSyi5ezaIcsCzHHQd62LKJNnABAGcdwT61l20byXHzDbCo2rn0H8q6i3hRUXAOMbzj17CqbTRg3dnM+JISIyvBYfp7VytsN9ko6NyM+vNdj4iQmFyQoPJx/WuM0xgsBAJ4JGfxrEkS3TZMVJOR0FXoGO394mRnk5qEZ3llGd33s9qkgRw7ICCp5zQBDd2ihfMjJwTnbVQRlyeg9q1VLq+WwFAxtI5qM2rOwCkfNzn3pqTGzKeLDYXlO49DULQExAqDnPOa1GhVA6uNsmfXOailgyoVCxY9qtPQmxjm3z84AyDjA4qvK53HI2kevetwREnDDDAYyaiezBwGwfencaKNu7GMYfg09pnK8g5J4qz9kwSNucdhTIrVjMCV6n7pouBWwzZ28s3p2qVcoAhOT3b1q4lvhmUDAPQDtS/ZWzxjdU3AqwRPI+XJ2g9MVKIwoyAGz0HpVz7JJgbnyv8qkFrh0TdtxzuFFwKgiRiFCs2KVIxuKtwAe1XJUj2hVZiFbFTSIowuPm647VPMNbkcSL8gGVJPU1bTaAy5KjPYdagRwzAcfL1FaOk4XVLWeXiCGVXZevAPWpZpypalx9OjQmGa9gguAcmLazbT/tFRgEenaqF7BcQ3BgnUBhhgVwQwPcEdQfWurNsVvrBjcSRtbDAVIWfzOcl0KjDb885/GsfxO0LTxQFF3QxsHVTnbliwTI/uggUCT1PJZUAjdh1XGKjP3Vboc0UV3dDmRbU4APcH86uKoQEAk7cgZNFFYyLiTyEgqM53kZz3rc0xcqDk5AoorB7m8djRtxjdtJG1scHrmrOoK0entNHI6vheRjuaKKfUYkSbpBGWfa8ZLc9eM1RlYC4BKKQ5Hy4wBwOmKKKuOw5Fi6Gbfd0KjjHFZzcuWGEZUJyvf6+tFFDJRfthtQ4/h5Ge1X7P5powQCCoPQUUVl1NEXvKVYA4GD5h+n5VVuWZPlBJ3HJJ60UUwZJnaQ/wDERjPoPakT543zgEdx160UU0SQ3Q2tvBO8nk96VV/eRNk5Y8nPX2ooqnsIilOGMagBWBzgVWUsrjDNgdB2oopx2A2bWR5XhiZjhgQSOvHSi6neOaNF24245Ge9FFX0IkTTwws6SSRI7F15bJxxUN7aQLGrmMM7ZYk/y+lFFQxrczrK1hikykag78AkZwMVt6VBGPKfHzzMyufYelFFZlEsVw32SRtqZ6DjoPasa9YpEoXje3J/GiigfU1LWJPPmXaMAZrdUkQkjriiitIdTM5vxGP9Fl9sL+GK4bSwGSUEYw56UUVmJ7lyUkYHb+VPt5WMbjONvpRRTZJYVRIgLddpOar9EjOeSuTRRUlBc/vGJbkgCmRoMv1z60UVa2JBvmOD2qaCBHGCOp7GiipG9yKVQGbAxyRTXjVUV1GGxnNFFA0KqBzubk1IQMx8Dmiigb2Gklrjyz9zb0/GkAxKEH3c0UUC6Ekkaxqdo5yetNYbdpySSQMmiikiomhHGsYJVQD60xyfnHTjtRRUsoljvLqG2EcNzPHGeqpIQD+FQoihC2MnBPNFFVED/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple acrally distributed target lesions and mucosal erosions are present in this patient with erythema multiforme majus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Erythema multiforme",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple erythematous plaques with dusky centers are present on the arms of this patient with erythema multiforme.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Erythema multiforme",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This patient with erythema multiforme presented with non-targetoid erythematous papules on the face.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Erythema multiforme",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Target lesions are present on the palm of this patient with erythema multiforme.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Erythema multiforme",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 325px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple typical target lesions are present on this extremity.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Erythema multiforme",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This child with widespread erythema multiforme had multiple lesions on the trunk and extremities.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_56_42890=[""].join("\n");
var outline_f41_56_42890=null;
var title_f41_56_42891="ACOG fragile X screening";
var content_f41_56_42891=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F65747&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F65747&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    American College of Obstetricians and Gynecologists Committee on Genetics recommendations for testing for fragile X syndrome",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        1. DNA-based molecular analysis (eg, Southern blot analysis and polymerase chain reaction) is the preferred method of diagnosis for fragile X syndrome and its premutations (FMR1 triplet repeat number). In rare cases where there is discordance between the triplet repeat number and the methylation status, the patient should be referred to a genetic specialist.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Women with a family history of fragile X related disorders, unexplained mental retardation or developmental delay, autism, or premature ovarian insufficiency should receive genetic counseling and should be offered genetic testing (fragile X premutation carrier screening) to assess their risk of having an affected child.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Prenatal testing for fragile X syndrome by amniocentesis or CVS should be offered to known carriers of the fragile X full mutation or premutation. Although it is reliable for determining the number of triplet repeats, CVS many not adequately determine the methylation status of the FMR1 gene.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4. Women who request fragile X carrier screening should be offered FMR1 DNA mutation analysis after genetic counseling that includes the risks, benefits, and limitations of screening.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5. If a woman has ovarian failure or an elevated follicle-stimulation hormone level before the age of 40 years without a known cause, fragile X carrier screening should be considered to determine whether she has a premutation.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6. Carriers of a fragile X premutation or full mutation should be referred for genetic counseling to discuss the frequency and range of potential outcomes in offspring. Options including prenatal diagnosis, preimplantation genetic diagnosis, and use of donor eggs should be discussed.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: ACOG committee opinion. No. 469: Carrier screening for fragile X syndrome. Obstet Gynecol 2010; 116:1008.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_56_42891=[""].join("\n");
var outline_f41_56_42891=null;
var title_f41_56_42892="Recom Adj Sys Rx in Older women with br ca";
var content_f41_56_42892=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F81185&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F81185&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommendations for adjuvant systemic therapy in women older than 70 years of age with breast cancer",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"20%\">",
"     </colgroup>",
"     <colgroup span=\"2\" width=\"40%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Risk category",
"       </td>",
"       <td class=\"subtitle1\">",
"        Definition",
"       </td>",
"       <td class=\"subtitle1\">",
"        Suggested therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Very low",
"       </td>",
"       <td class=\"sublist1_start\">",
"        If all of the following:",
"       </td>",
"       <td rowspan=\"2\">",
"        No treatment or hormonal therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        <p>",
"         Tumor size &lt;1 cm",
"        </p>",
"        <p>",
"         Histologic grade 1",
"        </p>",
"        <p>",
"         ER/PR-positive",
"        </p>",
"        <p>",
"         HER2-negative",
"        </p>",
"        <p>",
"         No angiolymphatic invasion",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Low",
"       </td>",
"       <td class=\"sublist1_start\">",
"        If all of the following:",
"       </td>",
"       <td rowspan=\"2\">",
"        Hormonal therapy alone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        <p>",
"         Tumor size &le;2 cm",
"        </p>",
"        <p>",
"         Node-negative",
"        </p>",
"        <p>",
"         Favorable histopathologic features (eg, grade 1)",
"        </p>",
"        <p>",
"         ER/PR-positive",
"        </p>",
"        <p>",
"         HER2-negative",
"        </p>",
"        <p>",
"         No angiolymphatic invasion",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        Intermediate",
"       </td>",
"       <td class=\"sublist1_start\">",
"        If node negative and at least one of the following:",
"       </td>",
"       <td rowspan=\"4\">",
"        <p>",
"         Hormonal therapy is recommended if ER/PR-positive",
"        </p>",
"        <p>",
"         Addition of chemotherapy suggested if patient healthy and willing to accept risks",
"        </p>",
"        <p>",
"         If HER2-positive, addition of trastuzumab is suggested, if the patient is healthy, lacks cardiac comorbidity, and is willing to accept the risks",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        <p>",
"         Tumor size &gt;2 cm",
"        </p>",
"        <p>",
"         Unfavorable histopathologic features (eg, grade 2 to 3)",
"        </p>",
"        <p>",
"         ER/PR-negative",
"        </p>",
"        <p>",
"         HER2-positive",
"        </p>",
"        <p>",
"         Presence of angiolymphatic invasion",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        <p>",
"         <strong>",
"          OR",
"         </strong>",
"        </p>",
"        <p>",
"         Tumor &ge;2 cm and ER/PR-positive and high risk gene expression analysis (eg, Oncotype DX)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        <p>",
"         <strong>",
"          OR",
"         </strong>",
"        </p>",
"        <p>",
"         If one to three involved axillary nodes and ER/PR-positive and HER2-negative",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        High",
"       </td>",
"       <td class=\"sublist1_start\">",
"        If one to three involved axillary nodes and ER/PR-negative, or HER2-positive",
"       </td>",
"       <td rowspan=\"2\">",
"        <p>",
"         Chemotherapy recommended",
"        </p>",
"        <p>",
"         If HER2-positive, add trastuzumab",
"        </p>",
"        <p>",
"         If ER/PR-positive, add hormonal therapy",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        <p>",
"         <strong>",
"          OR",
"         </strong>",
"        </p>",
"        <p>",
"         Four or more involved axillary nodes",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ER/PR: estrogen and/or progesterone receptor.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_56_42892=[""].join("\n");
var outline_f41_56_42892=null;
var title_f41_56_42893="Td for multiple myeloma";
var content_f41_56_42893=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F82300&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F82300&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Thalidomide plus dexamethasone (Td) for multiple myeloma",
"    <sup>",
"     [1,2]",
"    </sup>",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr class=\"divider_bottom\">",
"       <td colspan=\"4\">",
"        Cycle length: 28 days.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose and route",
"       </td>",
"       <td class=\"subtitle1\">",
"        Administration",
"       </td>",
"       <td class=\"subtitle1\">",
"        Given on days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Thalidomide",
"        </strong>",
"       </td>",
"       <td>",
"        200 mg by mouth",
"       </td>",
"       <td>",
"        Take with water on an empty stomach at least one hour after the evening meal.",
"       </td>",
"       <td>",
"        Daily on days 1 through 28",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Dexamethasone",
"        </strong>",
"       </td>",
"       <td>",
"        40 mg* by mouth",
"       </td>",
"       <td>",
"        Take with food (after a meal or with food or milk) in the morning.",
"       </td>",
"       <td>",
"        Days 1, 8, 15, and 22",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Pretreatment considerations:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Emesis risk:",
"        </strong>",
"        LOW or VERY LOW. Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Prophylaxis for thrombosis:",
"        </strong>",
"        Without prophylaxis, the TD regimen is associated with thrombosis or embolism in up to 25 percent of patients",
"        <sup>",
"         [3]",
"        </sup>",
"        . As such, routine thromboprophylaxis is recommended for all patients",
"        <sup>",
"         [4]",
"        </sup>",
"        . Options for prophylaxis are discussed in detail separately. Refer to UpToDate topic on \"Thrombotic complications following treatment with thalidomide and its analogues\", section on Thalidomide plus dexamethasone.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Infection prophylaxis:",
"        </strong>",
"        Primary prophylaxis with G-CSF is not indicated (rate of severe neutropenia &lt;5 percent)",
"        <sup>",
"         [2]",
"        </sup>",
"        . Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Dose adjustment for baseline liver or renal dysfunction:",
"        </strong>",
"        Dose adjustments are not recommended for either drug in patients with preexisting renal or hepatic insufficiency",
"        <sup>",
"         [5,6]",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Pregnancy warning:",
"        </strong>",
"        Thalidomide can result in severe, life-threatening human birth defects. Strict birth control regulations are in place for all patients taking thalidomide. This drug is approved for marketing only under a special restricted distribution program approved by the US Food and Drug Administration called the \"system for thalidomide education and prescribing safety\" (S.T.E.P.S.) program",
"        <sup>",
"         [5]",
"        </sup>",
"        . Pregnancy testing is required within 24 hours prior to initiation of thalidomide therapy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Monitoring parameters:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; CBC with differential, serum electrolytes, and serum uric acid.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Assess fluid status, blood pressure, central nervous system status and dermatologic toxicity.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Monitor for signs of neuropathy monthly for the first three months, then periodically thereafter. Neuropathic complications include constipation. As such, many clinicians provide a prophylactic bowel regimen for patients taking thalidomide.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Pregnancy testing should be performed weekly during the first four weeks, and then every two to four weeks, depending upon menstrual cycle regularity.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Suggested dose modifications for toxicity:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Myelotoxicity:",
"        </strong>",
"        Thalidomide should be withheld if the ANC falls below 750/mm",
"        <sup>",
"         3",
"        </sup>",
"        . Restart after ANC recovers to &gt;1500/mm",
"        <sup>",
"         3",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Rash:",
"        </strong>",
"        Thalidomide has been associated with rashes including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). If a rash develops, thalidomide should be discontinued and the rash further evaluated. Thalidomide should not be administered again if the rash is exfoliative, purpuric, bullous, or if SJS or TEN is suspected.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Neuropathy:",
"        </strong>",
"        Thalidomide should be discontinued or dose reduced if a patient develops paresthesias accompanied by pain, motor deficit, or interference with activities of daily living",
"        <sup>",
"         [7]",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.",
"    </strong>",
"    <div class=\"footnotes\">",
"     G-CSF: granulocyte colony-stimulating factors; CBC: complete blood count; ANC: absolute neutrophil count.",
"     <br/>",
"     * The dexamethasone dose is lower than what was used in the original studies, and is based on subsequent studies suggesting a higher mortality with high dose dexamethasone compared with low dose dexamethasone given in combination with the thalidomide analog, lenalidomide",
"     <sup>",
"      [4]",
"     </sup>",
"     .",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br/>",
"     <ol>",
"      <li>",
"       Rajkumar SV, et al. J Clin Oncol 2006; 24:431.",
"      </li>",
"      <li>",
"       Rajkumar SV, et al. J Clin Oncol 2008; 26:2171.",
"      </li>",
"      <li>",
"       Palumbo A, et al. Leukemia 2008; 22:414.",
"      </li>",
"      <li>",
"       Lyman GH, et al. J Clin Oncol 2007; 25:5490.",
"      </li>",
"      <li>",
"       Thalomid (thalidomide). US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on January 6, 2012).",
"      </li>",
"      <li>",
"       Decadron (dexamathasone). US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on January 6, 2012).",
"      </li>",
"      <li>",
"       Delforge M, et al. Lancet Oncol 2010; 11:1086.",
"      </li>",
"      <li>",
"       Rajkumar SV, et al. Lancet Oncol 2010; 11:29.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_56_42893=[""].join("\n");
var outline_f41_56_42893=null;
var title_f41_56_42894="Plasma concentrations B";
var content_f41_56_42894=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F72099&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F72099&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Increase in plasma concentrations of insulin (top) and c-peptide (bottom) for type 2 diabetic patients and healthy subjects after ingestion of a mixed breakfast meal",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 486px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Data are means &plusmn;SE.",
"    <div class=\"footnotes\">",
"     * p &lt;0.05 for differences between type 2 diabetic patients and healthy subjects.",
"    </div>",
"    <div class=\"reference\">",
"     Modified with permission from: Vilsboll, T, Krarup, T, Deacon, C, et al. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 2001; 50:609. Copyright &copy; 2001 The American Diabetes Association.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_56_42894=[""].join("\n");
var outline_f41_56_42894=null;
var title_f41_56_42895="Pelvic congestion syndrome 11a";
var content_f41_56_42895=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F52370&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F52370&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Left ovarian venogram",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 332px; height: 475px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Left ovarian venogram in a 37-year-old woman with chronic pelvic congestion syndrome demonstrates dilated left ovarian vein and filling of uterine venous plexus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_56_42895=[""].join("\n");
var outline_f41_56_42895=null;
